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SUMMARY 
INTRODUCTION 
Lung cancer is the most commonly diagnosed cancer worldwide. In Denmark lung cancer accounts for 
about 13% of all new cancers in males and 12% in females. Lung cancer is now the leading cause of 
cancer death among both females and males. Since the 1950s the incidence of lung cancer has steadily 
increased among females while leveling off and declining for males after the 1980s. It has been 
estimated that about 4% till 8% of lung cancer cases may be related to asbestos exposure. 
It is difficult to decide when asbestos exposure is sufficient to cause of lung cancer in individual cases. 
Estimating previous asbestos exposure is uncertain. Many different methods have been used to 
measure asbestos fibers in the air, but results from differing measuring methods cannot be readily 
compared. Asbestos air measurements are seldom available when individual compensation cases are 
evaluated. The fiber for fiber potency to cause lung cancer probably varies with fiber type, fiber size 
and possibly industry. However, these differences are still not disentangled and somewhat 
controversial. Most occupational exposures involve exposure to both fiber types. In addition the 
majority of previously asbestos-exposed workers who contract lung cancer are also smokers. Thus the 
complex   interaction between smoking asbestos should also be taken into consideration.  
The aim of this project is to produce a stringent and critical review of the scientific literature 
concerning asbestos exposure and its causation of lung cancer. Particular emphasis has been placed on 
the dose-response relationship at low-level asbestos exposure. This document provides updated 
evidence upon which guidelines concerning the identification and recognition of asbestos-related lung 
cancer can be based.  
METHODS 
Based on the posted grant proposal 19 search questions were extracted. These search questions 
corresponded directly to the requested information. Two broad systematic literature searches were 
performed with PubMed and EMBASE. They were combined and doublets removed resulting in 4,088 
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references. These references were systematically combined into 4 main groups: lung cancer, asbestos 
exposure, dose-response as well as competing and predisposing factors. They were initially sorted by 
title then by abstracts. Thereafter specific “bottom up” PubMed searches were performed for each 
search question and integrated into the existing reference groups. References were further sorted 
according to inclusion and exclusion criteria. 
A writing and an internal expert group each with 8 members were established. Key cohort and case-
control studies (N=28) were read by 2 writing group members and evaluated using a SIGN-based data 
extraction sheet. Key review and meta-analyses articles (N=10) were evaluated likewise using the R-
AMSTAR assessment sheet. Reviewed articles were described as narratives and in evidence tables.  
A working seminar was held on November 22 and 23 in Odense for the writing and internal expert 
groups. The 4 seminar working groups thoroughly discussed and revised the manuscript draft. 
Twenty-one useful statements were discussed, edited and graded based on the quality of evidence: 
good evidence (+++), some evidence (++) or limited evidence (+). Consensus concerning the grading 
of the edited statements was obtained. The revised draft was sent to two external reviewers. The final 
version was redrafted in accordance with these 2 reviewers’ comments and presented to the National 
Board of Industrial Injuries for approval. 
RESULTS 
Cell type and location of asbestos-related lung cancer does not differ from that of non-asbestos-related 
lung cancer. There is very little information concerning the prognosis of asbestos-related lung cancer. 
Our own data showed no differences in survival when comparing those with and without asbestos 
exposure. It is unlikely that the prognosis of asbestos-related lung cancer differs from non-asbestos-
related lung cancer. 
Asbestos exposure assessment should be based on a thorough occupational history. This should be 
supplemented with expert opinion, appropriate job exposure matrices and published air measurements 
that can be related to the exposure in question. The presence of pleural plaques, either on one or both 
sides, increases the likelihood of previous asbestos exposure with relevant lung cancer latency, when 
competing causes can be eliminated. However, they do not reflect the degree of such exposure. The 
presence of asbestos bodies or asbestos fibers in either lung tissue or lung washings increases the 
likelihood of asbestos exposure. However, they do not reflect the degree or time window of exposure. 
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The absence of pleural plaques, asbestos bodies or asbestos fibers does not rule out that there has been 
considerable asbestos exposure. 
All forms of asbestos are associated with lung cancer. The evidence is not conclusive concerning 
differential lung cancer risks associated with fiber type and fiber dimensions, when other relevant 
aspects are taken into account in meta-analyses. For practical purposes most occupational exposures 
can be assumed to be of a mixed type. The dose-response between asbestos exposure and lung cancer 
risk is basically linear. However, it levels off at very high exposures around 150 f-y/ml. The majority 
of studies demonstrate that the relative risk for lung cancer increases between 1 and 4 % per f-y/ml. 
This corresponds to a doubling of risk at 25-100 f-y/ml. However, 1 high quality study has shown that 
a doubling of lung cancer risk was seen at about 4 f-y/ml. There is not good evidence that a no-effect 
threshold exists. No minimal latency time for asbestos-related lung cancer has been established. 
However, for practical purposes it can be assumed to be 10 years after the onset of exposure. Limited 
evidence suggests that lung cancer risk from asbestos decreases decades after exposure.  
Although there is some tendency for lung cancer risk to run in families, there is not enough evidence 
to include age, sex or family lung cancer history when evaluating cases of potential asbestos-related 
lung cancer. Neither should most other diseases be taken into consideration when evaluating these 
cases. However, lung fibrosis from whatever cause is associated with an increased lung cancer risk. 
This is particularly true of lung fibrosis from asbestos (asbestosis). Asbestosis is caused by a 
considerable degree of asbestos exposure, which also embodies an increased lung cancer risk. 
Exposure to other acknowledged occupational lung cancer risks, such as welding and polycyclic 
aromatic hydrocarbons (PAH), should be taken into consideration. Exposure to environmental 
pollutants such as radon and air pollution in Denmark are generally low and thus should not be 
considered when evaluating individual cases of possible asbestos-related lung cancer.  Asbestos-
exposed smoking workers have a greater lung cancer risk than asbestos-exposed non-smokers. The 
increased risk is between additive and multiplicative. About 20 years after smoking cessation the 
relative risk from smoking is reduced by 90% or more. 
CONCLUSION 
The dose-response between asbestos exposure and lung cancer risk is basically linear, but may level 
off at very high exposures. Many studies demonstrate that the relative risk for lung cancer increases 
between 1 and 4 % per f-y/ml, corresponding to a doubling of risk at 25-100 f-y/ml. Cell type and 
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location of lung cancer is not helpful in differentiating asbestos-related lung cancer from other lung 
cancers. The presence of pleural plaques, asbestos bodies or asbestos fibers is useful as markers of 
asbestos exposure and as such helpful in supporting previous asbestos exposure. The interaction 
between asbestos and smoking regarding lung cancer risk is between additive and multiplicative. 
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POPULAR DANISH SUMMARY 
INTRODUKTION 
På verdensplan er lungekræft den hyppigst diagnosticerede kræftform. I Danmark kan 13% af alle nye 
kræfttilfælde blandt mænd tilskrives lungekræft, mens det for kvinder er 12%. Ligeledes er lungekræft 
den førende årsag til kræftdød blandt mænd og kvinder. Siden 1950´erne har antallet af nye 
kræfttilfælde blandt kvinder været stadigt stigende, mens man blandt mænd har set en udjævning og et 
fald siden 1980´erne. Man regner med, at ca. 4-8% af alle lungekræfttilfælde skyldes asbestudsættelse. 
Det er svært at afgøre, hvilket omfang af asbestudsættelse, der er tilstrækkeligt til at forårsage 
lungekræft i det enkelte individ. Dette skyldes flere ting, bl.a. usikkerheden omkring estimering af 
tidligere asbestudsættelse. Mange forskellige metoder har været anvendt til at måle asbestfibre i luften, 
men resultater med forskellige målemetoder kan ikke umiddelbart sammenlignes. Desuden er 
asbestmålinger i luften sjældent tilgængelige, når der føres erstatningssager. Den karcinogene effekt af 
asbest afhænger af fibertype, fiberstørrelse og eventuelt af industri, men disse forskelle er endnu ikke 
helt afklarede, ligesom erhvervsmæssig asbesteksponering ofte også betyder eksponering for flere 
forskellige asbesttyper. Endvidere er en stor andel af de personer, der tidligere har været udsat for 
asbest, også rygere, hvilket betyder, at den komplekse interaktion mellem asbest og rygning, ligeledes 
skal tages i betragtning. 
Formålet med dette projekt er at producere en stringent og kritisk gennemgang af den videnskabelige 
litteratur om asbest og dens årsagssammenhæng med lungekræft. Særlig vægt er lagt på dosis-respons-
forholdet i lavdosisområdet. Dette dokument bidrager således med en opdateret gennemgang af 
evidensen vedrørende asbestrelateret lungecancer. Retningslinjer for identifikation og anerkendelse af 
asbestrelateret lungekræft kan baseres på dette arbejde. 
METODE 
På baggrund af Arbejdstilsynets opslag blev der udarbejdet 19 spørgsmål. For at besvare disse 
spørgsmål, blev foretaget to brede, systematiske litteratursøgninger i henholdsvis PubMed og 
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EMBASE. Det gav 4,088 hits, når resultaterne blev kombineret og dubletter fjernet. Disse referencer 
blev systematisk sorteret, først i 4 hovedgrupper: lungekræft, asbest, dosis-respons samt 
konkurrerende og prædisponerende faktorer på baggrund af titel, og sidenhen i 19 undergrupper 
(svarende til de 19 spørgsmål) på baggrund af resume. Herefter blev der udført specifikke søgninger i 
PubMed for hvert af de 19 spørgsmål (bottom-up søgning). Disse referencer blev ligeledes sorteret 
efter titel og resume og efterfølgende integreret i de eksisterende 19 undergrupper. Grupperne med 
referencer blev sorteret en sidste gang efter inklusions og eksklusionskriterier. 
To arbejdsgrupper med hver 8 personer blev etableret: en skrive- og en intern ekspertgruppe. Hver 
enkelt kohorte- og case-kontrolstudie, der skulle indgå i besvarelsen af dosis-respons sammenhængen 
mellem asbest og lungekræft (n=28), blev læst af 2 personer fra skrivegruppen og efterfølgende 
evalueret efter et SIGN-inspireret skema. Reviews og metaanalyser blev gennemgået på samme måde, 
men evalueret med et R-AMSTAR skema. Kohorte- og case-kontrolstudierne blev beskrevet 
tabellarisk såvel som narrativt. 
Den 22.-23. november 2012 blev der i Odense afholdt et seminar for de to arbejdsgrupper, hvor det 
foreløbige manuskriptudkast blev drøftet og revideret. 21 statements blev ligeledes diskuteret, 
redigeret og bedømt på baggrund af kvaliteten af den foreliggende evidens for årsagssammenhæng: 
god evidens (+++), nogen evidens (++) eller begrænset evidens (+). Det reviderede manuskriptudkast 
blev sendt til to eksterne bedømmere. Efterfølgende blev deres kommentarer indarbejdet i teksten, og 
det endelige manuskript blev herefter sendt til godkendelse hos Arbejdsskadestyrelsen. 
RESULTER 
Celletype og placering for den asbestrelaterede lungekræft adskiller sig ikke fra den ikke-
asbestrelaterede lungekræft. Det foreligger meget lidt viden om prognosen for asbestrelateret 
lungekræft. Egne data viste heller ingen forskelle i overlevelse ved sammenligning af 
lungekræfttilfælde med og uden asbestudsættelse. Det er derfor mindre sandsynligt, at prognosen for 
asbestrelateret lungekræft adskiller sig fra ikke-asbestrelateret lungekræft.  
Vurdering af asbesteksponering bør baseres på en grundig gennemgang af erhvervsmæssig historik 
suppleret med eksponeringsmatricer og luftmålinger relateret til den aktuelle eksponering. 
Tilstedeværelsen af pleurale plaques, enten ensidigt- eller dobbeltsidigt, øger sandsynligheden for, at 
tidligere asbesteksponering med relevant latenstid for lungekræft har fundet sted. Dog er de ikke en 
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markør for omfanget af asbesteksponering. Asbestlegemer eller asbestfibre i enten lungevæv eller 
lungeskyllevask øger ligeledes sandsynligheden for asbesteksponering har fundet sted, men afspejler 
ikke omfanget eller tidsvinduet for eksponering. Samtidig udelukker fraværet af pleurale plaques, 
asbestlegemer eller asbestfibre ikke, at en betydelig asbesteksponering har fundet sted.  
Alle former for asbest er forbundet med lungekræft, men evidensen for, at den karcinogene effekt 
afhænger af fibertype og –dimension, er stadig ikke tilstrækkelig, når metaanalyser gennemgås. Det 
kan bl.a. tilskrives, at erhvervsmæssig asbesteksponering sjældent kun afspejler eksponering for én 
type asbest. Dosis-respons sammenhængen mellem asbest og lungekræft er tilnærmelsesvis lineær, 
men udjævnes ved meget høje eksponeringsniveauer på omkring 150 fiber-år/ml. De fleste studier 
viser, at den relative risiko for lungekræft stiger med 1-4% pr fiber-år/ml. Dette svarer til en 
fordobling af risikoen ved 25-100 fiber-år/ml asbestudsættelse. Dog har et studie af høj 
epidemiologisk kvalitet vist, at risikoen for lungekræft blev fordoblet allerede ved 4 fiber-år/ml. Der er 
ikke solid evidens for eksistensen af et no-effect tærskelniveau samt en nedre grænse for latenstiden 
for asbestrelateret lungecancer. Det kan antages at latenstid er ca. 10 år fra eksponeringens start. 
Begrænset data indikerer, at risikoen for lungekræft falder årtier efter eksponering. 
Selv om der en vis tendens til familiær arvelighed for lungekræft, er der ikke evidens for at inkludere 
faktorer som alder, køn eller familiær lungekræft i vurderingen af potentiel asbestrelateret lungekræft 
hos individer. Ej heller bør de fleste andre sygdomme tages i betragtning i vurderingen af disse sager. 
Undtagelsesvis er lungefibrose, som er associeret med øget risiko for lungekræft, især hvis den kan 
tilskrives asbesteksponering (asbestose). Asbestose skyldes en betydelig grad af asbesteksponering, 
hvilket ligeledes er forbundet med øget risiko for lungekræft. Eksponering for andre anerkendte 
erhvervsbetingede risikofaktorer, såsom svejsning og polycykliske aromatiske kulbrinter (PAH), bør 
tages i betragtning. Eksponering for miljøforenende stoffer som radon og luftforurening er generelt 
lavt i Danmark, og bør således ikke indgå i den individuelle vurdering af potential asbestrelateret 
lungekræft. Asbesteksponerede arbejdstagere, der samtidig ryger, har højere risiko for lungekræft end 
asbesteksponerede ikke-rygere. Den øgede risiko er et sted mellem additiv og multiplikativ. Omkring 
20 år efter rygeophør er den relative risiko for lungekræft i forbindelse med rygning reduceret med 
minimum 90%. 
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KONKLUSION 
Sammenhængen mellem asbest og lungekræft er tilnærmelsesvis lineær, men stabiliserer sig ved 
meget høje doser. Flere undersøgelser viser, at den relative risiko for lungekræft stiger mellem 1 og 
4% pr. fiber-år/ml, svarende til en fordobling af risikoen ved 25-100 fiber-år/ml. Celletype og 
lokaliteten af asbestrelateret lungekræft adskiller sig ikke fra lungekræft udløst af andre faktorer. 
Tilstedeværelsen af pleurale plaques, asbestlegemer eller asbestfibre er anvendelige som markører for 
tidligere asbesteksponering. Samspillet mellem asbest og rygning for udviklingen af lungekræft er 
mellem additiv og multiplikativ.  
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1. INTRODUCTION
It is often very difficult to decide when previous asbestos exposure is sufficient to cause of lung cancer 
in individual cases. Estimating previous asbestos exposure is often extremely uncertain. The vast 
majority of asbestos-exposed workers are also smokers. Thus, the interaction between smoking 
asbestos must also be taken into consideration. On this background the Danish National Compensation 
Board has requested a scientific reference document concerning low dose asbestos exposure and lung 
cancer. The Department of Occupational and Environmental Medicine, Odense University Hospital 
applied for and received the grant to write this document. 
The aim of this project is to produce a stringent and critical review of the scientific literature 
concerning asbestos exposure and its causation of lung cancer. There will be particular emphasis on 
the dose-response relationship between low-level asbestos exposure and lung cancer. The possibility 
of establishing a safe low-level no effect threshold will be investigated. The project will elucidate how 
asbestos should be compared to and weighed against other lung cancer causes. The resulting document 
will provide a solid evidence base for developing new guidelines how asbestos-related lung cancer can 
be identified and recognized as a compensable occupational disease. 
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2. BACKGROUND
2.1 LUNG CANCER 
EPIDEMIOLOGY 
There is strong evidence that exposure to asbestos causes asbestosis, pleural and peritoneal 
mesotheliomas as well as lung cancer [1-4]. The evidence is based on both human and animal 
evidence. 
Lung cancer is the most commonly diagnosed cancer worldwide with an estimated 1,600,000 new 
cases and 1,380,000 deaths in 2008 [5, 6]. In Denmark lung cancer accounts for 13.3% of all new 
cancers in males and 12.3% of all new cancers in females. Since the 1950s lung cancer incidence has 
steadily increasing among females.  In males morbidity and mortality was declined after the 1980s [7]. 
Smoking is the main cause, but occupational, environmental and life style exposures may play a role. 
HISTOLOGY, STAGING OF LUNG CANCER AND CHANGES IN CELL TYPE OVER TIME 
Lung cancer is classified according to pathohistological types into two major groups: small cell lung 
cancer (SCLC) and non–small cell lung cancer (NSCLC). SCLC accounts for about 15% of all cases 
and is characterized by early hematogenous dissemination, rapid progression and poor prognosis [8]. 
NSCLC includes squamous cell carcinoma, adenocarcinoma, large-cell carcinoma and some rare 
subtypes. NSCLC (approximately 30% of all cases) has been shown to be more frequent in men, 
whereas adenocarcinoma (approximately 30%–40% of all lung cancer cases) is more frequent in 
women. Adenocarcinoma is more frequent in non-smokers than in smokers. Patients are staged 
according to the International System for Staging Lung Cancer. Over the last few decades, the 
proportion of squamous-cell carcinomas, which used to be the predominant type, has decreased while 
adenocarcinomas have increased [9]. 
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VALIDITY OF LUNG CANCER DIAGNOSIS 
Most lung cancer cases in Denmark are diagnosed pathologically based on cytology or histology. 
Standardized methods are used for both preparing and reading specimens [10, 11]. NCH has reviewed 
all cases of lung cancer diagnosed at the Department of Pulmonary Medicine, Odense University 
Hospital between 2007 and 2010. A total of 856 lung cancer cases were diagnosed. Of these 40 (4.7 
%) were based only on a clinical diagnose. Thus, 95.3 % had a pathological diagnosis. Data for all 
lung cancer cases in Denmark were not available.  
2.2 ASBESTOS 
DEFINITION OF FIBER TYPES AND EXPOSURE CATEGORIES 
Asbestos is a generic term that represents six naturally occurring fibrous minerals that can be generally 
grouped based on chemical composition differences into two distinct classes: serpentine and 
amphibole. The serpentine class includes chrysotile (white), while the amphibole class includes 
amosite (brown), crocidolite (blue), tremolite, actinolite, and anthophyllite asbestos [1].The two main 
classes differ significantly in terms of their physical and chemical properties, which result in a much 
greater degree of biopersistence of amphibole fibers. Chrysotile fibers form large parallel sheets, but 
are curly and pliable due to the misfit between the two layers [12]. In contrast to chrysotile, 
amphiboles are arranged in long, linearly-organized chains, forming straight, inflexible, rod-like and 
relatively acid-resistant fibers that have more tensile strength than chrysotile [13]. Chrysotile fibers are 
cleared more readily by mucociliary action and more easily broken down [14]. Amphibole fibers are 
far more resistant with a much longer residence time [15-17]. The biological half-life of inhaled 
amphibole fibers is in the range of years to decades, whereas the half-life of chrysotile fibers is only 
days to weeks [13, 18, 19]. 
Assessment of asbestos exposure can be grouped into three categories: occupational exposure (worker 
and by-stander), non-occupational exposure, and environmental exposure. Occupational exposure 
occurs in the workplace where asbestos-containing products were manufactured or used.  There is also 
potential for by-stander exposure in the occupation setting [20]. Non-occupational exposure may 
involve non-occupational asbestos containing product use and secondary exposure from 
occupationally exposed worked, “take-home” exposure [21]. Environmental exposure may result from 
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either a naturally occurring point source or contamination of the water or air supplies from 
anthropologic means. 
MEASURING METHODS IN A HISTORICAL PERSPECTIVE 
A reliable means to collect and quantify airborne levels of asbestos is required to accurately evaluate 
lung cancer risk in relation to occupational asbestos exposure. Unfortunately, there are many 
uncertainties pertaining to historical airborne fiber concentration data. Methods to collect as well as 
analyze airborne fiber samples have changed dramatically over the past 80 years. Prior to the 
impinger, early methods of dust collection included the sugar tube, the Palmer apparatus, the 
konimeter, the filter paper thimble, and the dust determinator. However, the results from these 
methods were not regarded as absolute. The impinger and later the midget impinger were devised to 
reconcile the comparability issues starting in the 1930s [22]. The concentrations of particulates were 
first assigned units of million particles per cubic foot (mppcf; 0.1 mg/m3 = 1 mppcf). The usefulness 
of the impinger method is limited by short sampling periods, difficulty in differentiating asbestos from 
non-asbestos fibers and poor efficiency [23, 24]. 
The membrane filter method from the late-1950s allowed for full-shift sampling and could be used 
with PCM and TEM [25, 26]. PCM does not discriminate between asbestos and other fibers. The 
concentrations of fibers were assigned units of fibers per milliliter (f/ml=f/cc) and defined being 
greater than 5 µm in length, 0.25 µm in diameter, and having greater than a 3 to 1 aspect ratio [27]. 
Unlike PCM, TEM can differentiate between asbestos mineral fiber types and distinguish asbestos 
fibers from non-asbestos fibers [28, 29]. The reference TEM method specifies asbestos structures 
(fibers, bundles, clusters, and matrices), all sizes, widths, and aspect ratios [29]. Although TEM has 
much greater sensitivity than PCM and scanning electron microscopy (SEM), TEM data cannot be 
compared to historical airborne fiber concentrations collected by PCM. 
UNCERTAINTIES IN ASBESTOS AIR MEASUREMENTS 
Many historical studies collected exposure data using the impinger (and midget impinger) method. 
Therefore, it is necessary to convert this data, which is reported as mppcf (or mg/m3) to f/ml in order 
to be used in a contemporaneous exposure assessment. Unfortunately, there are no standard methods 
to convert mppcf to f/ml. One mppcf using the impinger method was roughly equivalent to 6 f/mL 
when counting fibers >5µm in length using the membrane filter method [23]. Historical measurements 
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can only be converted using this conversion if sample was collected using the impinger method. The 
use of other collection methods would add further uncertainty to this estimated conversion. 
HISTORICAL TREND IN ASBESTOS USE IN DENMARK 
Denmark has no asbestos mines. Thus all asbestos has been imported. The first partial ban was 
introduced in 1980. Asbestos cement products were however not included. Six years later a complete 
ban on amosite and crocidolite asbestos, including asbestos cement products was enacted. Only 
asbestos gaskets for special purposes were allowed. Finally, in 2004 chrysotile was included. Figure 1 
shows the annual imported asbestos to Denmark from 1943 to 2003. 
Figure 1 Annual imported asbestos to Denmark, 1943-2003 [30]. 
INDUSTRIES AND JOBS WITH POTENTIAL ASBESTOS EXPOSURE 
The most important sources of asbestos exposure are described in the table below. 
20 
Table 1. Industries with potential asbestos exposure [31]. 
239 cases of ARLC were recognized by the National Board of Industrial Injuries in Denmark between 
2207 and 2010. The main occupations are describes in table below. All DISCO codes for the 239 cases 
are shown in appendix 1. 
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Table 2. Main occupational groups with recognized ARLC in Denmark 2007-2010 [32]. 
DANISH OCCUPATIONAL ASBESTOS MEASUREMENTS 
In appendix 2 occupational asbestos measurements are presented. There are measurements from 4 
Danish sources. In addition, the data is supplemented with measurements from a Swedish asbestos 
cement industry as well as with data from a Danish review article that presents a summary of 
international asbestos measurements. 
Unfortunately information about measurement methods and how they counted and analyzed the data is 
not available. For example is it unknown how an asbestos fiber is defined, if TEM or scanning has 
been used, and for most studies if it is person-borne or area measurements. This un-standardized 
method for asbestos measurements made comparison between data from different studies problematic.  
REPORTED AND COMPENSATED ARLC IN DENMARK 
The below table (men only) shows the number of reported and compensated ARLC cases in Denmark 
between 2004 and 2010. The total number of lung cancer cases from the entire country obtained from 
the Danish Cancer Registry is also included in the table. 
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Table 3. Reported, compensated and total lung cancer cases among Danish men 2004-10 (Data 
from The National Board of Industrial Injuries in Denmark [33]. 
2.3 HISTORICAL REVIEW OF RISK ASSESSMENTS OF ARLC 
The U.S. Environmental Protection Agency (EPA) and the Occupational Safety and Health 
Administration  have developed and evaluated several risk models. The basic approach was developed 
in the early 1980s. Briefly, data on asbestos exposure and cancer outcomes was drawn from fifteen 
epidemiologic studies (11 lung cancer and 4 mesothelioma). It should be noted that each of these 
studies individually have issues, such as data gaps and classification problems. A dose-response 
relationship, called the potency factor (K), was then developed for each individual study. Potency 
factors were generated for both lung cancer (KL) and mesothelioma (KM). Finally, a new dose-
response model was constructed based on the composite potency factors for lung cancer and 
mesothelioma. The 1983 Nicholson dose-response model is based on the following assumptions: 
• Chrysotile and amphiboles have equal potency.
• All fibers longer that 5 µm have equal potencies.
• There is no threshold exposure level for carcinogenicity.
• There is a multiplicative interaction between smoking and asbestos for lung cancer.
• Relative risks for lung cancer are linearly with cumulative exposure based on 10 year lag
time.
23 
Both OSHA and the EPA have used this model for more than 25 years. In 1993, the EPA further 
developed the Nicholson model and formed their current asbestos policy: Carcinogenicity over Life-
time Exposure [34]. The EPA repeated their previous caution that quantitative estimates are limited by 
uncertain exposure estimates, lack of early exposure data and uncertain conversion between various 
analytic measurements. In the mid-1990s the EPA attempted to develop a more comprehensive and 
updated risk model [35]. The Berman & Crump model added 6 modifications to Nicholson’s original 
model. 
• Twenty lung cancer and 14 mesothelioma studies were included
• Chrysotile and amphibole potency factors were estimated separately
• New fiber dimension categories were used
• Correction factors were applied to historic fiber counts based on selected TEM
• A new parameter was added to the lung cancer model in an attempt to account for
differences between background lung mortality rates and rates in studied populations
• Statistical models to calculate uncertainty ranges in exposure data were added
The 2003 final report acknowledged key data flaws: unrepresentative sampling strategies, use of 
surrogate estimates in the absence of actual asbestos measurements, lack of data from earlier time 
periods and use of area samples instead of personal breathing zone measurements. However, this final 
report was never adopted by the EPA.  
In 2003, the EPA initiated a renewed attempt to further develop the asbestos risk model. The new 
proposed OSWER risk assessment model, based on 23 lung cancer and 8 mesothelioma studies, was 
completed in 2008 [36]. A new Bayesian Markov Chain Monte Carlo statistical method was adapted 
to better fit risk models with epidemiological data. The model estimated cancer potency for 20 “bins”; 
each bin is composed of different combinations of asbestos fiber types and dimensions. It was 
reviewed by the EPA’s Scientific Advisory Board (SAB), which found that the scientific basis for the 
model was weak and inadequate primarily due to the lack of available TEM data to estimate exposure 
levels. The EPA agreed that exposure data was inadequate and the proposed model was not pursued 
further. 
Many countries including Denmark base their compensation policies on the 1997 Helsinki criteria (see 
appendix 3). 
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3. METHODS
This review was performed by following standard methodology inspired of Wright and colleagues 
[37]: formulating primary research questions, devising of a research protocol, literature search, data 
extraction, quality appraisal, data analysis with a simple descriptive evaluation of each study and 
finally interpretation of results. The formulation of research questions was obtained directly from the 
grant announcement and resulted in 19 search questions divided into 4 main groups: lung cancer (LC), 
asbestos exposure (AE), dose- response (DR) and competing and predisposing conditions (CPC) with 
4, 5, 5 and 5 questions, respectively (appendix 4). On the basis of these search questions, relevant key 
statements for each main area were composed (appendix 5). These statements were carefully thought 
out as to be particularly useful when evaluating compensation cases. 
3.1 SEARCH STRATEGY 
To reach all relevant original epidemiological articles the search strategy consisted of a series of top-
down and bottom-up librarian-assisted searches. The top-down searches were performed on July 2-3, 
2012 in the electronic bibliographic databases PubMed Medline and EMBASE with the search terms 
asbestos and lung cancer. The combination of the two databases was chosen to achieve the best 
coverage of both U.S. and European Journals. Afterwards, the hits from the two databases were 
merged and duplicates removed. 
The bottom-up search to identify additional relevant studies consisted of 19 specific searches for each 
of the predefined search questions. This procedure was performed between July 23 and 27, 2012 and 
was restricted to PubMed Medline. An overview of search details is given in appendix 6. Before the 
pools of hits from the top-down and bottom-up searches were merged a comprehensive citation 
selection was performed. 
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3.2 SELECTION OF PUBLICATIONS USED IN THE ANALYSIS 
The selection of publications to be included in the analysis was a multistep, iterative process. A flow 
diagram of the process is given in appendix 7. Studies were included when the main focus was on 
associations between lung cancer and asbestos exposure. The exclusion criteria were: 1: case reports, 
case series or expert opinions, 2: very old publications and/or small study populations, 3: high risk of 
bias and 4: older studies that were follow-up with a more recent updated publication. 
Step 1 - 1st screening 
The initial top-down broad literature searches in PubMed Medline and EMBASE yielded 4,088 
discrete publications. The citations were rapidly screened for inclusion eligibility. If the title was out 
of the scope of the review one member of the writing group (DS) deemed the citation ineligible for 
further consideration (n=3,677). An example of an ineligible citation is: A breath test for malignant 
mesothelioma using an electronic nose [38]. In addition the remaining citations were grouped into four 
groups: Lung cancer (LC) (n=88), asbestos exposure (AE) (n=119), dose-response (DR) (n=155) and 
competing and predisposing conditions (CPC) (n=93) with the possibility for a citation to appear in 
more than one group. Even articles not primarily in English were considered eligible and grouped if 
they included an English language abstract (n=4). This was done to reduce the risk of English 
language bias because positive findings are more likely to be published in English [39]. 
Step 1 - 2nd screening 
After the first screening and grouping the 455 citations in the four groups (LC, AE, DR and CPC) 
were further screened for inclusion eligibility based on their abstracts. This was done by the same 
member of the writing group (DS). Afterwards the remaining citations were sub-grouped according to 
the 19 search questions, i.e. citations from the LC group were grouped into LC1-4B, and citations from 
AE, DR and CPC were grouped into AE1-5B, DR1-5B and CPC1-5B respectively. B refers to the broad 
search, resulting in 166 citations in the 19 groups. Again, it was possible for a citation to appear in 
more than one group (see appendix 7). 
Step 2 – 3rd screening 
The next step consisted of the PubMed Medline specific bottom-up searches based on the 19 search 
questions. The citations were grouped according to their associated search question, which resulted in 
19 groups: LC1-4S, AE1-5S, DR1-5S and CPC1-5S, where S refers to specific search. DS screened the hits 
in each group for inclusion eligibility based on title and abstract. 
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Step 3 – Merging of hits 
The hits in the 19 groups from the top-down search were merged with the hits in the corresponding 19 
groups from the bottom-up searches and doublets removed: LC1B was merged with LC1S and called 
LC1B+S, LC2B was merged with LC2S and called LC2B+S etc. 
Step 4 – 4th screening 
In order to exclude papers that lacked sufficient data or analytic structure to warrant in-depth review 
DS made a fourth screening of the articles in the 19 groups based on exclusion criteria. The numbers 
of articles in each group after this procedure are shown in appendix 7 under 4th screening. 
The pool of citations from the electronic searches was supplemented with additional relevant citations 
achieved by manual review of the bibliographies. In addition, bibliographies of review articles and 
meta-analysis were searched as well as inputs from the writing group given (n=123). Finally, a few 
recent citations were identified through PubMed alerts that appeared after July 3, 2012, which was cut-
off for the broad electronic key word electronic search. The added number of citations for each 
subgroup is shown in brackets in the rightmost column in appendix 7. 
3.3 DATA EXTRACTION OF PUBLICATIONS DEEMED ELIGIBLE 
For the original studies a data extraction sheet based on the Scottish Intercollegiate Guidelines 
Network and adjusted to the present review was developed (appendix 8) [40]. In addition to the 
generic items containing study design, study population, exposure measurement, outcome 
measurement, potential study limitations and description of key findings, more specific data collection 
items on exposure and outcome measurement were added. 
Initially it was planned to double review all included articles with the data extraction sheets. However, 
due to time limitations, the main focus was placed on the key questions concerning dose-response as 
well as lung cancer histology and location. The 6 meta-analyses and 3 reviews related to the dose-
response questions were double evaluated with the R-AMSTAR checklist quality assessment sheet 
(appendix 9) [41]. 
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3.4 QUALITY APPRAISAL 
In August 2012 the members of the writing group (DS, JB, JR, SD, MA and LSN) were divided into 
review teams to systematically read, evaluate and quality grade the full papers concerning the dose-
response association. Each of the 28 original articles of cohort and case control studies, 6 meta-
analysis and 3 reviews were read and graded by two members of the writing group. Afterwards, the 
quality appraisals were compared and discrepancies reconciled by mutual agreement. A member of the 
group (MA) was co-author of one of the included publications and was therefore disqualified as a 
reviewer of that publication. Five publications related to the two lung cancer questions LC3 and LC4 
were subsequently evaluated with the same method (DS and KEO). Cohort and case-control studies 
were restricted to 2++ (very low risk of confounding, bias, chance), 2+ (low risk of confounding, bias, 
chance) or 2- (high risk of confounding bias, chance), with 2+ as the most common grade. For meta-
analysis and reviews the R-AMSTAR score was a mean of the two independent scores. 
3.5 STRUCTURE OF DATA PRESENTED 
The result section is structured around the 4 main question groups: Lung cancer, asbestos exposure, 
dose-response and competing and predisposing conditions. Data presentation is structured differently 
depending on whether data extraction sheets had been completed. For two lung cancer questions (LC3 
and LC4) and the key dose-response question (DR1) the meta-analyses and reviews as well as original 
studies achieving 2+ or better quality appraisal were included and presented as both narratives and 
tabular format. In addition, original studies with a 2- grade are also presented in table form as they also 
added useful information. The narrative descriptions in appendix include basic study design 
information and key findings. The table presentation includes more details of the study including 
strengths and limitations as well as the final quality grading. All included references concerning the 
questions where data extraction sheets were not filled out were carefully read and relevant and 
essential results were summarized in text form. A brief summary of key findings concludes each result 
section. Information in the summaries is particularly relevant to the related statements. 
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3.6 ASSESSMENT OF CAUSAL ASSOCIATION 
The final evaluation the causal association of each statement was assessed using the evidence model 
recommended by the Danish Working Environmental Authority (appendix 10). The model uses the 
following categories: 
+++ Strong evidence for a causal association 
++ Moderate evidence for a causal association 
+ Limited evidence for a causal association 
0 Insufficient evidence for a causal association 
- Evidence suggesting lack of a causal association 
3.7 REVIEW AND REVISION OF THE FINAL REPORT 
In November 2012, the first draft of the document was sent to an expert group (internal reviewers) for 
comments and corrections. In addition, a two-day seminar with 15 participants from the writing and 
internal expert groups was held to discuss major issues and reach a consensus regarding statement 
grading (see appendix 11 for the seminar program and list of participants). After revising the first 
draft, a second draft was provided to two external reviewers for their comments. The third and final 
draft was edited based on the external reviewers’ comments. 
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4. RESULTS
4.1 ARLC: HISTOLOGY, LOCATION, PROGNOSIS AND SCREENING 
SUMMARY 
Earlier studies were poorly controlled and showed inconsistent results concerning lobe of origin and 
histology of ARLC. More recent well-controlled studies have failed to show any significant 
differences between ARLC and non-ARLC regarding cell type or location. Our literature search did 
not find any references that specifically dealt with the prognosis of ARLC. The only available data 
was obtained from reviewing lung cancer cases at the Pulmonary Department, Odense University 
Hospital. No survival differences were seen in Kaplan-Meier curves when ARLC and non-ARLC 
cases were compared (see appendix 12, figure A2). The U.S. National Lung Screening Trial (NLST) 
has recently demonstrated a relative mortality reduction of 20%. On this background the National 
Comprehensive Cancer Network (NCCN) published recommendations in 2012 concerning low-dose 
CT screening for heavy smokers including those with previous asbestos exposure. Screening is costly 
and complicated by numerous false positives. Results from the ongoing European prospective 
screening trials are not yet available [20, 42-72]. These subjects are reviewed in appendix 12. 
Statement 1 
When evaluating ARLC location and cell types do not differentiate asbestos and non-asbestos related 
lung cancer. (+++) 
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4.2 ASBESTOS EXPOSURE 
EXPOSURE ASSESSMENT 
Reliable and valid assessment of asbestos exposure is critical in risk estimations, since exposure 
misclassification might bias and attenuate risk estimates. In general, three steps are involved in an 
exposure assessment: hazard identification, dose-response analysis, and exposure quantification. The 
results of these steps are combined to produce an estimate of risk. Reliable retrospective asbestos 
exposure assessment continues to be a challenge in most population-based studies [73]. 
An asbestos exposure assessment should comprise a multidimensional approach. A careful exposure 
history from a face-to-face interview is the first and most important step. Questionnaire, expert 
assessments, job exposure matrices (JEMs) and measurement data from the workplace and the 
published literature can provide useful supplementary information [69, 70, 74]. For the purpose of 
conducting an exposure assessment, it is acceptable to rely on a combination of qualitative, semi-
quantitative and quantitative exposure metrics. 
Case-by-case expert assessment is generally considered the best possible method for assessing 
exposure in population-based studies. Expert assessment enables one to take into account exposure 
differences between individuals with similar jobs, which can result in less exposure misclassification.  
However, the estimate of an expert can also be of such poor quality that true exposure-effect 
relationships can be obscured or even reversed in direction [75]. In comparison to measured 
exposures, expert assessments are usually slightly better than self-reports, but then again there is great 
variability in reliability and validity estimates by agent and study [76]. 
Questionnaires are frequently used in the exposure assessment of occupational and environmental 
epidemiological studies. Questionnaires may allow a larger study size and greater statistical power 
than would be possible with more accurate measurement techniques. However, very few standardized 
exposure questionnaires have been validated and therefore the extent of exposure misclassification and 
the effect on risk estimates leaves uncertainty whether the questionnaire actually measures what it 
needs to measure [76].  
Retrospective occupational exposure assessments remain a challenge in most population-based 
studies, because accurate exposure measurements are not available. The main advantage of using a 
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JEM is that occupations are translated into specific exposures in a standardized way giving a more 
reproducible methodology [73]. The job titles, collected from a questionnaire, can then be applied to a 
JEM where coded job titles can be converted to estimates of exposure levels for known/suspected 
occupational lung carcinogens including asbestos [77]. JEMs allocate the same exposure estimate to 
all workers within a job code, thereby disregarding possible inter-individual variability within job 
codes. This is a major drawback since there may be large differences in exposure levels between 
individuals with the same job in the same company. JEMs can be quite different in their assessment 
approach e.g. DOMJEM (asbestos, PAHs), FINJEM (asbestos, PAHs and welding fumes) and 
Asbestos JEM [78]. Therefore, care should be taken when choosing the appropriate JEM. 
Uncertainties in exposure assessment may have strong implications for both the health risks of 
exposed workers and for the industries to achieve safe exposure levels [79]. Although, case-by-case 
expert assessment and JEMs are commonly used, reliability of questionnaires and of a JEM depends 
on study design, exposure of interest, and the quality of work history/exposure information available. 
Case-by-case expert assessment is generally considered the best possible method for assessing 
occupational exposures in population-based studies; however, it requires considerable resources [80-
82]. JEMs have proven to be rather similar in agreement when compared with the expert assessment 
and could therefore be appropriate to use in asbestos exposure assessment. 
In summary, a sufficient occupational history combined with an appropriate JEM and published 
measurements can be considered to give the most reliable estimate of asbestos exposure. 
Statement 2 
Job Exposure Matrices (JEMs) are useful in estimating previous asbestos exposure in addition to 
individual exposure evaluation. (+) 
BIOLOGICAL MARKERS: PLEURAL PLAQUES (PP), ASBESTOS BODIES (AB) AND 
ASBESTOS FIBERS (AF) 
SUMMARY 
Numerous studies have verified that PPs are associated with previous asbestos exposure. They usually 
develop after about 20 years, but may occur as early as 10 years after exposure. PPs are particularly 
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useful as a marker of asbestos exposure when they are bilateral and other causes have been eliminated. 
They are best identified with CT scans. PPs do not reflect the degree of exposure. AF and AB counts 
in BAL and lung tissue are associated with asbestos exposure. In Denmark there is neither tradition 
nor routine in identifying and counting ABs and AFs. Identifying ABs and AFs in BAL or lung tissue 
reflects some degree of asbestos exposure. However, the absence of PPs, ABs or AFs does not 
preclude considerable previous asbestos exposure [83-108]. This area is reviewed in appendix 13. 
Statement 3 
The existence of pleural plaques increases the likelihood of previously asbestos exposure. (++) 
Statement 4 
The presence of pleura plaques cannot be used to estimate degree of previous asbestos exposure (+++) 
Statement 5 
The presence of asbestosis is a marker of previously high asbestos exposure and is associated with an 
increased risk of lung cancer. (+++) 
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4.3 DOSE RESPONSE 
INTRODUCTION 
Estimation of dose–response has been dealt with in numerous studies, which have been analyzed in 
reviews and meta-analyses. In the individual studies the validity of the measured dose-response 
relation relies on the following parts: 
Quality criteria for individual exposure: 
Coverage with measurements, quality of measurements, conversion factors between 
different methods. 
The dose implies an at least semi-quantitative, but preferably quantitative estimation of the individual 
lifetime asbestos dose expressed as the average air concentration in fibers per ml times the number of 
years exposed (f-y/ml). In most studies exposure has been collected in categories where all persons 
have been assigned the mean or median group exposure. At least two groups are needed, but 
preferable more. Categorical analysis may be sensitive to the choice of cut-off points. 
Quality criteria for response measures: 
Length and completeness of follow-up of cases and survivors, diagnosis quality. 
Comparison with a relevant reference population without exposure.  
The response in a group has been estimated as a relative risk (RR) in relation to the unexposed 
controls. Most cohort studies have used Standard Mortality Ratio (SMR), which calculates an 
expected number of deaths in the exposed group having the same age- and sex-specific mortality 
/morbidity as the reference population. SMR is then obtained from the number of observed cases 
divided by the number of expected cases. The age distribution of the cohorts has a considerable 
influence on SMR. 
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Quality criteria for the analysis: 
A sufficient span in exposure levels and number of observations in each group. 
Information about competing factors for lung cancer among the studied population, 
mainly smoking habits and other occupational exposure to carcinogens. 
Analysis of dose-response relationship implies a hypothesis in the form of the curve. A linear relation 
has been the primary model where the RR increases steadily with the dose (in f-y/ml) and RR.  In a 
formula this can be shown as: 
RRexp i = 1 + kL * expi
This model suggests that RR is 1 when exposure is 0, and kL denotes the increase in RR per unit of 
exposure measure, i.e. the potency of carcinogenicity. 
However, as the investigated population is not always compatible with the reference population a 
constant link is inserted 
RRexp i = ai (1 + kL * expi) 
where ai is the RR of  population i with no exposure. In the case of lung cancer, ai >1 is often assumed 
to be due to more smoking in the exposed population than in the reference population. However, it 
may also be due to misclassification of exposure (e.g. subjects with high exposure being misclassified 
as having low exposure). 
Various ways of expressing kL have been shown in different articles. In the present paper all these 
have been expressed as the number x 10-3 (f-y/ml)-1 (i.e. n excess cases in 1000 persons for each 
increase in f-y /ml).  
A deviation from linearity has also been tested.  This can be lower than expected at low exposures 
suggesting a threshold for the carcinogenicity, or lower than expected at high exposures, suggesting 
competing causes of death (e.g. a high proportion of workers dying from asbestosis since this occurs 
earlier than lung cancer at high exposure intensities), or misclassification of exposure. More recently 
methods to analyze dose-response, which do not assume linearity have been introduced (fractional 
polynomial and spline regression), but they have only been used in few studies included in this review.  
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Since solid cancers, like lung cancer, usually develop over more than a decade from initiation until 
clinical diagnosis (latency time). Cancers occurring during the first 10-15 years after onset of exposure 
have often been excluded in cohort analyses. In analogy, the exposure accumulated during the last 10-
15 years before end of follow-up is sometimes excluded from the total dose metric (10-15 year lag).  
The influence of life style factors, mainly smoking, has been included to a various degree. Few studies 
have individual information, while others make assumptions of trade- and job-related smoking 
frequencies in the different time periods. These factors and the fact that exposure has taken place over 
several decades adds to the large heterogeneity of the dose-response estimate. 
ORIGINAL STUDIES 
There are 28 original studies of which 24 are cohort studies and 4 are case control studies [109-136]. 
A tabular presentation of the studies inclusive their distinctive features, strengths, limitations and a 
grading are given below. In addition, narratives of the studies are presented in appendix 14. 
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Table 4. Tabular presentation of cohort studies 
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Table 5. Tabular presentation of case-control studies 
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REVIEWS 
Hendersson, 2004 [137] 
This review includes studies between 1997 and 2004 containing information on: interactive effects of 
asbestos and smoking, lung cancer-/mesothelioma ratios and the cumulative exposure model for lung 
cancer. The search methodology is weak and does not include search terms and number of hits. 
However, this review is extremely informative based on the extensive number of references (346), 
which are insightful organized and discussed by an obviously very knowledgeable author. There were 
no significant differences in the phenotypic repertoire or the anatomical distribution of lung cancers 
related to asbestos versus those that are not. All 4 major lung cell types occur among asbestos-exposed 
subjects with no differences when compared to controls. For asbestos-exposed patients with PPs as the 
only tissue marker of past exposure, the increase in lung cancer RR may be too small (<1.5) after 
allowance for other factors such as tobacco smoke. Thus the use of PP as a marker of significant 
asbestos exposure is questionable. Evidence supports a cumulative exposure model. Different 
attribution criteria (e.g. greater cumulative exposures) are appropriate for chrysotile-only exposures. 
There is insufficient evidence to draw meaningful conclusions concerning variation in asbestos-
mediated lung cancer risk relative to individual resistance and susceptibility factors. R-AMSTAR 
score 16 of 33. 
 
Pierce, 2008 [138] 
This review concentrates on the stratification of mortality or RR for predominantly chrysotile-exposed 
cohorts. A systematic literature search found over 300 studies. After careful review only 14 studies 
were included. The preponderance of cumulative “no-effect” exposures (i.e. no statistical significance) 
for lung cancer were about 25-1000 f-y/ml.  However, many studies were too small and thus lacked 
statistical power to assess possible increased risk at the reported “no effect” level. This is an 
interesting review, but due to the above mentioned limitations a lack of statistical significant increased 
risk cannot be equated with true no effect level. R-AMSTAR score 20.5 of 44. 
 
Steenland, 1997 [139] 
This older review was quite broad covering silica, man-made mineral fibers as well as asbestos. 
Twenty four asbestos cohort studies were included. A systematic literature search was not performed. 
Among these studies 15 showed an exposure response. The lowest lung cancer risk among workers 
was found in cement and friction products industries. Highest risks were among mining and textile 
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workers. Smoking differences could not explain the variable industry risks. Smoking-asbestos 
interaction is between additive and multiplicative. R-AMSTAR score 15 of 44. 
META-ANALYSIS 
A series of meta-analyses elucidating dose-response relationships based on more than 50 
epidemiological studies have been carried out (appendix 15). They cover different aspects of asbestos 
exposure, mainly related to type of asbestos (amphiboles vs. chrysotile) and type of industry, mining 
milling, asbestos cement workers, textile fiber processing, brake production and repair). 
The oldest is the paper by Michael Goodman et al. [140]. They collected 69 cohorts of various 
asbestos exposed groups and various forms of cancers. Lung cancer was analyzed based on 37 /69 
studies including 10 or more years latency and 55/69 studies without. They only looked on SMRs in 
the various groups and did not take into account any exposure level information. Analyses were made 
both without and with 10 years latency. A rough indication of exposure was suggested by grouping the 
studies in three groups according to the percentage of deaths of mesothelioma. 
The main result was very large heterogeneity of the studies with SMRs ranging from unity (=100) to 
1,700 in Finnish asbestos sprayers. Including latency increased the common SMR from 148 (144-152) 
to 163 (158-169), but it was not shown whether this increase was due to exclusion of 18 studies or 
inherited within the single study. 
Some variation between different occupations was seen, with asbestos product manufacturing and 
cement workers having the highest SMRs (196 (95% CI 176-209) and 170 (156-185), respectively. 
Railroad workers and friction material workers having the lowest (90 (79-101) and 112 (101-124), 
respectively. All estimates included 10 years latency. 
An attempt to show some dose-response was done by stratifying studies by the proportional 
mesothelioma mortality. 13 studies with more than 2.4% mesothelioma deaths  showed a common 
SMR of 285 (271-299) while the those below 0.6% and between 0.6% and 2.4 % had values of 127 
(121-134) and 138 (126-151), respectively. Without latency the latter two groups differ a bit more. 
However, the expert group noted that mesothelioma mortality is not an optimal marker for cumulative 
dose, since mesothelioma risk is heavily dependent also of latency time and fiber type. Also, variation 
in proportional mortality is determined not only by the index disease but also by the total mortality. 
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Given the very large heterogeneity and varying quality of the studies included, only limited 
information on dose-response can be obtained from this meta-analysis. R-AMSTAR score 16 of 44. 
 
Lash et al [141] explored dose-response associations, based on cumulative dose, in cohort studies 
published 1966-1995 with a focus on sources of heterogeneity. Based on 15 cohorts (reported in 22 
publications) they found that estimates of the study specific dose-response coefficient (kL) ranged 
from 0 to 42 x 10-3 f-y/ml. They identified mainly smoking habits and type of asbestos industry, but 
also standardization to different populations between the cohorts, and possibly conversion between 
different measures of asbestos exposure (i.e. between mppcf and f/ml), as sources of heterogeneity. 
The effect of fiber type (predominantly chrysotile, mixed, or other) was not significant when type of 
industry (mining and milling, asbestos cement and cement products, or manufacturing and textile 
products) was accounted for, nor was cohort age, calendar period of exposure, or duration versus 
concentration of exposure. Under the random effects model, implemented due to the heterogeneity 
between the studies: the maximum likelihood estimate of kL was found to be 2.6 x 10-3 (95% CI 0.65 
to 7.4 x 10-3) (f-y/ml)-1 and the estimate for the intercept (ai) to be 1.36 (95% CI 1.05 to 1.76). The 
expert group noted that study quality was not included in the assessment. R-AMSTAR score 19 of 44. 
 
Hodgson (2000) [142] reviewed cohort mortality based on studies with quantified exposure data. 
Seventeen studies were selected, from the studies included in 3 earlier reviews: Doll and Peto, 1985 
[143]; Health Effects Institute, 1991 [4]; INSERM, 1996 [144]. For each study a single risk rate per f-
y/ml was calculated and common values were calculated for amphiboles, mixed fibers, and pure 
chrysotile. Excess lung cancer risk for amphibole exposure was about 5% per f-y/ml. For mixed fibers 
and chrysotile large heterogeneities were seen. Chrysotile risk was less consistent, around 0.1 to 0.5% 
per f-y/ml with very large span, especially between the Quebec miners and the South Caroline textiles. 
Inter-study dose-response for amphibole suggests a non-linear relationship, between linear and square. 
However, due to statistical uncertainties a linear relationship remains arguable for lung cancer. The 
study confirms the very large heterogeneity also shown by Lash et al. [141]. No specific evaluation of 
study quality was made. R-AMSTAR score 21 of 44. 
 
A recent meta-analysis conducted by Lenters et al. (2011) [145] explored the slope of the dose-
response associations in 19 original epidemiological studies (including one population-based case-
control study) from a literature search covering the period 1950-2009, based on classification of five 
aspects of the quality of the exposure assessment (documentation, contrast in exposure, conversion 
factor between measurement methods, coverage of exposure data, completeness of job histories). 
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Three independent quality assessments were performed for each study. Stratified by quality in the 
exposure assessment, they found that studies with better exposure assessment generally had higher kL 
values, and that this was most pronounced for studies with better exposure data, and better 
completeness of job histories. There was much less effect on the intercept. However, the studies with 
lower quality had on average higher intercepts, indicating that an observed intercept above RR=1 may 
partly be due to misclassification of exposure. Under the random effects model, the unrestricted meta-
kL was 1.3 x 10-3 (95% CI 0.4 to 2.2 x 10-3) (f-y/ml)-1, increasing by step-wise exclusion to kL 5.5 x 10-
3 (f-y/ml)-1, however only based on two studies. An effect of fiber-type was no longer evident when the 
analysis was restricted to high-quality studies, but the data for such comparisons were sparse in this 
category and thus inconclusive. Indications of publication bias were observed. The expert group 
observed that this paper met most quality requirements for a systematic review. R-AMSTAR score 34 
of 44. 
The paper by Lenters et al was based on a Dutch governmental expert report on asbestos [146]. A 
slightly different approach was taken her including 18 studies, which were excluded stepwise 
according to lack of information down to 4 with sufficient information. Furthermore a regression 
forced to origin (not including a constant) gave kL values increasing from 7.2 (CI95%:4.8-9.6) *10-3 (f-
y/ml)-1 to 16.4 (CI95%:3.4-29.5) *10-3 (f-y/ml)-1. 
A possible heterogeneity in the slope of the dose-response associations at high-dose and low-dose was 
investigated in a companion paper [147] covering the same 19 studies as Lenters et al. [145]. They 
fitted both linear and non-linear models to risk estimates of 104 exposure categories extracted from 
these studies. The best fit was obtained with a natural spline model. This model suggested a nearly 
linear increase in the relative lung cancer risk at low levels of exposure, and a slight decrease in the 
slope at exposures > 150 (f*y/ml)-1. The highest estimates were obtained when the model was fitted 
without an intercept (thereby not assuming a difference in background rate between exposed and non-
exposed subjects). For a cumulative exposure level of 4 f-y/ml the RR for lung cancer was estimated 
to be between 1.013 and 1.027, and for 40 f-y/ml to be between 1.13 and 1.30. The predicted risk was 
higher in studies that used a 10 year lag time (i.e. discarded exposure 10 years before end of follow-
up) as compare to those which did not (4 f-y/ml: RR=1.030 vs. RR= 1.012; 40 f-y/ml: RR= 1.329 vs. 
RR=1.126). Also, as observed by Lenters et al. (2011) [145], restriction of the analyses to studies with 
few or no limitations in the exposure assessment provided higher risk estimates than a non-restricted 
on (e.g. 40 f-y/ml: RR=1.301 vs. RR=2.019 for model fitted without intercept). A non-significant 
difference (3-4 folds) in the RR was observed between exposure to amphibole and mixed fibers versus 
chrysotile fibers for exposures below 40 f-y/ml. A sensitivity analysis showed that the estimates of the 
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lung cancer risk from low chrysotile exposure were heavily influenced by the Quebec mining 
(downwards) and South Caroline textile (upwards) studies. The authors suggest that the discrepant 
slopes in mining and textile may be due lower quality in exposure assessment and significant presence 
of non-asbestos structures counted as asbestos by phase-contrast microscopy in mining. The expert 
group noted that this review overall had a high quality? R-AMSTAR score 26 of 44. 
Berman and Crump (2008) [148] had access to and re-analyzed the raw data from the four major 
cohorts, the South Carolina textile cohort [112], The Australian Wittenoom cohort exposed to mainly 
amphiboles [149-151], the Quebec chrysotile mining cohort [120], and the New Jersey  insulation 
manufacturers cohort [127]. In addition they analyzed a number of studies from the published data in 
order to see the variation in kL and analyzed the different studies for uncertainty factors assigned to 
problems in exposure estimation, conversion factors, job histories with the former being by far the 
largest giving combined uncertainty factors between 1.5 [116] and 5.9 [152]. 
In the analysis of raw data they found that kL values were 3 to 10 times lower in models assuming α 
being estimated than when α was set to 1. However, they stated that the variability of α was far larger 
than differences in background rates could explain, but also reflecting uncertainties in exposure 
estimation.  In the study of published results including many of the same studies as Lash et al. they 
calculated “uncertainty intervals” based on the above-mentioned factors for each study. Using this 
method they showed a blurred picture. The association with industry seems to be at least as strong as 
for fiber type, mining being the least and textile production by far the highest. For mining, however, 
exposure to mixed or amphibole fibers showed higher kL values than chrysotile. As in other reviews a 
sharp discrepancy between the Quebec mining and South Carolina textile factory handling the same 
chrysotile asbestos stands out (values with the uncertainty intervals 0.29 (0.085-1.1) vs. 1.8 (7.5-5.6) x 
10-3 (f-y/ml)-1. 
Using the same studies, but categorizing the exposure according to fiber type, length and width the 
authors tried to correlate lung cancer and mesothelioma risk with these factors across the studies [148]. 
Contrary to mesothelioma the difference between chrysotile and amphiboles was less pronounced. 
Long fibers were more potent than short. However, these analyses still do not resolve the unexplained 
differences in potency seen in the different studies. 
 The expert group finds that the review is of high quality contributing with valuable information about 
uncertainties in the calculation of k L. R-AMSTAR score 23 of 44. 
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Statement 6 
The dose-response relationship is approximately linear, but levels off at very high doses (>150 f-y/ml). 
(+++) 
 
Statement 7 
An increase in RR of 1-4% per f-y/ml (corresponding to a doubling of risk at 25 to 100 f-y/ml) has 
been observed with the higher estimates obtained in the few high quality epidemiological studies. One 
high quality population-based case-control study in the low-dose range found a higher risk estimate (a 
doubling of risk around 4 f-y/ml). (++) 
NO OBSERVED EFFECT LEVEL (NOEL) 
The possible existence of a level where no cancer risk due to asbestos exposure exists has been 
discussed. Browne [153] looked at data from a series of cohorts and looked at risk rates at various 
exposure levels. Based on visual inspection of these dose-response patterns the author suggests that no 
increased lung cancer risk was seen below a dose of about 25 f-y/ml or at a level of risk for clinical 
asbestosis. The paper does not provide any formal statistics to back up the statement. 
 
On the other hand the various meta-analyses all have been based on linear models, which imply no 
threshold. In the population based study by Gustavsson [134] an elevated risk was seen at an estimated 
dose of 4 f-y/ml. The recent meta-analysis by van der Bij et al. [154] has analyzed the dose-response at 
especially low exposures and they calculate from a series of studies relative risks of 1.2 to 3% at 4 f-
y/ml and 12 to 32% at 40 f-y/ml not indicating any threshold, albeit in the lower doses the 
uncertainties in risk estimates causes them to be not significant from unity. 
 
Conclusion: the expert group does not evidence for a threshold for lung cancer risk due to asbestos. 
 
Statement 8 
There is no evidence for a NOEL concerning ARCL. (++) 
 
Statement 9 
The lowest documented increased ARLC risk is seen at about 4 f-y/ml. (+) 
52 
LATENCY 
Two types of latency have been defined assuming that it takes at least 10 years to develop a solid 
tumor as lung cancer. In studies two approaches have been taken, one is to only including subjects 
who were observed 10 years or more after first exposure (latency time). The other approach has been 
to exclude the last 10 years of exposure (lag time). 
Berman and Crump [155] on the other hand looked at the possible decrease in lung cancer risk after 
cessation of exposure based on re-analysis of the data from the two of the main cohorts (Wittenoom 
miners and South Carolina textiles) and find a striking difference with only a marginal decline in the 
Witttenoom cohort [149-151] exposed to crocidolite even after 40 years while a decline in RR was 
seen after 20- 30 years in the South Carolina cohort [112] exposed predominantly to chrysotile. 
The expert group concludes that lung cancer probably first develop some years after start of exposure. 
The risk of lung cancer after cessation of exposure does not decrease significantly before about 20 
years, but may not decrease at all. 
Statement 10 
Lung cancer risk decreases decades after the cessation of exposure. (+) 
Statement 11 
No minimal latency time for ARLC has been established. For practical purposes it can be assumed to 
be 10 years after exposure onset. (+) 
Statement 12 
The prognosis of ARLC does not differ from that of other lung cancers. (+) 
Statement 13 
All types of asbestos fibers are associated with lung cancer. (+++) 
Statement 14 
Different dose-response estimates for lung cancer have been reported according to fiber type 
(amphibole vs. chrysotile), size, distribution and industry. However, these patterns are not clear, when 
study quality is taken into account. Thus, there is not sufficient evidence to derive different risk 
estimates for different fiber types. (++) 
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4.4 COMPETING AND PREDISPOSING CONDITIONS 
DISEASES AND CONDITIONS INFLUENCING THE DEVELOPMENT OF ARLC 
SUMMARY 
Lung cancer develops in a minority of individuals exposed to carcinogens such as asbestos or tobacco 
smoke. This suggests that individual susceptibility is important. Family history of lung cancer predicts 
lung cancer risk. The risk of developing a second primary cancer is 5-11 times greater compared with 
patients without a malignancy. The genetics and molecular epidemiology of lung cancer are actively 
investigated. However, present knowledge is insufficient to calculate susceptibility when evaluating 
most cases of potential ARLC [156-175]  
A full review of this topic is though beyond the scope of this report. The above areas are reviewed in 
appendix 16. 
Statement 15 
There is insufficient evidence to include predisposing factors (age, sex, and genetics) in the individual 
apportionment of ARLC. (++) 
Statement 16 
It is rarely relevant to account for other diseases or disorders in individual apportionment assessments 
in Denmark. However, this does not apply to lung fibrosis of any origin. (+++) 
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RISK FACTORS FOR LUNG CANCER OTHER THAN ASBESTOS 
OCCUPATIONAL RISK FACTORS 
SUMMARY 
Asbestos workers have frequently been exposed to other occupational exposures, which should be 
considered when evaluating ARLC. Welding and PAH are among those often encountered. Two 
epidemiological studies describe a synergistic effect between PAH and asbestos exposure. Gustavsson 
et al. (2003) [176] analyzed 1042 lung cancer cases. The RR for asbestos exposure was 1.61, for 
combustion products 1.67 and for both exposures 2.24, suggesting an additive effect. In a case control 
study of 204 lung cancer cases Pastorino et al. (1984) [177] found a RR for PAH exposure of 1.6, for 
asbestos exposure 1.9 and for both exposures 3.3, consistent with a multiplicative effect (figure 2) [1, 
156, 176-178]. The area is reviewed in appendix 17.  
Figure 2. Interaction between exposure to PAH and asbestos [177] 
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Additive: 1.0 + 0.6 + 0.9 = 2.5 
Multiplicative: 1.6 x 1.9 = 3.04 
Statement 17 
Assessment of work-related risk for lung cancer needs to consider all established occupational lung 
carcinogens in the individual case (+++). 
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ENVIRONMENTAL RISK FACTORS 
SUMMARY 
Radon and air pollution have been associated to increased lung cancer risks. The excess risk of lung 
cancer from exposure to radon is dose-dependent and ranges between 2 and 25% per 100 Bq/m3. 
About 25% of houses in Denmark are estimated to have a radon concentration >100 Bq/m3 and 5% 
above 200 Bq/m3. The number of annual deaths in the Danish population attributable to radon is 
estimated to be about 240, the majority of this being the joint effect of radon and smoking. Overall it 
has been estimated that 1 to 2% of lung cancers in Denmark may be related to air pollution which 
corresponds to 35-70 cases annually in Denmark. As exposure ranges are generally low in Denmark 
they can usually be discounted when considering ARLC apportionment [137, 156, 158, 179-195] 
Results concerning lung cancer and environmental factors are reviewed in appendix 18. 
Statement 18 
In Denmark, there is no need to include environmental radon and air pollution exposures in individual 
apportionment assessments. (++) 
SMOKING AND OTHER LIFE STYLE RISK FACTORS 
SUMMARY 
There is some evidence in the literature that smoking filtered cigarettes is less hazardous than smoking 
unfiltered cigarettes, but evidence is inconsistent. There is also concern about potential new harmful 
effects due to cigarettes’ additives. There is no proof that any cigarette is safe and there is no substitute 
for stopping smoking. Passive smoking is more weakly associated with lung cancer than active 
smoking. The excess risk of second-hand tobacco smoke at home is of the order of 20% for women 
and 30% for men. Second-hand tobacco smoke at the workplace increases risk for lung cancer by 
12−19%. 
56 
Although several studies have reported that more physically active individuals have a lower risk for 
all-site cancers the results for lung cancer are less clear. The latest cohort studies suggest a slight 
protective effect of physically activity on lung cancer incidence. Smoking and physical activity 
interactions have not been delineated. Cigarette smoking needs to be considered as an alternative 
explanation when evaluating life style factors, including diet, due to potential confounding [196-209]. 
This area is reviewed in detail in appendix 19. 
ACQUIRED LUNG DISEASES AND LUNG CANCER RISK 
SUMMARY 
Pulmonary fibrosis is associated with an increased lung cancer risk. The presence of asbestosis is 
associated with considerable asbestosis exposure, sufficient to cause ARLC. Pulmonary tuberculosis 
has also been associated with increased lung cancer risk. Those with primary cancer have an increased 
risk of developing a second primary cancer, including lung cancer. Numerous studies have 
demonstrated associations between lung cancer risk and COPD. As smoking is the main cause of both, 
it is difficult to completely control for.[156, 166, 210-224]. This subject is reviewed in appendix 20. 
NON-OCCUPATIONAL/ENVIRONMENTAL ASBESTOS EXPOSURE AND LUNG 
CANCER 
SUMMARY 
Non-occupational asbestos exposure is not significantly related to lung cancer except in special e.g. 
household exposure inhabited by asbestos workers, areas with very high exposures (residence near 
mines or processing plants), and areas where asbestos occurs naturally in the soil. The level of 
environmental asbestos exposure in Denmark is not known, but based on Dutch and English studies 
the background level in outdoor city air is about 0.0001-0.0005 f/ml. This is orders of magnitude 
below the levels measured in occupational settings on which risk is assessed and extrapolated. WHO 
estimates that based on a lifetime exposure of 1,000 f/m3 (0.001 fiber/ml) the excess lung cancer risk 
would be in the order of 10–6–10–5. In Denmark this would account for 10 out of 3,600 lung cancer 
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deaths, based on an exposure level about 10 times higher than expected based on exposure 
measurements from comparable countries [142, 143, 179, 184, 225-240]. This subject is fully 
reviewed in appendix 21. 
Statement 19 
In Denmark, there is no evidence that non-occupational asbestos exposure is associated with lung 
cancer (+++) 
INTERACTION BETWEEN ASBESTOS AND SMOKING 
SUMMARY 
There has been inconsistent data on the interaction between asbestos exposure and smoking and their 
joint impact on lung cancer risk. Some studies have suggested a multiplicative effect, others an 
additive model, where asbestos exposure and smoking are independent of each other. Studies from the 
1970s or earlier based on populations with very high asbestos exposures tended to support the 
multiplicative model. Later studies with low or moderate exposures including mathematical and 
statistical analyses tend to conclude, that the effect is “more than additive and less than multiplicative 
relation”. This rather imprecise statement seems to be representative for the present state of 
knowledge. With risk expressed as attributable proportion due to asbestos among never-smokers 
estimates are approximately 30%-40%. Recent data from Great Britain with exposure levels and 
regulations comparable to the Denmark are in accordance with that, and showed that risk attributable 
to the combined effect of asbestos and smoking was 96% among smoking asbestos workers. Thus 
about 96% of lung cancer deaths could have be avoided by avoiding both asbestos and smoking [229, 
241-247]. This subject is reviewed in appendix 22. 
Statement 20 
Asbestos exposed smokers are at higher risk of lung cancer compared to asbestos exposed non-
smokers. (+++) 
Statement 21 
20 years after smoking cessation relative risk of lung cancer due to smoking is reduced by about 90%. 
(+++) 
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5. DISCUSSION
Asbestos is one of the most carefully characterized and researched occupational hazards. Numerous 
risk assessment models have been developed in an attempt to provide reliable information about 
workplace lung cancer risks. In spite of these efforts important knowledge gaps exist generating both 
scientific interest and difficulties in establishing regulations. Some of the key issues concern the 
validity of exposure assessments, the validity of outcome measures as well as  study bias, confounding 
and effect modification.  
Asbestos exposure 
As previously mentioned methods for both sampling and analyzing of asbestos have changed 
dramatically through the years. Unfortunately these developments have introduced substantial 
uncertainties that still are difficult to overcome. Exposure misclassifications may make it difficult or 
impossible to demonstrate true associations between exposures and effects. Systematic 
misclassification may lead to risk estimates that are either too low or too high. True associations may 
be masked by random misclassifications. Below some of the key reasons for uncertainty are discussed. 
Research has shown that thin fibers (defined as fibers with a width less than 0.25 µm) are more 
carcinogenic than thicker ones [248, 249]. Unfortunately, early airborne concentration measurements 
using PCM did not account for these thin fibers, thereby potentially underestimating asbestos 
exposures to the thinnest fibers. As PCM is limited and cannot identify thin fibers, incorrect risk 
attributions may be attributed to the countable thicker fibers. Including these less biologically relevant 
exposures in most cases leads to an overestimation of the dose, and thereby to a less steep dose 
response-curve. 
There are more than 30 “standard” methods of analyzing asbestos fibers. The same sample analyzed 
by different methods can vary 2 or 3 orders of magnitude [35]. A U.S. program for standardizing the 
testing and measurements of asbestos samples (The National Voluntary Laboratory Accreditation 
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Program) was first introduced in 1976. Many of the measurements in epidemiologic studies were 
obtained before 1976. 
 
In the various studies the type of asbestos fiber measurements have been unclear, in the earlier studies 
stationary or area samples have predominated, while samples using personal samplers has been the 
standard during the last decades. Area samples are less connected to the individual exposure, an may 
either under- or overestimate this. Besides it has often been unclear if the measurement was taken to 
evaluate worst case of especially dusty processes or aimed at being representative for a typical full 
working day. Worst case measurements tend to overestimate the exposure. Lack of data concerning 
local ventilation and respiratory protection add additional uncertainties when using area sampling to 
estimate personal exposures. Measurements from one job may be used to estimate exposures at other 
jobs, other shifts or time periods, which may add uncertainties that cannot be adequately evaluated. In 
addition work histories are often incomplete with possible job misclassifications. Relative air 
concentrations of amphibole and chrysotile are often unknown. The relative amounts of purchased 
amphibole and chrysotile have been used as a proxy.  
 
There have been numerous attempts to convert historical air measurements to newer units. There have 
been two types of conversion attempts. Midget impinger dust counts have been converted to PCM 
fiber counts. Based on paired analyses conversion multipliers are generated. A number of studies have 
used 1 mppcf = 3 f/ml. However, generated conversion factors from parallel sampling have actually 
ranged between 0.1 and 52 [36].  
 
The other conversion area has been from total fiber counts to specific fiber counts with fiber type, 
length and diameter.  These specific fiber counts were made with TEM starting around 1980, but this 
technique still not a routine method for monitoring occupational asbestos exposures. These 
measurements were applied to earlier epidemiological studies where exposures were judged to be 
similar. Thus, measurements from one time and place are applied to another time and place. 
Additional uncertainties arise when PCM fiber data are converted to TEM exposures. There is only a 
reasonable correlation for fibers > 5 µm in length. TEM measurements have shown substantial 
variation in the ratio of total fibers to fibers over 5 µm, which can vary from 2 to > 130 [250]. Thus 
there is generally poor correlation between PCM and TEM measurements. 
 
Reliability and validity of outcome measurements 
Besides the above-mentioned problems with exposure assessment, the reliability and validity of 
outcome measurements is associated with uncertainties. In the cohort studies SMR has mainly been 
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used to estimate RR. Using SMR induces variation, as the comparison is made with a hypothetical 
population with the same age distribution as the exposed cohort, and not that of the background 
population. In the very old cohorts [115, 120] this will automatically tend to give SMRs close to 100 
due to high background mortality [251]. Another factor is that very high exposure levels give rise to 
high absolute rates of cancer as well as competing risks (i.e. for asbestosis). As you can only die once, 
this may tend to underestimate the risk, when interpolating to lower levels 
Problems dealt with in the various studies are also other influencing factors, of which smoking is 
predominant. Smoking is the main risk factor for lung cancer and the interaction with asbestos is still 
not totally clear. Very few studies have sufficient information on smoking habits. Others looking 
especially at this interaction have come to various results. However, the initial pure multiplicative 
effect claimed by Hammond et al in 1979 has never been reproduced. A model somewhere between 
additive and multiplicative is the most likely. This has some effect on the estimated relative etiological 
fractions due to smoking and asbestos but not least on the common estimated risk in the 
epidemiological studies., 
Dose response analyses 
A very large variation in the dose-response calculated increase per f-y/ml has been shown ranging 
from almost zero in Quebec miners[120], over high values in the textile factories [116] to very high 
values in a Swedish case-control study [134, 252]. 
In case-control studies exposure has mainly been to end products or waste, either as the main task or 
only occasionally. Therefore the estimated exposures tend to be much lower, and more in agreement 
with the exposure of the more recent lung cancer cases. The very high kL (140* 10-3 (f*y/ml)-1) of 
Gustavsson is mainly based on exposures below 5 f-y/ml, while most studies in the meta-analyses 
have much higher exposures Lash (1997) [253], Lenters (2011) [145], van der Bij (2012) [147]. The 
other case-control study [136] showed an intermediary kL (40* 10-3 (f-y/ml)-1 and suggested a curve 
linear dose-response in accordance with the Swedish study. A joint ongoing analysis of several case 
control studies (SYNERGY) will be anticipated to get a better estimate of kL in these low doses in 
various jobs. 
Based on the reviews and meta-analyses it seems that kL increases with increasing study quality. The 
best estimate may be taken from Lenters (2011) [145] and the Dutch position paper[146], kL being 4-6 
*10-3 (f-y/ml)-1 calculated to double lung cancer risk at 150-250 f-y/ml, a kL considerably lower than
estimated from the more recent case-control studies. Therefore weighing the evidence between a series 
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of mainly older studies based on high asbestos concentrations in selected trades and a few newer 
studies with lower exposures with various tasks in different jobs is still an enigma. 
 
Possible under reporting of ARLC and etiological fraction 
As shown in table 3 between 2004 and 2010 there were 524 reported and 232 compensated cases of 
ARLC among men in Denmark. This corresponds to about 3.4 and 1.5 % of all male lung cancer cases 
in Denmark in the same period. Some evidence suggests that ARLC may be under reported. Our own 
data has shown that 25.8 % of male lung cancer cases from Odense had reported asbestos exposure. 
This is somewhat greater than Gustavsson’s study (2000) [134] where 12.2 % of lung cancer cases in 
the largely non-industrial Stockholm area reported asbestos exposure. The may be explained by the 
fact that our lung cancer patients were directly interviewed while they were alive and that two major 
asbestos industries were near the city of Odense. Gustavsson reported a 4 % attributable fraction for 
asbestos. If this attributable fraction is used as a conservative estimate for Denmark, then around 619 
of the 15,466 male lung cancer cases diagnosed in Denmark between 2004 and 2010 could be 
attributed to asbestos while only 238 were compensated 
62 
6. CONCLUSION
Lung cancer accounts for about 13% of all new cancers in males and 12% in females in Denmark. It 
has been estimated that about 4% till 8% of lung cancer cases may be related to asbestos exposure. 
Data suggests that there is an underreporting of asbestos-related lung cancer in Denmark. There is not 
enough evidence to include age, sex or family lung cancer history when evaluating cases of potential 
asbestos-related lung cancer. Neither should most other diseases be taken into consideration except for 
lung fibrosis. Exposure to radon and air pollution in Denmark is generally low and thus should not be 
considered when evaluating individual cases of possible asbestos-related lung cancer. 
The dose-response between asbestos exposure and lung cancer risk is basically linear, but may level 
off at very high exposures. Many studies demonstrate that the relative risk for lung cancer increases 
between 1 and 4 % per f-y/ml, corresponding to a doubling of risk at 25-100 f-y/ml. However, one 
high quality study has shown that a doubling of lung cancer risk was seen at about 4 f-y/ml. Cell type 
and location of lung cancer are not helpful in differentiating asbestos-related lung cancer from other 
lung cancers. The presence of pleural plaques, asbestos bodies or asbestos fibers is useful as markers 
of asbestos exposure and as such helpful in supporting previous asbestos exposure. The interaction 
between asbestos and smoking regarding lung cancer risk is between additive and multiplicative. 
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7. APPENDICES
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APPENDIX 1. OCCUPATIONAL GROUPS WITH COMPENSATED 
ASBESTOS RELATED LUNG CANCER, FUNEN (DK) 2007-2010. 
65 
APPENDIX 2. DANISH ASBESTOS MEASUREMENTS (2.2) 
DANSK ETERNIT FABRIK, LTD 
Dansk Eternit Fabrik LTD, founded in 1927 in Aalborg, was a manufacturer of asbestos fiber-cement 
products e.g. roofing and interior and exterior cladding. The average annual consumption of asbestos, 
mainly chrysotile, increased dramatically from 500 metric tons in 1928 to the highest of 26,000 metric 
tons in the early 1970s [254]. Between 1945 and 79 some amosite was also used, and between 1950 
and 1969 in addition, crocidolite was used.  
In 1949 the first measurement of asbestos exposure was taken at two processes: asbestos mill during 
unloading and fill up and at “Dutchman” during fill up (Table A2). The result for asbestos milling 
showed 85 and 150 asbestos particles/cm3 for 2-15 and 15-200 µm, respectively. The concentration for 
the “Dutchman” was 350 and 800 asbestos particles/cm3 for 2-15 and 15-200 µm, respectively [254]. 
Follow up measurements at the same factory given in another report were 10-100 fiber/ml in 1957 and 
<5 fiber/ml in 1973 [233]. 
Table A2. Abestos measurements from Dansk Eternik Fabrik LDT, 1949 [254] 
Particles of dust/cm3 Asbestos particles/cm3 
0.5-5 µm 2-15 µm 15-200 µm 
Asbestos mill during 
unloading and fill up 
990 85 150 
“Dutchman” during fill up 5500 350 800 
Interpretation problems: 
• Fiber type and the proportion of chrysotile to crocidolite are unknown.
• Unknown how asbestos particles were measured (TEM?) or estimated?
• Was the size of the asbestos particles width or length measured?
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THE NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT (NFA) 
Between 1982 and 1987 the National Research Centre for the Working Environment performed 
personal airborne asbestos concentration measurements in different industries (table A3). Most 
measurements were below 1 f/ml. However, a few very high asbestos levels were seen in electricity 
production (46.51 f/ml) and for carpenters (30.00 and 47.00 f/ml).  
Table A3. Asbetos measurements 1982-1987 (filter measurements, person-borne). Information 
from the Danish National Institute of Occupational Health. 
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Problems: 
• Unknown method of measurement and analysis
• The industries are not further described
ASBESTOS ABATEMENT MESUREMENTS 
In a report by Baelum & Staun [255] data from three types of abatement of asbestos-containing 
building materials are given: Dismantling of ceiling tiles, removal of pipe insulation and prying up 
floorings. The highest fiber exposures among asbestos abatement workers were seen in those prying 
up floorings with an average fiber exposure of 48.9 f/ml (3.3-92.0 f/ml). The second most exposed 
process was dismantling of ceiling tiles with an average fiber exposure of 2.8 f/ml (1.41-4.93 f/ml) 
followed by removal of pipe insulation with 1.7 f/ml (0.24-4.11).  
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Table A4. Personal airborne asbestos concentration measurements from Nordgårdsskolen in 
Aarhus, Aarhus Kommunehospital and Randers Centralsygehus [255] 
DISMANTLING OF CEILING TILES 
STUDY 1 STUDY 2 
Fiber/ml 
(95% CI) 
Fiber/ml 
(95% CI) 
Day 1 Day 1 
Person C 3.62 (3.42-3.87) Person F 4.93 (4.52-5.50) 
Person E 2.63 (2.46-2.84) Person G 1.41 (1.28-1.62) 
Day 2 Day 2 
Person C 4.14 (3.89-4.45) Person F 2.18 (1.96-2.49) 
2.79 (2.55-3.13) 
Person D 3.03 (2.84-3.26) Person G 2.39 (2.16-2.72) 
2.12 (1.92-2.42) 
Day 3 
Person C 1.77 (1.65-1.93) 
 Person D 2.67 (2.53-2.83) 
Day 3 (cleaning) Day 3 (cleaning) 
Person C 0.02 (0.00-0.07) Person F 
Person F 
(under 
mask) 
4.64 (4.24-5.11) 
8.70 (7.98-9.71) 
0.02 (0.02-0.03) 
Person D 0.95 (0.87-1.06) Person G 
Person G 
(under 
mask) 
2.19 (1.99-2.48) 
1.87 (1.67-2.18) 
0.74 (0.64-0.93) 
0.004 (0.00-0.02) 
REMOVAL OF PIPE INSULATION 
STUDY 1 STUDY 2 
Fiber/ml 
(95% CI) 
Fiber/ml 
(95% CI) 
Day 1 Day 1 (2nd measurement) 
Person A 0.24 (0.20-0.30) Person A 1.17 (1.01-1.47) 
1.64 (1.44-1.96) 
1.57 (1.35-2.00) 
Person B 0.31 (0.27-0.38) Person B 0.40 (0.33-0.61) 
2.76 (2.49-3.15) 
4.11 (3.70-4.73) 
(cont.) 
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REMOVAL OF PIPE INSULATION (cont.) 
Day 2 Day 2 
Person A 
Person B 
1.34 (1.20-1.57) 
0.84 (0.73-1.02) 
Person A 
Person A 
(under 
mask) 
1.74 (1.52-2.13) 
3.46 (3.07-4.08) 
2.47 (2.18-2.95) 
0.058 (0.05-0.07) 
0.018 (0.00-0.04) 
0.007 (0.00-0.03) 
Day 2 (2nd measurement) 
Person A 1.46 (1.35-1.63) 
Person B 1.59 (1.46-1.77) 
PRYING UP ASBESTOS FLOORINGS 
STUDY 1 
Fiber/ml 
(95% CI) 
Day 1 (removal of the upper 
layer) 
Person H 3.3 (3.01-3.64) 
92.0 (86.7-98.0) 
Person I 17.2 (15.8-19.0) 
71.9 (67.3-77.3) 
Day 2 (scrapping of concrete 
floor) 
Person H 61.2 (58.2-64.5) 
36.0 (34.1-38.0) 
Person I 60.5 (57.2-64.6) 
ROULUND FABRIKKER (ROULUNDS BRAKING) 
Roulunds Braking was founded in 1736 in Odense, Denmark as a manufacturer of friction materials to 
the automotive industry. The portfolio includes flexible brake linings, brake pads, brake shoes, brake 
discs and brake shoe kits, for passenger car and light commercial. No information about amount of 
asbestos is available. 
70 
Table A5. Asbestos measurements (f/ml) 1980-1997 (4th quarter of the year) personal 
information from Roulunds Braking. 
SWEDISH ASBESTOS CEMENT INDUSTRY 
The tables below give measurements from a Swedish asbestos cement industry. 
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Table A6. Measured values of fibers and total dust in air at different times and operations [256] 
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Table A7. Estimated average exposures to asbestos in air1 for various jobs and professions in an asbestos cement industry [256] 
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INTERNATIONAL ASBESTOS MEASUREMENTS 
Table A8. International asbestos measurements [233] 
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APPENDIX 3. HELSINKI CRITERIA (2.3) 
The Helsinki criteria were adopted in 1997 [107]. An international expert meeting was held January 
20-22, 1997 in Helsinki. Nineteen asbestos experts from 8 countries participated and discussed 
asbestosis, pleural disorders, mesothelioma, and lung cancer [104]. For clinical purposes any of the 
following were recommended to identify individuals with a high probability of asbestos exposure at 
work: 
• Over 0.1 million amphibole fibers (>5 µm) per gram dry lung tissue
• Over 1 million amphibole fibers (>1 µm) per gram dry lung tissue
• Over 1000 asbestos bodies per gram dry lung tissue or 100 per gram wet lung tissue
• Over 1 asbestos body per ml bronchoalveolar lavage fluid
The significance of pleural plaques and diffuse pleural thickening was evaluated. Pleural plaques 
mainly involve the parietal pleura and may be calcified. Diffuse pleural thickening mainly involves the 
visceral pleural. The specificity of pleural plaques as defined by the ILO 1980 International 
Classification of Radiographs of Pneumoconiosis is low unless the plaques are well defined. Low 
exposure levels from work-, households or natural environmental sources can induce pleural plaques, 
while diffuse pleural thickening may require higher exposure levels. 
Lung cancer and asbestos was thoroughly discussed. All 4 major lung cancer cell types can be 
associated with asbestos-related lung cancer. Both the histology and location of lung cancer had no 
significant value in deciding whether or not an individual lung cancer could be attributable to asbestos. 
The following examples of asbestos exposure were judged adequate to increase the risk of lung cancer 
by two-fold or more: 
• 1 year of heavy exposure (e.g. manufacturing of asbestos products, asbestos spraying,
insulation work with asbestos, demolition of old buildings)
• 5-10 years of moderate exposure (e.g. construction, shipbuilding)
The relative risk of lung cancer was estimated to increase 0.5-4% for each f-y/ml. Based on the upper 
boundary of this range 25 f-y/ml was associated with a two-fold increased lung cancer risk. This limit 
has been and is still widely used in many countries including Denmark, Germany, and the 
Netherlands. Tissue sample measurements related to the same two-fold risk were recommended: 2 
million amphibole fibers (>5 µm) per gram dry lung, 5 million amphibole fibers (>1 µm) per gram dry 
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lung, 5,000 to 15,000 asbestos bodies per gram dry lung or 5-15 asbestos bodies per ml of 
bronchoalveolar lavage fluid. Chrysotile fibers do not accumulate in lung tissue at the same rate as 
amphiboles due to faster clearance rates. Thus f-y/ml is probably a better indication of previous 
exposure than tissue measurements for chrysotile-exposed individuals. 
 
Indicators of exposure were also evaluated. The presence of asbestosis indicates high exposure. 
Pleural plaques also indicate exposure. However, as low-level exposure can cause pleural plaques, the 
attribution of lung cancer to asbestos exposure should be supported by an occupational history of 
substantial asbestos exposure. Diffuse pleural thickening is often associated with moderate or heavy 
asbestos exposures.  A minimum lag-time of 10 years from first asbestos exposure is required to 
attribute a lung cancer to asbestos. Tobacco smoking affects the total lung cancer risk. However, this 
effect does not detract from the risk of lung cancer attributable to asbestos exposure. The Helsinki 
report did not attempt to apportion the relative contributions of asbestos exposure and tobacco 
smoking.  
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APPENDIX 4. RESEARCH QUESTIONS (3.) 
 
LUNG CANCER 
1) How valid is the diagnosis of lung cancer? (LC1) Search words: validity, lung cancer, lung 
neoplasm. Diagnostic validity is not a problem and does not require a search  
2) How has the distribution of lung cancer cell types changed over time? (LC2). Search words: 
lung cancer, lung neoplasm, cell type, year, change over time  
3) Does the distribution of cell type of asbestos-related lung cancer differ from that of other lung 
cancers? (LC3) Search words: asbestos, asbestos-related, non-asbestos-related, lung cancer, 
lung neoplasm, cell type 
4) Does the location of asbestos-related lung cancer differ from that of other lung cancers? (LC4) 
Search words: asbestos, asbestos-related, non-asbestos-related, lung cancer, lung neoplasm, 
location, lobe  
 
 
ASBESTOS EXPOSURE 
1) Which jobs and industries can be associated with asbestos exposure? (AE1). Search words: 
job, occupation, industry, asbestos, asbestos exposure*** 
2) Can the presence of bilateral pleural plaques be used to estimate previous asbestos exposure? 
(AE2). Search words: asbestos, asbestos exposure, pleural plaques, pleural thickening, pleural 
calcification*** 
a. Can the presence of diffuse pleural thickening be used to estimate previous asbestos 
exposure? (AE2a) 
3) Can the presence of asbestos bodies be used to estimate previous asbestos exposure? (AE3). 
Search words: asbestos, asbestos exposure, asbestos bodies, sputum, BAL, lung tissue*** 
4) How can the degree of exposure (intensity) be evaluated? (AE4). Search words: asbestos, 
exposure, f/ml, f-y, MPCC (million particles per cubic centimeter), air measurements, JEM, 
job exposure matrix, monitoring (1 MPCC = 3 f/ml)*** 
5) How can the length of exposure be evaluated? (AE5). Search words: asbestos exposure, year, 
length, duration, f-y/ml, fiber/mix year, MPCC-year*** 
 
 
DOSE-RESPONSE  
1) What is the dose-response and dose-effect response between asbestos and lung cancer? (DR1). 
Search words: asbestos, asbestos-related, lung cancer, lung neoplasm, asbestos-related, dose-
response, dose-effect*** 
2) Has a no effect level for asbestos and lung cancer been described in humans or laboratory 
animals? (DR2). Search words: NOEL, LOEL, LOAEL, no effect level, asbestos, lung cancer, 
lung neoplasm, asbestos-related, in-vivo, in-vitro***  
3) What is the latency between asbestos exposure and the development of lung cancer? (DR3). 
Search words: asbestos, exposure, asbestos-related, latency, lag time, time since onset of 
exposure, lung cancer, lung neoplasm, asbestos-related*** 
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a. How does lung cancer risk develop after the cessation of asbestos exposure? (DR3a)
4) What is the prognosis for asbestos-related lung cancer? (DR4). Search words: asbestos, lung
cancer, lung neoplasm, asbestos-related, prognosis
5) How does the degree of asbestos exposure effect prognosis? (DR5). Search words: asbestos
exposure, asbestos-related, f-y/ml, lung cancer, lung neoplasm, prognosis
COMPETING AND PREDISPOSING CONDITIONS 
1) Which other diseases or conditions can influence the development of asbestos-related lung
cancer? (CPC1). Search words: asbestos, lung cancer, lung neoplasm, asbestos-related,
predisposing conditions, predisposing diseases***
a. What is the risk of developing lung cancer among those with asbestosis? (CPC1a)
2) What are the non-occupationally related causes of lung cancer? (CPC2). Search words: non-
occupational, smoking, tobacco, radon, lung cancer, lung neoplasm
3) Is non-occupational asbestos exposure related to lung cancer? (CPC3). Search words: non-
occupational, private, asbestos, exposure, lung cancer, lung neoplasm, asbestos-related***
4) How do other non-occupationally related factors influence the development of lung cancer (e.g.
sex, age, genetics)? (CPC4). Search words: sex, age, genes, lung cancer, lung neoplasm,
interaction, effect modification***
5) How can the effect of occupational-related asbestos exposure compared to non-occupational
factors be measured? (CPC5). Search words: risk, risk assessment, asbestos, asbestos-related,
smoking, tobacco, radon, lung cancer, lung neoplasm, interaction, effect modification***
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APPENDIX 5. STATEMENTS (3.) 
LUNG CANCER 
Statement 1 
When evaluating ARLC location and cell types do not differentiate asbestos and non-asbestos related 
lung cancer. 
ASBESTOS EXPOSURE 
Statement 2 
Job Exposure Matrices (JEMs) are useful in estimating previous asbestos exposure in addition to 
individual exposure evaluations. 
 
Statement 3 
The existence of pleural plaques increases the likelihood of previously asbestos exposure. 
 
Statement 4 
The presence of pleura plaques cannot be used to estimate degree of previous asbestos exposure. 
 
Statement 5 
The presence of asbestosis is a marker of previously high asbestos exposure and is associated with an 
increased risk of lung cancer. 
DOSE-RESPONSE 
Statement 6 
The dose-response relationship is approximately linear, but levels off at very high doses (>150 f-y/ml). 
 
Statement 7 
An increase in RR of 1-4% per f-y/ml (corresponding to a doubling of risk at 25 to 100 f-y/ml) has 
been observed with the higher estimates obtained in the few high quality epidemiological studies. One 
high quality population-based case-control study in the low-dose range found a higher risk estimate (a 
doubling of risk around 4 f-y/ml). 
 
Statement 8 
There is no evidence for a NOEL concerning ARCL. 
 
Statement 9 
The lowest documented increased ARLC risk is seen at about 4 f-y/ml. 
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Statement 10 
Lung cancer risk decreases decades after the cessation of exposure. 
Statement 11 
No minimal latency time for ARLC has been established. For practical purposes it can be assumed to 
be 10 years after exposure onset. 
Statement 12 
The prognosis of ARLC does not differ from that of other lung cancers. 
Statement 13 
All types of asbestos fibers are associated with lung cancer. 
Statement 14 
Different dose-response estimates for lung cancer have been reported according to fiber type 
(amphibole vs. chrysotile), size, distribution and industry. However, these patterns are not clear, when 
study quality is taken into account. Thus, there is not sufficient evidence to derive different risk 
estimates for different fiber types. 
COMPETING AND PREDISPOSING FACTORS 
Statement 15: 
There is insufficient evidence to include predisposing factors (age, sex, and genetics) in the individual 
apportionment of ARLC. 
Statement 16 
It is rarely relevant to account for other diseases or disorders in individual apportionment assessments 
in Denmark. However, this does not apply to lung fibrosis of any origin. 
Statement 17 
Assessment of work-related risk for lung cancer needs to consider all established occupational lung 
carcinogens in the individual case. 
Statement 18 
In Denmark, there is no need to include environmental radon and air pollution exposures in individual 
apportionment assessments. 
Statement 19 
In Denmark, there is no evidence that non-occupational asbestos exposure is associated with lung 
cancer. 
Statement 20 
Asbestos exposed smokers are at higher risk of lung cancer compared to asbestos exposed non-
smokers. 
Statement 21 
20 years after smoking cessation relative risk of lung cancer due to smoking is reduced by about 90%.
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APPENDIX 6. SEARCH DETAILS (3.1) 
Table A9. Search details 
Step	  1.	  Broad	  searches	  in	  PubMed	  and	  Embase	  DATABASE	  AND	  DATE	   SEARCH	  TERM	   HITS	  PubMed	  3.7.2012	   ("asbestos"[MeSH	   Terms]	   OR	   "asbestos"[All	   Fields])	   AND	   ("lung	  neoplasms"[MeSH	   Terms]	   OR	   ("lung"[All	   Fields]	   AND	  "neoplasms"[All	   Fields])	   OR	   "lung	   neoplasms"[All	   Fields]	   OR	  ("lung"[All	   Fields]	   AND	   "cancer"[All	   Fields])	   OR	   "lung	   cancer"[All	  Fields])	  
3,132	  
Embase	  4.7.2012	   (asbestos	  and	  lung	  cancer).mp.	  [mp=title,	  abstract,	  subject	  headings,	  heading	  word,	  drug	  trade	  name,	  original	  title,	  device	  manufacturer,	  drug	  manufacturer,	  device	  trade	  name,	  keyword]	  	   2,732	  Total	  number	  of	  discrete	  publications	   4,088	  Step	  2.	  Specific	  searches	  in	  PubMed	  SEARCH	  QUESTION	  AND	  DATE	   SEARCH	  TERM	   HITS	  LC1A	  23.7.12	   "diagnostic	  validity"[All	  Fields]	  AND	  "lung	  Cancer"[All	  Fields]	   4	  LC2A	  23.7.12	   "lung	   Cancer"[All	   Fields]	   OR	   "lung	   neoplasm"[All	   Fields]	   AND	   "cell	  type"[All	   Fields]	   AND	   (("Change"[Journal]	   OR	   "change"[All	   Fields])	  AND	   over[All	   Fields]	   AND	   ("time"[MeSH	   Terms]	   OR	   "time"[All	  Fields]))	  
2	  
LC3A	  23.7.12	   "lung	   Cancer"[All	   Fields]	   OR	   "lung	   neoplasm"[All	   Fields]	   AND	   "cell	  type"[All	   Fields]	   AND	   ("asbestos"[MeSH	   Terms]	   OR	   "asbestos"[All	  Fields])	   17	  LC4A	  23.7.12	   "lung	   cancer"[All	   Fields]	   OR	   "lung	   neoplasm"[All	   Fields]	   AND	  (("asbestos"[MeSH	   Terms]	   OR	   "asbestos"[All	   Fields])	   AND	  location[All	  Fields])	   20	  AE1A	  23.7.12	   "asbestos	   exposure"[All	   Fields]	   AND	   job[All	   Fields]	   AND	   "lung	  cancer"[All	  Fields]	   31	  AE2A	  24.7.12	   "asbestos	   exposure"[All	   Fields]	   AND	   "pleural	   plaques"[All	   Fields]	  AND	  ("review"[Publication	  Type]	  OR	  "review	   42	  AE3A	  24.7.12	   "asbestos	   bodies"[All	   Fields]	   AND	   ("sputum"[MeSH	   Terms]	   OR	  "sputum"[All	  Fields])	  "asbestos	   bodies"[All	   Fields]	   AND	   "bronchoalveolar	   lavage"[All	  Fields]	  "asbestos	  bodies"[All	  Fields]	  AND	  "lung	  tissue"[All	  Fields]	  
43	  69	  120	  AE4A	   "asbestos	  exposure"[All	  Fields]	  AND	  measurements[All	  Fields]	   82	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23.7.12	   "asbestos	   exposure"[All	   Fields]	   AND	   "job	   exposure	   matrix"[All	  Fields]	   25	  AE5A	  	  23.7.12	   "asbestos	  exposure"[All	  Fields]	  AND	  duration[All	  Fields]	  AND	  "lung	  cancer"[All	  Fields]	   62	  DR1A	  25.07.12	   (("asbestos"[MeSH	   Terms]	   OR	   "asbestos"[All	   Fields])	   OR	   "asbestos	  exposure"[All	   Fields])	   AND	   ("lung	   cancer"[All	   Fields]	   OR	   "lung	  neoplasm"[All	   Fields])	   AND	   ("dose	   response"[All	   Fields]	   OR	   "dose	  effect"[All	  Fields])	  
87	  
DR2A	  23.7.12	   ("asbestos"[MeSH	   Terms]	   OR	   "asbestos"[All	   Fields])	   AND	   "lung	  cancer"[All	   Fields]	   AND	   "No	   observed	   adverse	   effect	   level"[All	  Fields]	   3	  DR3A	  23.7.12	   ("asbestos"[MeSH	   Terms]	   OR	   "asbestos"[All	   Fields])	   AND	   "lung	  cancer"[All	  Fields]	  AND	  ("lag	  time"[All	  Fields]	  OR	  latency[All	  Fields]	  OR	   (("time"[MeSH	   Terms]	   OR	   "time"[All	   Fields])	   AND	   onset[All	  Fields]	  AND	  exposure[All	  Fields]))	  
101	  
DR4A	  23.7.12	   (("asbestos"[MeSH	   Terms]	   OR	   "asbestos"[All	   Fields])	   OR	   "asbestos	  exposure"[All	   Fields])	   AND	   ("lung	   cancer"[All	   Fields]	   OR	   "lung	  neoplasm"[All	   Fields])	   AND	   ("prognosis"[MeSH	   Terms]	   OR	  "prognosis"[All	  Fields])	  
77	  
DR5A	   (Se	  ovenfor	  –	  del	  af	  samme	  spørgsmål)	   	  CPC1A	  23.7.12	   (("asbestos"[MeSH	   Terms]	   OR	   "asbestos"[All	   Fields])	   OR	   "asbestos	  exposure"[All	   Fields])	   AND	   ("lung	   cancer"[All	   Fields]	   OR	   "lung	  neoplasm"[All	   Fields])	   AND	   ("predisposing	   conditions"[All	   Fields]	  OR	  "predisposing	  diseases"[All	  Fields]	  OR	  "predisposing	  factors"[All	  Fields])	  
2	  
CPC2A	  27.7.12	   ("lung	   cancer"[All	   Fields]	   OR	   "lung	   neoplasm"[All	   Fields])	   AND	  (non-­‐occupational[All	   Fields]	   OR	   (residential[All	   Fields]	   AND	  ("etiology"[Subheading]	   OR	   "etiology"[All	   Fields]	   OR	   "causes"[All	  Fields]	   OR	   "causality"[MeSH	   Terms]	   OR	   "causality"[All	   Fields])))	  AND	   ("review"[Publication	   Type]	   OR	   "review	   literature	   as	  topic"[MeSH	  Terms]	  OR	  "review"[All	  Fields])	  
39	  
CPC3A	  26.7.12	   ("lung	   cancer"[All	   Fields]	   OR	   "lung	   neoplasm"[All	   Fields])	   AND	  ("asbestos"[MeSH	   Terms]	   OR	   "asbestos"[All	   Fields])	   AND	   (non-­‐occupational[All	  Fields]	  OR	  residential[All	  Fields])	   28	  CPC4A	  26.7.12	   ("lung	   cancer"[All	   Fields]	   OR	   "lung	   neoplasm"[All	   Fields])	   AND	  exposures[All	   Fields]	   AND	   ("effect	   modification"[All	   Fields]	   OR	  ("Interaction"[Journal]	  OR	  "interaction"[All	  Fields]))	   81	  CPC5A	  26.7.12	   ("lung	   cancer"[All	   Fields]	   OR	   "lung	   neoplasm"[All	   Fields])	   AND	  (("asbestos"[MeSH	   Terms]	   OR	   "asbestos"[All	   Fields])	   AND	  exposure[All	   Fields])	   AND	   ((non-­‐occupational[All	   Fields]	   AND	  exposures[All	  Fields])	  OR	  ("environmental	  exposure"[MeSH	  Terms]	  OR	   ("environmental"[All	   Fields]	   AND	   "exposure"[All	   Fields])	   OR	  "environmental	   exposure"[All	   Fields]	   OR	   ("environmental"[All	  Fields]	   AND	   "exposures"[All	   Fields])	   OR	   "environmental	  exposures"[All	   Fields]))	   AND	   ("Measurement	   (	   Mahwah	   N	  J)"[Journal]	  OR	  "measurement"[All	  Fields])	  
14	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APPENDIX 7. FLOW DIAGRAM (3.2) 
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APPENDIX 8. DATA EXTRACTION SHEET FOR ORIGINAL STUDIES (3.3) 
Key	  question:	  	  
First	  author:	  	  
Title:	  	  
Journal	  year,	  number,	  pages:	  
Study	  design:	  
Meta-­‐analysis	   Systematic	  review	   Cross	  sectional	  study	  
Cohort	  study	   Case	  control	  study	   Economic	  analysis	  
Survey	   Longitudinal	  follow-­‐up	  of	  cases	   Other,	  specify:	  
Case	  series	   Case	  report	  
Descriptive	  study	  of	  disease	  register	  (reporting/surveillance)/occupational	  statistics	  
Selection	  of	  study	  population/patients:	  
Convenience	  sample	   Consecutive	  sample	   Random	  selection	  
Not	  reported	   Other,	  specify:	  
Population/patient	  characteristics	  (age,	  sex,	  country,	  …):	  
Type	  of	  industry/job:	  
Comparison	  group:	   	   Yes	  
Characteristics	  (age,	  sex,	  country,…):	  
No	  
Not	  applicable	   Do	  not	  know	  
Response	  rate:	   %	  
Sample	  size:	  n	  =	   of	  which	  number	  with	  lung	  cancer:	  	  	   n	  =	   (	   	  %	  )	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Measurement	  of	  exposure:	  
Industry	   Self-­‐reported	  agents	  
Occupation	   Group	  measurement	  in	  the	  workplace	  
Task	   Individual	  measurement	  in	  the	  workplace	  
	  	   Other,	  specify:	  
Type	  of	  exposure:	  	  
Chrysotile	   Amphiboles	  
	  	   Mixed	   Unknown	  
Level	  of	  exposure:	  
Unit	  (e.g.	  fiber/ml,	  mppcf):	  
Mean/median:	   	  	   Minimum:	   Maximum:	  
	   Not	  specified	   Low	   	  	  Moderate	   High	   	  Various	  
Duration	  of	  exposure:	  
Is	  the	  exposure	  adequately	  described?	  
Yes	   Breathing	  zone	   No	  mention	  
Yes,	  partly	   No	   Do	  not	  know	  
Stationary	   Not	  applicable	  
Measurement	  of	  outcome	  
Questionnaire	   Cancer	  Register	   Hospital-­‐based	  register	  
Death	  certificates	   Other,	  specify:	  
Is	  the	  outcome	  adequately	  described?	  
Yes	   No	   Not	  applicable	  
Yes,	  partly	   No	  mention	   Do	  not	  know	  
Was	  the	  measurement	  of	  the	  outcome	  sound?	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   Yes	   	   	  	   	   No	   	   	   	   	  	   	   Not	  applicable	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	   	   Yes,	  partly	   	   	  	   	   No	  mention	   	   	  	   	   Do	  not	  know	   	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
Limitations:	   	   	   	   	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
Data	  probably	  confounded?	  	   	   	   	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	   	   Yes	   	   	  	   	   Yes,	  partly	   	   	  	   	   Not	  applicable	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	   	   Yes,	  by	  smoking	   	  	   	   No	   	   	   	   	  	   	   Do	  not	  know	   	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	   	   Other,	  specify:	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
Potential	  confounders	  taken	  into	  account?	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
Data	  probably	  biased?	   	   	   	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	   	   Yes	   	   Yes,	  partly	  misclassification	  of…	   	  	   	   Other,	  specify:	  	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	   	   No	   	   	  	   	   Exposure	   	   	   	   	   	  	   	  	   	  	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	   	   Not	  applicable	   	  	   	   Disease	   	   	   	   	   	  	   	  	   	  	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	   	   Do	  not	  know	   	  	   	   Selection	  of	  study	  population	   	   	   	  	   	  	   	  	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	   	   Healthy	  worker	  effect	  adequately	  addressed	   	   	   	   	  	   	  	   	  	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
Are	  the	  results	  probably	  due	  to	  chance?	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	   	   Yes	   	   	  	   	   Yes,	  partly	  (confidence	  interval	  contains	  1	  or	  p-­‐value	  ≥	  0.05)	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	   	   No	   	   	  	   	   No	  mention	   	   	  	   	   Not	  applicable	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	   	   Do	  not	  know	   	   	   	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
Key	  findings	  that	  are	  relevant	  to	  the	  key	  question:	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
Source	  of	  funding:	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First	  author,	  journal	  year:	  
Grading	  of	  the	  study:	  
Meta-­‐analysis	  or	  systematic	  reviews	  of	  RCTs	  /	  RCT	  with	  risk	  of	  bias	  
1++	   	   	  	  	  1+	   1	  -­‐	  
(High	  quality/very	  low	  risk)	  
(	   Well	   conducted	   /	   low	  
risk)	   (High	  risk)	  
Case	  control	  or	  cohort	  studies	  with	  risk	  of	  confounding,	  bias,	  or	  chance	  
	   2++	   	  	  	  2+	   2	  -­‐	  
(Very	  low	  risk	  of	  	   (Low	  risk)	   (High	  risk)	  
confounding,	  bias	  or	  chance)	  
3	  Non-­‐analytic	  studies	  
4	  Expert	  opinion	  
89 
APPENDIX 9. R-AMSTAR DATA EXTRACTION SHEET FOR META-
ANALYSIS AND REVIEWS (3.3) 
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APPENDIX 10. EVIDENCE MODEL (3.6) 
Degree of evidence of a causal association between an exposure to a specific risk factor and a specific 
outcome (Danish Working Environment Authority, 2010)  
THE FOLLOWING CATEGORIES ARE USED 
+++ strong evidence of a causal association 
++ moderate evidence of a causal association 
+ limited evidence of a causal association 
0 insufficient evidence of a causal association 
- evidence suggesting lack of a causal association 
DESCRIPTION OF CATEGORIES 
Strong evidence of a causal association (+++):  
A causal relationship is very likely. A positive relationship between exposure to the risk factor and the 
outcome has been observed in several epidemiological studies. It can be ruled out with reasonable 
confidence that this relationship is explained by chance, bias or confounding.  
Moderate evidence of a causal association (++):  
A causal relationship is likely. A positive relationship between exposure to the risk factor and the 
outcome has been observed in several epidemiological studies. It cannot be ruled out with reasonable 
confidence that this relationship can be explained by chance, bias or confounding, although this is not 
a very likely explanation.  
Limited evidence of a causal association (+):  
A causal relationship is possible. A positive relationship between exposure to the risk factor and the 
outcome has been observed in several epidemiological studies. It is not unlikely that this relationship 
can be explained by chance, bias or confounding.  
Insufficient evidence of a causal association (0):  
The available studies are of insufficient quality, consistency, or statistical power to permit a 
conclusion regarding the presence or absence of a causal association.  
Evidence suggesting lack of a causal association (-):  
Several studies of sufficient quality, consistency and statistical power indicate that the specific risk 
factor is not causally related to the specific outcome.  
COMMENTS 
The classification does not include a category for which a causal relation is considered as established 
beyond any doubt.  
The key criterion is the epidemiological evidence.  
The likelihood that chance, bias and confounding may explain observed associations are criteria that 
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encompass criteria such as consistency, number of ‘high quality’ studies, types of design etc.  
Biological plausibility and contributory information may add to the evidence of a causal association. 
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APPENDIX 11. SEMINAR PROGRAM AND LIST OF PARTICIPANTS (3.7)
PROGRAM FOR ASBESTOS SEMINAR 
ODENSE, 22.-23. NOVEMBER 2012 
Thursday 
10-12 Plenum 
12-13 Lunch 
13-15 Working groups 
15-15.30 Coffee 
15.30-16.30 Working groups 
16.30-18 Plenum 
18-19.30 Break/walk (rapporteurs revise text and mail it to working group) 
19.30 Dinner 
Friday 
8.30-9.00 Read revisions 
9-10.30 Working groups (possible to shift group) 
10.30-11 Coffee 
11-13 Plenum (statements) 
13-14 Lunch 
Working groups: 
Lung cancer:  David Sherson (CM), Niels Christian Hansen (R), Karen Ege  
(LC) Olsen  
Asbestos exposure: Jesper Rasmussen (CM), Lene Snabe Nielsen (R), Christy Barlow 
(AE) 
Dose response (DR) Maria Albin (CM), Jesper Bælum (R), Dick Heederik, Panu Oksa, 
Marcello Lotti 
Competing and pre- Thomas Kraus (CM), Søren Dahl (R), Sverre Langård, Johnni 
disposing factors: Hansen 
(CPC) 
CM: Chairman 
R: Rapporteur 
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Nov. 30: Deadline for major disagreements/revisions 
 
 
Participants 
Christy Barlow, USA  cbarlow@chemrisk.com 
David Sherson, Denmark  david.sherson@ouh.regionsyddanmark.dk 
Dick Heederik, The Netherlands d.heederik@uu.nl 
Jesper Bælum, Denmark  jesper.baelum@ouh.regionsyddanmark.dk 
Jesper Rasmussen, Denmark jesper.rasmussen@slb.regionsyddanmark.dk 
Johnni Hansen, Denmark  johnni@cancer.dk 
Karen Ege Olsen, Denmark karen.ege.olsen@ouh.regionsyddanmark.dk 
Lene Snabe Nielsen, Denmark lenesnabe@gmail.com 
Marcello Lotti, Italy  marcello.lotti@unipd.it 
Maria Albin, Sweden  maria.albin@med.lu.se 
Niels Christian Hansen, Denmark niels.christian.hansen@ouh.regionsyddanmark.dk 
Panu Oksa, Finland  panu.oksa@ttl.fi 
Sverre Langård, Norway  svlangaa1@online.no 
Søren Dahl, Denmark  soren.dahl@svs.regionsyddanmark.dk 
Thomas Kraus, Germany  thomas.kraus@post.rwth-aachen.de 
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APPENDIX 12. ARLC: HISTOLOGY, LOCATION, PROGNOSIS AND 
SCREENING (4.1) 
LOCATION AND HISTOLOGY 
Tumor location and histology may be two discriminating features pointing to the cause of lung 
cancer. Many studies have examined possible relationships between asbestos-related lung cancer and 
both tumor location and cell type. Tobacco-related lung cancers often occur in the upper lobes with a 
typical upper: lower lobe ratio of about 2.5:1.0 [42-44] In contrast, there is considerable conflicting 
data concerning the lobe of origin associated with asbestos-related lung cancer. A number of earlier 
studies demonstrated a reverse location for asbestos-related lung cancer. A lower lobe association 
with asbestos exposure was described by Antilla & Karjalainen, Hillerdal (1983), Sluis-Cremer 
(1980) and Weiss (1981) [45-48]. This was thought to be biologically plausible as asbestos-related 
fibrosis is typically found in the dependent lung portions [47, 49]. However, other studies have 
shown upper lobe location similar to tobacco-related lung cancers ([43, 51, 52, 257]. Concerning 
histology of ARLC some studies have shown excess adenocarcinomas  [51, 53-55]. However, many 
other studies have failed to show increased risk of adenocarcinoma [43, 52, 56-58, 258]. Thus, as in 
the case of tumor location results concerning histology of asbestos-related lung cancer are 
conflicting. As many of the above studies have not adequately controlled for smoking and sex the 
associations between asbestos and lung cancer, histology and location become even less distinct.  
THE FOLLOWING 5 STUDIES WERE REVIEWED WITH SIGN (SEE TABLE A11) 
Brodkin and colleagues (1997) [60] performed a nested case-control study, which investigated the 
consecutive hospitalized lung cancer cases. Histology and lobe origin in 78 asbestos-exposed and 214 
non-exposed heavy smokers was evaluated. All subjects were from the prospective U.S. CARET 
Study, where randomized preventive treatment with carotene and retinol was tested. The asbestos-
exposed subjects had at least 5 years in high-risk trade or radiographic evidence of asbestos- related 
effects. No significant differences in cell types in exposed and non-exposed: adenocarcinoma 
32%/30%, squamous 32%/20%, large cell 16%/24% and small cell 15%/21%. There was a tendency 
for asbestos-exposed to have more lower lobe tumors, OR 1.92 (95% CI 1.03-3.55). However, both 
exposed (67%) and non-exposed (80%) had mainly upper/middle lobe tumors. SIGN 2+. 
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A recent cohort study from 2012 investigated tumor location in 1,701 consecutive lung cancer cases 
diagnosed 1997 and 2009 at two French University Hospitals. [61] Asbestos-exposed had a minimum 
exposure of 6 months obtained by a standard questionnaire. Cumulative exposure scores were 
calculated for lung cancer cases. Tumors were subdivided into central or peripheral locations. Central 
tumors were defined as those accessible and visible by white light bronchoscopy. Smoking data was 
obtained from face to face interviews. Histology was strongly related to tumor location. More 
adenocarcinoma tumors (53.9%) were located peripherally (OR=4, CI 2.88-5.54). Asbestos-exposure 
was associated with a more central location: 65%vs 58.9% in non-exposed (p=0.016). A positive 
dose-response relationship with cumulative exposure index to asbestos and central location was 
demonstrated (p=0.001). SIGN 2+. 
 
Karjalainen et al. (1999) [62] carried out a large study in 1999, which included all notified cases of 
asbestosis (n=1376) and benign pleural disease (n=4887) in Finland between 1967 and 1995. 13 job 
titles were identified. Subsets were compared to compensation decisions with a high degree of 
agreement (92% and 94%). Cancer cases were identified by the Finnish Cancer Registry. SIR 
calculated from date of notification. No data on smoking or non-occupational exposures were 
available. Men with asbestosis had a lung cancer SIR of 6.7 (95% CI 5.6-7.9). Lung cancer risk was 
raised for all cell types and did not change markedly over time. Men with benign pleural disease had 
an increased mesothelioma risk (SIR 5.5, 95% CI 1.5-14) and a slightly elevated risk of lung cancer 
(SIR 1.3, 95% CI 1.0-1.8). SIGN 2-. 
 
A U.S. case-control study from 1998 investigated 456 lung cancer cases [42]. An asbestos exposure 
index was calculated and different jobs and different time periods were weighed differently. Tumors 
were divided into upper and lower lobe locations. Adenocarcinoma tumors were compared to the 
other cell types. Sex, age, family history and smoking were controlled for. Heavy smokers tended to 
have more upper lobe tumors: 54.7 vs. 46.2% (p=0.07). Asbestos exposure was associated with upper 
lobe location. Of upper lobe tumors 14.6% were associated with significant asbestos exposure, 
compared with 5.4% associated with lower lobe tumors (p<0.01). Asbestos exposure did not predict 
tumor histology in multiple regression analyses. SIGN 2+. 
 
In 2003 Paris and colleagues studied 1,493 consecutive lung cancer cases from two French hospitals 
diagnosed between 1997 and 2006 [259, 260]. Face-to-face interviews including an occupational 
questionnaire were performed. Minimum occupational exposures were defined by at least 5% of 
work time for at least 1 year. Sex, age and smoking were controlled. Significant associations were 
observed between adenocarcinoma and exposure to welding fumes and silica, but not to asbestos. No 
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associations were demonstrated between adenocarcinoma and age, sex or smoking except for a 
negative association with smoking duration (p<0.0001). SIGN 2+. 
A recent Danish study evaluated 857 consecutive hospitalized lung cancer cases. All subjects were 
asked if they had been exposed to asbestos: Table A10 shows results from the 423 male. There were 
no significant differences in cell type between asbestos exposed and non-exposed.  
Table A10. Lung cancer subtypes for 423 consecutive male patients with or without self-
reported occupational asbestos exposure. All diagnosed at Department of Respiratory 
Medicine, Odense University Hospital 2007 to 2010. (Hansen NC. Personal communication). 
Occupational asbestos 
exposure 
Yes No Total 
15 51 66 Small cell lung cancer 
14.0% 16.1% 15.6% 
31 85 116 Squamous cell carcinoma 
29.0% 26.9% 27.4% 
30 89 119 Adenocarcinoma 
28.0% 28.2% 28.1% 
27 74 101 Other non small cell lung cancer 
25.2% 23.4% 23.9% 
4 17 21 Clinical diagnosis 
3.7% 5.4% 5.0% 
107 316 423 Total 
100.0% 100.0% 100.0% 
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Table A11. Tabular presentation of LC3+LC4 studies 
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LUNG CANCER PROGNOSIS 
The 5-year survival rate has changed very little in the past 50 years. The 5-year survival for Danish 
males was 7 % in 1964-68 and 9 % in 1999-2003. Lung cancer prognosis is directly dependent on the 
stage of diagnosis. Thus data concerning stage at diagnosis will predict survival.  
Figure A1 shows diagnoses stages of all lung cancer cases in Denmark from 2003-2011 [72]. No 
improvement in earlier diagnosis is evident. 
Figure A1. Stage at diagnosis of 4918 primary lung cancer cases in Denmark [59] 
The only available data concerning the diagnosis stage of ARLC shows no differences when compared 
to other lung cancers [59]. Table A12 below shows data from 857 male and female lung cancer cases 
from the island of Funen compared with all lung cancer cases in Denmark. Of the 857 cases 118 had 
previous asbestos exposure. 
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Table A12. Stage at diagnosis for lung cancer cases in men and women from Funen compared 
with all Danish cases 2007-2010 [59] 
 
Denmark  Funen 2007-2010 
  Asbestos exposure 
 2007-2010  Yes No 
Total 
IA 8.4%  
IB 9.3%  
IIA 0.7%  
IIB 5.3%  
IIIA 8.5% 
32.3% 
 
8.5% 
11.0% 
0.8% 
1.7% 
8.5% 
9.6% 
7.3% 
2.0% 
2.6% 
10.6% 
9.5% 
7.8% 
1.9% 
2.5% 
10.3% 
31.9% 
IIIB 19.2%  
IV 48.6% 67.7%  
17.8% 
51.7% 
11.8% 
56.2% 
12.6% 
55.5% 68.1% 
Total 10.0% 100%  100% 100% 100% 100% 
 
 
There is very little data concerning survival of ARLC cases. No survival differences are seen in figure 
A2 where ARLC and non-ARLC cases are compared. There is no reason to suspect that survival for 
these cases would differ significantly from other cases of lung cancer. 
 
Figure A2. Survival curves (Kaplan-Meier) for 423 consecutive male lung cancer patients with 
or without self-reported occupational asbestos exposure. All diagnosed at Department of 
Respiratory Medicine, Odense University Hospital 2007 to 2010. Estimated survival curves 
(Hansen NC. Personal communication) 
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LUNG CANCER SCREENING CONSIDERATIONS FOR ASBESTOS EXPOSED WORKERS 
It has now been shown that annual low-dose CT screening can reduce mortality. This was clearly 
demonstrated last year with the large randomized control trial, the National Lung Screening Trial 
(NLST) [65]. A relative mortality reduction of 20% was demonstrated. In March 2012 the National 
Comprehensive Cancer Network published their recommendations concerning low-dose CT screening 
[66]. The NCCN panel recommended annual low-dose CT screening for 2 high risk groups:  
1. 30 pack-years or more, age 55-74 and smoking cessation < 15 years. This is a category 1
recommendation, meaning that all members were in agreement and the evidence is strong.
2. 20 pack-years or more, age > 50 plus an occupational exposure not including second-hand
smoke.   The following occupational carcinogens were included: asbestos, silica, cadmium,
arsenic, beryllium, chromium, diesel fumes and nickel. This is a category 2B
recommendation. The evidence is somewhat less without unanimous agreement among panel
members.
This is the first time an international organization has recommended annual screening for well-defined 
high risk groups. However, this remains controversial and has been recently reviewed [67].  The two 
key problems are many false positives and high costs. In the NLST study 94% of the positive 
screening tests were false positives. To further complicate the question a recent randomized controlled 
trial in Denmark did not show mortality reduction so far, but the observation period continues [68]. 
This study was much smaller than the NLST with less power. 4104 individuals were randomized and 
the risk group wasn’t as high based on 20 pack-years or more. The borderline significant increase in 
all mortality causes in the screened group suggests that this group may have been sicker than the 
control group. There are ongoing screening trials in several European countries. Should we wait for 
these results? It will probably be a number of years before these trials are completed and data can be 
integrated in a meta-analysis. 
Another key question is how can previously exposed asbestos workers be identified? Factory 
personnel files are ideal, but may have been destroyed after workplaces close. Once workers with 
previous asbestos exposure have been identified, how can their level of risk be estimated? Existing air 
measurements are only available in a minority of workplaces. There are published reviews of 
previously published asbestos measurements as well as a few attempts at job-exposure matrices.  [20, 
69-71]. These may be useful. The next key question is how the asbestos-exposure level should be 
fined. Which of the previous asbestos-exposed workers should be screened? Should the level of 25 
fiber/cm3-years be chosen? Or is this too high? 
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Workers with previous asbestos exposure are getting older and older. Low-dose screening programs of 
this population may reduce their mortality from lung cancer. However, screening is costly and 
complicated with many false positives. Coming screening results from European studies may help 
clarify this dilemma.  
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APPENDIX 13. BIOLOGICAL MARKERS: PLEURAL PLAQUES (PP), 
ASBESTOS BODIES (AB) AND ASBESTOS FIBERS (AF) (4.2) 
Pleural abnormalities are divided into PP (localized pleural thickening) and diffuse pleural thickening, 
DPT [83]. PPs represent localized pleural thickening, generally of the parietal pleura, and may be seen 
on the diaphragm, on the chest wall and at other sites. According to the ILO 2000 Classification a 
minimum width of about 3 mm is required for an in-profile plaque to be recorded as present [83]. DPT 
is thickening of the visceral pleura. For the purpose of the ILO 2000 Classification DPT extending up 
the lateral chest wall is recorded only in the presence of, and in continuity with, an obliterated 
costophrenic angle. Its extent is recorded in the same manner as for pleural plaques. A minimum width 
of about 3 mm is required for in-profile DPT to be recorded as present [83]. PP and DPT can also be 
classified with the International Classification of HRCT for Occupational and Environmental 
Respiratory Diseases[84]. 
PLEURAL PLAQUES [261] 
The occurrence of bilateral PP on a chest X-ray is a strong indicator of previous exposure to asbestos 
fibers with a specificity of 80-90% [86]. This specificity has been observed after applying strict 
criteria for occurrence of PP on the chest X-ray: Bilateral lesions, at least 5 mm thick and/or calcified, 
well demarcated, and no remnants of pleurisy, i.e., costophrenic angles not obliterated [85]. These 
criteria are more specific than the ILO criteria from 1980 [87]. 
Most authors state that PP are rarely seen until 20 years after the initial exposure to asbestos. 
However, by re-evaluating previous chest X-rays in exposed workers who all later had developed PP, 
it was possible retrospectively to identify PP as early as 10 years after initial exposure [88]. A recently 
published study has found that smokers for the same degree of asbestos exposure more easily develop 
PP as found on chest X-ray [89]. A positive association between the degree and duration of asbestos 
exposure and the likelihood of finding PP on a chest X-ray has recently been confirmed [90]. 
In a review from 2011 [91] it is emphasized that most of the current knowledge about the relation 
between PP and thoracic malignancies is based on the detection on PP from chest X-ray. However, 
studies using CT for detection of CT have become more common in recent years. An early study 
showed that CT of the chest could detect PP in subjects without any signs of PP on chest X-ray 
according to ILO-criteria. In a group of 231 asbestos exposed workers seeking compensation and 
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having no PP according to ILO-criteria on a chest X-ray CT showed bilateral PP in 46 and unilateral 
PP in 26 [92]. Contrary to this, a recent review  stated, "when compared with computed tomography 
(CT) scan, most pleural plaques are in fact identified via CXR".[262] However, this seems to be a 
misinterpretation of the quoted reference Elshazeley et al could by CT confirm most PP found on chest 
X-ray, but no subjects without PP on chest X-ray where investigated by CT. [93]. 
As for chest X-ray CT has shown that longer time since first exposure and higher estimated dose 
increase the incidence of PP [94]. Despite the sensitivity of CT, lack of PP on a CT does not rule out 
asbestos exposure. In the study by Paris et al all participants were considered to have some degree of 
asbestos exposure, but no more than about 20% had PP in the most exposed group. Data from the 
same French cohort study have been used to study the agreement between the initial evaluation of the 
CT and a final consensus evaluation by a specialist panel. Only a moderate agreement with a kappa = 
0.58 was found. A recent study has shown that CT may systematically overestimate the true 
prevalence of PP, if the patient is only studied in the supine position. It was observed the some of the 
suspected PP disappeared when the CT was repeated in the prone position [95]. A CT did not find at 
relation between the PP area and the estimated asbestos exposure [96]. 
Many studies have investigated possible increased lung cancer risk among persons with PP. Weiss 
published a review of 13 studies in 1993 [97]. Ten of the reviewed studies showed no association 
between PP and lung cancer in subjects without asbestosis. A panel of French experts reanalyzed lung 
cancer mortality from the 6 cohort studies included in the Weiss review [91]. They found an SMR of 
1.5 (95% CI 1.2-1.9) based on 83 observed lung cancer cases in individuals with PPs. Hillerdal 
showed that asbestos-exposed individual have an increased lung cancer risk compared to the general 
population [85]. In the CARET study 2089 asbestos-exposed individuals were followed. A nearly 
doubling of lung cancer risk was observed among those with pleural thickening or plaques [RR = 1.91, 
95% CI 1.25-2.92]. Age, smoking and asbestos exposure duration were controlled for. However, there 
was no data on cumulative exposure (Cullen, 2005).  The American Thoracic Society concluded in 
2004 that PPs are associated with an increased lung cancer risk compared with those with similar 
exposure but without PPs [108]. 
Bilateral PPs on a chest X-ray are strong indicator of previous asbestos exposure beginning 20 or more 
years ago. Individuals with PPs have an increased lung cancer risk compared to the general 
population. However, there is insufficient and contradictory evidence concerning an increased lung 
cancer risk in persons with PPs compared to others with similar asbestos exposure but without PPs. 
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There is a lack of evidence concerning the importance of PP only visible on CT. There is a need for 
prospective CT studies of asbestos-exposed individual with PPs. 
 
ASBESTOS BODIES (AB) AND ASBESTOS FIBERS (AF) 
Asbestos bodies are asbestos fibers covered with an iron-protein coat [98] There are also a number of 
characteristics that asbestos fibers typically have in order to induce the formation of asbestos bodies:  
insoluble, length greater than 10 µm, diameter less than 1 µm, and a straight and rigid shape [99, 105]. 
Subsequently, asbestos bodies rarely form on chrysotile asbestos fibers.  It should be noted that 
ferruginous bodies are not the same as asbestos bodies as ferruginous bodies are any mineral fiber, 
non-mineral fiber, or non-fibrous particles that acquire an iron-containing coat,  
 
 
In Denmark there is no tradition for identifying and counting AF in biological specimens. Thus it is 
only relevant to look into possibility of using ABs as a marker of previous asbestos exposure. ABs are 
a hallmark of asbestos exposure. Studies have demonstrated good correlations between ABs recovered 
in bronchoalveolar lavage (BAL) and ABs in lung tissue [102, 103] ABs in BAL correlate well with 
the number of amphibole (amosite and crocidolite) fibers, but not chrysotile fibers in lung tissue [104] 
The European Respiratory Society has published recommended methods for identifying and counting 
ABs in BAL [263]. One AB/ml reflects between 100 to 10,000 ABs/cm3 wet lung tissue[100]. One 
AB/ml is considered to reflect asbestos exposure [103, 106]. However, it is not possible to estimate 
when the exposure has taken place. 
 
With this background, the Helsinki Criteria from 1997 recommended that the presence of >1 AB/ml 
should be used to indicate probable work-related asbestos exposure [107]. The American Thoracic 
Society [108] has adopted the position that the presence of ABs in BAL is a reliable and clinically 
useful marker of previous asbestos exposure.  
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APPENDIX 14. NARRATIVES OF COHORT AND CASE-CONTROL 
STUDIES (4.3) 
A number of articles arise from a limited number of cohorts, which are also basis for many of 
the meta-analyses shown in section 4.3. 
COHORT STUDIES 
Mining and milling 
The Quebec mining cohort. One of the oldest cohorts is the Canadian miners comprised of 
10,918 males and working with mining and milling in Quebec summarized by [120]. The 
persons were born between 1893 and 1920 and followed until 1992. The authors stated that 
there was a negligible excess lung cancer risk below 1,000 f-y/ml (300 mppcf-years). However, 
RRs were 1.3-1.5 for 100 f-y/ml (30 mppcf-years) and on. 
The Wittenoon crocidolite miners [150, 151, 264]. This Australian study comprised 6,910 men 
and 4,415 women employed between 1943 and 1966 and followed until 2007. Exposure was 
estimated from a survey in 1966 and was high with a median of 17.8 f/ml, while the period of 
employment was short, in median 128 days. Of the 2,421 deceased 222 died of mesothelioma 
and 302 from lung cancer. A relatively high loss to follow up was seen, 27%. This study has 
been the main source of dose response relation to crocidolite.   
In a South African study with 7,317 amphibole miners [265] there was a dose-response 
association for both years of exposure and cumulative exposure.  SMR values increased with 
increasing exposure time, starting 1-4 years of asbestos exposure. Increased SMR of 223.5 
(p<0.05) for 10-19 years residence time with 1-4 f-y/ml exposure. SMR for bronchogenic 
carcinoma according to cumulative dust exposure was 143.9 for the 1-5 f-y/ml group. The 
relative risk of lung cancer was 1.01 (1-1.01) for each increment of 1 f-y/ml (kL~ 10 *10-3 per f-
y/ml) and 1.12 (1.04-1.20) for each year of exposure.  
Sluis-Cremer and colleagues performed new analysis of the same study population of South 
African amphibole miners as Sluis-Cremer did in 1991 [130]. Data suggested that there were 
26.4 more deaths from lung cancer than expected, given a SMR of 172 (CI 132-221). 
Crocidolite had higher toxicity than amosite for lung cancer; SMRs were 138 (CI 97-191) and 
203 (CI 143-280) for amosite and crocidolite respectively.  
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The study of 1,672 American vermiculite mine, mill and process workers [132] exposed to 
amphibole asbestos showed clear dose-related increases in lung cancer mortality. There was an 
increased lung cancer SMR of 170 (CI 140-210) with 15 years lag time and a borderline 
significant SMR for low exposures (<4.5 f-y/ml) of 150 (CI90-230). Short-term employment (< 
1 year) also increased SMR to 160 (CI 110-210).  
Data from a study on mortality from cancer in the Balangero cohort of 1,056 chrysotile asbestos 
miners [126] showed no significant increased risk for lung cancer death in spite of high 
exposures over 400 f-y/ml, SMR 1.27 (CI 0.93-1.70). No dose-response association was shown 
for lung cancer.  
Asbestos textile manufacturing 
The South Carolina Textile study. A series of articles have dealt with this cohort of persons 
working at this plant producing asbestos textiles from mainly chrysotile but also small fraction 
crocidolite [112] reported about a cohort of 768 white males working with textile production 
and who were exposed to chrysotile asbestos suggested a linear dose-response relationship for 
lung cancer with no threshold. SMR = 223 for <275 f-y/ml, 357 for 275 -1,100f-y/ml, 978 for 
1,100 – 2,750 f-y/ml, 1,553 for 2,750-5,500f-y/ml. This steep dose-response as estimated from 
regression line based on categorical analysis gives RR of approximately 5 for 100 f-y/ml or a kL  
= 50 *10-3 per f-y/ml. 
In the subsequent follow up slightly different inclusion criteria were used [111]. The subjects 
were 3,022 white males and females and black males exposed to chrysotile and a little 
crocidolite. White males and females experienced statistically significant excess mortality due 
to lung cancer, SMR= 2.30 (1.88-2.79) and 2.75 (2.06-3.61) respectively. There was increased 
risk for death due to lung cancer with increasing cumulative exposure. The trend was significant 
for white males (Z=2.88; p<0.01) but not for white females (Z=1.71; p>0.05). Data for the 
entire cohort demonstrate an increase in the lung cancer relative risk corresponding to a kL of 
20-30 (f-y/ml)-1 of cumulative chrysotile exposure  
Stayner and colleagues [131] made a detailed dose-response analysis of this material using 
different models of life time risks. They concluded that a multiplicative model fitted the data 
better than a linear (additive) model. Moreover, there was no evidence for a threshold. The 
slope kL was estimated to 21 (95% CI 8-36)*10-3 per f-y/ml. 
Hein and colleagues [116] the same population with follow up till 2001 Dose response 
associations were observed with steeper slope for 10-year lag time than for no lag time or 5-year 
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lag time. The increase in relative risk of lung cancer after 10-year lag time was 19.8 * 10-3 per f-
y/ml. The lung cancer mortality was lower for females and non-whites. 
 
North Carolina and Pensylvania textile workers. A study from the American textile industry 
was conducted by McDonald and colleagues [122] and consisted of 4,137 males from a 
Pennsylvania textile factory. The subjects were mainly exposed to chrysotile asbestos and less 
to crocidolite. SMR for lung cancer increased from 66.9 to 416 for exposures from 0 to >80 
mppcf (corresponding to 250 f-y/ml)  
 
A relatively new study by Loomis and colleagues [121] analyzed the association between 
chrysotile asbestos and lung cancer death among 5,770 American men and women employed in 
North Carolina textile plants. The authors found significantly higher mortality from lung cancer 
than expected with SMR of 1.96 (95% CI 1.73-2.20). Also, the risk of lung cancer increased 
with cumulative fiber exposure (RR 1.102 per 100 f-y/ml, 95% CI 1.044 to 1.164) which 
amounts to about to a kL of 10.2 (95% CI: 44- 164)*10-3 per f-y/ml.  
 
In a recently published study the population comprised of 6,136 predominantly white American 
males exposed to chrysotile asbestos and small amounts of crocidolite and amosite in the North 
Carolina (NC) and South Carolina (SC) textile production industry [114]. The researchers found 
significantly higher lung cancer mortality than expected (SMR 1.90, 95% CI 1.70 to 2.11). 
However, a linear model did not give the best fit. The lung cancer slope was steeper for workers 
from SC than NC. Likely explanations were exclusion from work of workers with 
pneumoconiosis, workers with short exposure not being enumerated and less precise exposure 
information for NC workers. The slope for SC was judged to be less prone to such bias, and was 
20 * 10-3 per f-y/ml as excess RR (linear model).  
 
In Peto´s published article [124] with information on 679 males from United Kingdom working 
in the textile industry, RR from lung cancer death peaked 25-35 years since first exposure. No 
formal dose-response analysis was undertaken but there was an overall excess of lung cancer 
death, and findings claimed to be compatible with a RR of 2-3 for 200-300 f-y/ml.  
 
Among 3,211 male workers from United Kingdom Peto and colleagues [125] analyzed the 
relationship of mortality to measures of environmental chrysotile and crocidolite asbestos 
pollution in the Rochdale asbestos textile factory. The dose-response was SMR 1.53*10-4 per 
particle-year/ml, approximated for SMR 0.005 per f-y/ml (entire cohort) and SMR 0.015 (those 
employed 1951 or later), respectively. Suggested prediction: SMR = 1+0.01xf-y/ml. RR for 
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lung cancer was lower 35 years or more after first exposure as compared to 20-34 years. Risk 
was independent of age at first exposure. 
Insulation manufacturing and work 
The New Jersey insulation workers. In a study of 820 white American males exposed to amosite 
asbestos and very little chrysotile when working with insulation of pipes, boilers and turbines of 
ships [127] a linear zero threshold dose-response association seemed implausible. The SMR was 
541 for lung cancer from 5 to 40 years after onset of work. The heavier the dose, the greater the 
response tended to be in terms of higher SMRs.  Marked excesses were evident within 15 years 
for the longer-tern workers. For those worked shorter periods of time it took 25 years or more.  
Another study with insulation workers analyzed amphibole asbestos-associated deaths in a 
cohort of 17,800 American and Canadian males [128]. Large RRs of lung cancer was found. 
The RR increased from 2.32 at <15 years from start of exposure up to the maximum at 4.90 
after 30-40 years since onset.  
Asbestos cement workers 
Belgium data from an asbestos cement plant with 29,366 man-years of follow up [118] showed 
no significant (p=0.11) risk in respiratory cancers with increasing chrysotile, crocidolite and 
amosite asbestos exposure. 
A Swedish study of 1,465 chrysotile asbestos exposed cement workers (with nested case-control 
analysis for mesothelioma) found no significant increased risk of lung cancer death among the 
asbestos exposed [109]. Lung cancer RR incidence (f-y/ml): <15 f-y/ml= 1.8 (CI 0.8-3.9), 15-39 
f-y/ml= 1.9 (CI 0.7-5.3), >40 f-y/ml= 1.9 (CI 0.5-7.1).  
Mixed industries 
A study of Clin and colleagues [110] comprised of 2,004 French men and women working with 
textile, brakes and clutches. The subjects were mostly exposed to chrysotile (80%) but 
crocidolite was also present. There was no significant dose-response association between the 
number of years during which subjects were exposed (cumulative exposure) and lung cancer. 
However, the adjusted relative risk for lung cancer corresponding to the highest exposure tertile 
(140	  -­‐	  853	  f-­‐y/ml)	  was 3.99 (95% CI 1.15 to 13.86). 
586 Chinese men working with textile, brakes and cement were assessed for an association 
between chrysotile asbestos and lung cancer death [113]. Data suggested a strong significant 
association between exposure to chrysotile asbestos and lung cancer death (p<0.001) in which 
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clear exposure-response relationships were observed. No threshold for asbestos causing lung 
cancer was identified. The power model fitted best with 10-year lag time.  
 
Among 1,074 white men exposed to chrysotile, amosite and crocidolite in an American asbestos 
company manufacturing insulation, roof materials and engineered products, Enterline and 
colleagues [115] demonstrated a statistically significant dose-response relationship for lung 
cancer death that had become increasingly linear. SMR = 182, 203, 322, 405 and 699 for dust 
exposure <125, 125-249, 250-499, 500-749, and ≥750 mppcf-y  respectively.  
 
Data from an American study showed significant (p≤ 0.01) excess of death due to lung cancer 
among 6,931 black and white males working in two cement manufacturing plants and exposed 
to chrysotile (primarily), amosite and crocidolite asbestos [117]. The relation (RR = 1 + 0.0076 
x, for x in f/ml-years) predicts a relative risk of 1.038 for workers exposed to 0-2f/ml for 25 
work years, or about 2 lifetime lung cancers per 1000 workers based on United States male lung 
cancer rates.  
 
An American research group conducted a study of 1,121 males working with pipe insulation 
and exposed to amosite asbestos in 1998 [119] The study supported a significant excess of death 
from lung cancer due to amosite exposure, SMR = 277 (CI 193-385).  
 
Another study by McDonald and colleagues was based on data from an American chrysotile 
asbestos friction products plant [123]. Data from 3,641 males were analyzed. There was a raised 
risk of death from lung cancer with SMR of 148.7. However, any clear or systematic exposure-
effect pattern was lacking. A reverse exposure-response was shown with duration of exposure 
and SMR was greatest for those working <1 year. No dose-response association with 
cumulative exposures was shown (mppcf-year). 
 
CASE-CONTROL STUDIES 
In United Kingdom 106 men dead from lung cancer who had worked with production of friction 
materials   (chrysotile and crocidolite exposure) were matched with 318 workers from the same 
factory [133] There was no indication of an increased risk of lung cancer with either duration of 
exposure or cumulative exposure in the categorical analysis. A fitted coefficient for a linear 
relationship was estimated to 00.58 *10-3 per f-y/ml.  
 
Gustavsson and colleagues carried out a population-based case-referent study where the 1,038 
cases were all lung cancer cases from 1985 to 1990 in Stockholm aged 40-75 years [134] Two 
referent groups were used; the main group was population-based. However as most of the cases 
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(93%) were deceased, a separate group with the same mortality was included to analyze the 
possible bias due to different mortalities).  An elaborate estimation of life time exposure to 
asbestos, engine exhaust, metal dust, oil mists and welding was obtained by a combination of 
interview, and expert judgments, for asbestos supported by results from a nationwide 
measurement program from 1969-73. Exposure was categorized both according to probability 
and intensity distributed in classes unexposed, 0-0.99, 1-2.49, 2.5-4.99, and >4.5 f-y/ml. The 
highest exposure was 20.4 f-y/ml. Data indicated an excellent dose-response for mean 
cumulative exposure with an increased RR 149 (CI95% 119-187) *10-3 per f-y/ml [135]. There 
was poor correlation with length of exposure. Comparing the risk of lung cancer due to asbestos 
with the other exposures, asbestos clearly provided most lung cancers both estimated from the 
risk rates and from the attributable cases. 
Gustavsson and colleagues further analyzed the Stockholm lung cancer population in 2002 with 
focus on dose response relations and the interactive effect of asbestos and smoking ([135]. The 
authors found that lung cancer risk increased with cumulative exposure according to an almost 
linear relationship. The calculated risk at cumulative dose of 4.0 f/ml-years was 1.90 (95% CI 
1.32-2.74), and was 5.38 among never-smokers and 1.55 for current smokers. This 
corresponded to kL values much higher than from the industrial cohorts, about 480 *10-3 per f-
y/ml. The asbestos-smoking interaction was between additive and multiplicative but closest to 
additive.  
In 2002 results from a German two-phase case-control study was published [136]. The study 
population consisted of 1,678 West German lung cancer male patients from Bremen and a small 
group from Frankfurt between 1988 and 1993.  164 cases were matched with 164 controls 
according to asbestos exposure estimated by interview supported by expert judgment. Log 
transformation of exposure (ln[f-/ml+1]) gave the best fit. The estimate was ln(f-y/ml+1): OR = 
1.18 (95% CI 1.052-1.318), corresponding to a doubled risk from exposure to 25 f-y/ml. 
A project merging a set of different population based studies of asbestos and lung cancer  with 
updated exposure assessments, project SYNERGY [266, 267]  is underway. The status of the 
project is not known, but this study will give a more solid basis for estimating dose response in 
the lower range of exposure. 
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APPENDIX 15. LIST OF INCLUDED STUDIES IN THE META-ANALYSES 
(4.3) 
Table A13. List of included studies in the meta-analysis. 
First author, year of 
publication, (ref no.) 
Lash 
et al.,1997 
Goodman 
et al., 1999 
Berman et 
al., 2008 
Lenters 
et al., 2011 
van der Bij 
et al., 2012 
Hodgson et 
al., 2000 
Acheson, 1982 X 
Acheson, 1984 X 
Albin, 1990 X X X X X 
Alies-Patin, 1985 X 
Amandus, 1987 X X 
Armstrong, 1988 X X 
Berry, 1983 X X X 
Berry, 2004 X X X 
Blasetti, 1990 X 
Clemmesen, 1981 X 
Danielsen, 1993 X 
De Klerk, 1994 X 
Dement, 1983 X 
Dement, 1994 X X X 
Enterline, 1967 cohort 
I,II,III X 
Enterline, 1986 X 
Enterline, 1987 X X X X 
Finkelstein, 1983 X 
Finkelstein, 1984 X X X X X X 
Finkelstein, 1989 X 
Fletcher, 1993 X 
Gardner, 1986 X 
Giaroli, 1994 X 
Gurvich, 1993 X 
Gustavsson, 2002 X X 
Hein, 2007 X X X 
Henderson, 1979 X 
Hilt, 1991 X 
Hobbs, 1980 X 
Hodgson, 1986 X 
Hughes, 1987 X X X X X X 
Jones, 1980 X 
Kolonel, 1985 X 
Lacquet, 1980 X X X X 
Levin, 1998 X X X 
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First author, year of 
publication, (ref no.) 
Lash 
et al.,1997 
Goodman 
et al., 1999 
Berman et 
al., 2008 
Lenters 
et al., 2011 
van der Bij 
et al., 2012 
Hodgson et 
al., 2000 
Liddell, 1977 X 
Liddell, 1997 X X X X X 
Loomis, 2009 X X 
Magnani, 1986 X 
Magnani, 1996 X 
Mancuso, 1963 X 
McDonald, 1980 X 
McDonald, 1982 X X 
McDonald, 1983a X X 
McDonald 1983b X X X X X 
McDonald, 1984 X X X X X X 
McDonald, 1986 X 
McDonald, 1993 X X 
McDonald, 2004 X 
Menegozzo, 1993 X 
Meurman, 1994 X 
Morinaga, 1990 X 
Moulin, 1993 X 
Neuberger, 1990 X X X 
Newhouse, 1985 X 
Newhouse, 1985 X 
Newhouse, 1989 X X 
Nokso-Koivisto, 1994 X 
Ohlson, 1984 X 
Ohlson, 1985 X X 
Oksa, 1997 X 
Pang, 1997 X 
Peto cohort I,II,III 
1985 X X X X X 
X 
Piolatto, 1990 X X X X 
Pira, 2009 X X 
Puntoni, 1979 X 
Raffn, 1989, 1993, 
1996 X 
Robinson, 1979 X 
Rosler, 1994 X 
Rossiter, 1980 X 
Sanden, 1992 X 
Seidman, 1979 X 
Seidman, 1990 X 
Seidman, 1986 X X X X X X 
Selikoff, 1991 X X X X 
Sluis-Cremer, 1992 X X 
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First author, year of 
publication, (ref no.) 
Lash 
et al.,1997 
Goodman 
et al., 1999 
Berman et 
al., 2008 
Lenters 
et al., 2011 
van der Bij 
et al., 2012 
Hodgson et 
al., 2000 
Sullivan, 2007 X X X 
Szeszenia-Dabrowska, 
1986 X 
Szeszenia-Dabrowska, 
1991 X 
Talcott, 1989 X 
Tarchi, 1994 X 
Teta, 1988 X 
Thomas, 1982 X 
Tola, 1988 X 
Ward, 1994 X 
Weill, 1979 X 
Weiss, 1977 X 
Woitowitz, 1986 X 
a) Dust exposure and mortality in an American chrysotile textile plant. Br J Ind Med 1983; 39: 361-
367 
b) Dust exposure and mortality in an American factory using chrysotile, amosite, and crocidolite in
mainly textile manufacture. Br J Ind Med 1983; 40: 368-374 
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APPENDIX 16. DISEASES AND/OR CONDITIONS THAT INFLUENCE THE 
DEVELOPMENT OF ARLC (4.4) 
RACE AND ETHNICITY 
There are significant racial and sex differences in lung cancer incidence and mortality rates. The 
lowest incidence in the USA is 19.2 per 100,000, among white women in Utah, and the highest is 149 
per 100,000 among black men in Wisconsin. This difference likely reflects differences in smoking 
prevalence [166]. Lung cancer occurrence is approximately 45% higher among African-American men 
than among white men. This racial disparity may be partially due to greater susceptibility of African-
American smokers to smoking-induced lung carcinogenesis [156] Worldwide comparisons are 
hampered by differences in smoking habits and by the fact, that lung cancer is predominantly a disease 
of the elderly. It rarely occurs before age of 40 and in Denmark half of the cases occur in persons over 
70 years old. In countries with much lower life expectancy lung cancer incidence therefore might 
differ markedly. 
 
SEX 
Although sex differences largely reflects smoking differences, “true” sex differences might exist. 
Bilello et al. [166] reviewed both case-control and cohort studies on sex differences in lung cancer and 
found that in 4 case-control studies odds of developing lung cancer were from 1.2 – 2.8 folds higher in 
women than in men when adjusted for smoking habits. In contrast, five of six major cohort studies 
showed lower relative risks for lung cancer death among women than among men [166]. If women do 
have an enhanced biologic susceptibility to lung cancer, it could be related to endocrine factors or to 
sex differences in genetics and activation and detoxification of carcinogens. In support of a possible 
role of estrogens in the development of lung cancer, it has been shown that estrogen replacement 
therapy was associated significantly with lung adenocarcinoma (OR 1.7), with even higher risk among 
women who used estrogen and smoked (odds ratio 32.4). Conversely, early age at menopause (40 
years old or younger) was protective (odds ratio 0.3) [166]. 
 
Also major differences between men and women in the relative distribution of histologic types of lung 
cancer has been found. Adenocarcinoma used to be the most common type of lung cancer in women 
and squamous cell carcinoma in men [166]. Over the last few decades, the proportion of squamous cell 
carcinomas has decreased and an increase of adenocarcinomas has taken place in both sexes. The risk 
for all major histologic types is strongly associated with smoking in both sexes [172] The changes in 
117 
the prevalence of smoking among women in the past decades have been reflected in the increased 
incidence of lung cancer among women so that the former sex differences have almost disappeared in 
Denmark [7]. No evidence for sex differences in the susceptibility for tobacco smoking in relation to 
lung cancer was found in a Danish cohort study [173]. 
FAMILY HISTORY OF LUNG CANCER 
It has been estimated that between 3% and 6% of all lung cancer cases have a positive family history 
of the disease [158]. Familial aggregation of lung cancer has been studied in both case-control and 
cohort studies with conflicting results. Matakidou et al. [160] performed a systematic review of 28 
case-control, 17 cohort and 7 twin studies of the relationship between family history and risk of lung 
cancer. Meta-analysis of data from the case-control and cohort studies combined showed an increased 
lung cancer risk with a RR = 1.84 (CI: 1.64–2.05). Risk appeared to be greater in relatives of cases 
diagnosed at a young age and in those with multiple affected family members. Familial risks reflect 
both common exposures and genetic predisposition. Smoking is the most important environmental risk 
factor of lung cancer, and the association between a person’s smoking habits and that of his parents or 
siblings has been well documented. Only four of the studies included in the analysis attempted to 
address this issue by taking into account the smoking habits of both the study subjects and their family 
members. To minimize the impact of shared smoking habits in families, a few studies have estimated 
familial risks associated with nonsmoker status. Pooling of the data in never-smokers resulted in an 
elevated risk of lung cancer associated with a family history of the disease that was statistically 
significant; supporting the view that genetic or other environmental factor than smoking may play a 
role in familial aggregations. It is however noteworthy, that follow-up of 15,924 male twin pairs in the 
United States did not show greater concordance in monozygotic compared with dizygotic twins, and 
death rates from lung cancer were similar by zygosity group in surviving twins whose sibling died of 
lung cancer [167]. A larger study including 44,788 pairs of twins listed in the Swedish, Danish, and 
Finnish twin Registries found non-statistically significant hereditable factor of 0.27 (95% CI: 0 – 
0.49). The concordance for lung cancer in male monozygotic twins was 0.11. It was estimated that 
shared environmental factors accounted for 12%, and non-environmental factors for 62% of the 
variance in the cohort [170]. The familial relative risk of lung cancer decreased with increasing 
smoking prevalence [157] indicating the dominant role of this exposure in developing lung cancer. 
THE GENETIC BASIS OF LUNG CANCER 
Direct evidence for a genetic predisposition is provided by the increased risk of lung cancer associated 
with carriers of constitutional TP53, retinoblastoma, individuals with xeroderma pigmentosum, 
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Bloom’s and Werner’s syndromes [160]. These conditions are however so rare that they play an 
insignificant role in the development of lung cancer in the population at large. 
This rapidly expanding area includes research on several levels: dosimetry and metabolism of 
carcinogens at the cellular and molecular level, genetic determinants of susceptibility, and in vivo 
genetic tissue changes. An example of the latter is seen in epigenetic methylation of DNA cystine 
leads to hypermethylation of promoter regions that are frequently found in lung cancer [156] [268]. 
Much of this research is based on studying tobacco and lung cancer. Carcinogens are often 
metabolized in two phases. In phase 1 highly reactive intermediates are produced due to oxidation. For 
example cytochrome p450 forms (e.g. CYP1A1) reactive intermediaries that bind to DNA and cause 
genetic damage, which has been linked to lung cancer risk [156]. In phase 2 conjugant reactions phase 
1 intermediaries form complexes with conjugated molecules. Phase 2 enzyme glutathione S-
transferase (GST) detoxify reactive metabolites, e.g. polycyclic aromatic hydrocarbons (PAH). Gene-
gene interaction may be important. For example the combination of two variant genotypes, GSTM1 
null and CYP1A Ils462Val polymorphisms, are associated with a four-double lung cancer risk in non-
smokers [156]. 
Other factors determining lung cancer susceptibility in smokers are oncogenes, suppressor genes and 
DNA repair capacity. The tumor suppressor gene, p53, has particularly been in focus. This gene is 
muted in > 90% of small cell cancers. However, studies have found strong associations between the 
common p53 polymorphisms and lung cancer [156, 164]. Much research has focused on DNA repair 
and susceptibility. Historically, the classic example is the increased cancer risk among individuals 
with the rare recessive disorder, xeroderma pigmentosa. A number of DNA repair genes have been 
studied in relation to lung cancer susceptibility, but it has been difficult to demonstrate consistent and 
significant associations [159]. 
Genome-wide association studies (GWAS) have identified some novel loci for lung cancer risk. A 
recent study has looked specifically at the gene-environment interaction of asbestos exposure and lung 
cancer [165]. The most significant gene was C7orf54 located on 7q32.1. This pilot study attempts to 
evaluate how SNPs, genes and pathways are related to gene-asbestos interaction in lung cancer risk. 
Although interesting, this study does not present any clinically applicable information. Recently 
Wright et al. [175] have tried to differentiate ARLC from non-ARLC using whole genome array 
comparative hybridization profiling. Some regions with significant copy number gain and loss unique 
to ARCL were identified. 
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In a series of studies Nymark et al have identified genetic abnormalities related to lung cancer 
associated with asbestos exposure, and the findings may be helpful for identifying lung cancer caused 
by asbestos in the future. In a broad spectrum of 18 chromosomal regions with copy number 
alterations [269] there was 6 regions which also had miRNA changes [162]. 
These results were further studied on material from 13 asbestos exposed and 13 non-exposed lung 
cancer patients, matched for age, sex, nationality, smoking history, and histological cancer type. All 
were interviewed for smoking and work history. Quantization of fiber count of lung tissue was 
performed by electron microscopy with energy dispersive spectrometry. Analysis were performed with 
investigation of miRNA, mRNA and CGH (comparative genomic hybridization) from cancer and non-
cancer tissue from patients and 8 control samples of non-lung cancer patient: thirty-four miRNAs 
differed between paired samples of tumor and normal tissue.  In integration with mRNA and CGH 
there was association with copy number alterations [269] and inverse correlation with target genes 
[161]. 
The results were taken to a larger study of 225 patients with 126 asbestos exposed and 99 non-exposed 
based on pulmonary fiber count by electron microscopy with energy dispersive spectrometry ( not all 
materials were included in all tests). Based on the former study genomic alterations in 19p13, 2p16 
and 9q33.1 were investigated for CNA and allelic imbalance (AI). A combination of 2 out of 3 
genomic alterations (CNA and/or AI) was associated with asbestos exposure with a sensitivity of 38% 
and specificity of 96%. The study is confounded with smoking in the exposed group, and therefore the 
sensitivity and specificity might be higher. The combined test might be helpful in identifying asbestos 
exposed patients [163].  
MOLECULAR PATHOLOGY OF ARLC 
Molecular changes in asbestos-related lung cancer are relevant for tumor pathogenesis, for use in 
screening/identification and specific diagnosis, and for targeted therapy. Although a large amount of 
information is available on the responses of cells to asbestos, understanding the pathogenesis of ARLC 
has been hampered by the complexity of and differences between fiber types and multiple interactions 
between tobacco smoke and asbestos. More recent studies of the mechanisms of asbestos-induced 
injury and disease have focused on the importance of the creation of reactive oxygen species (ROS) 
and reactive nitrogen species (RNS), which can lead to cellular damage and toxicity. In vitro, asbestos 
fibers have been shown to stimulate the production of ROS and RNS though iron-mediated and cell-
mediated mechanisms. These mechanisms involve indirect effects that are thought to lead to DNA 
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damage, and in some cases, may lead to carcinogenesis. Several different explanations have been put 
forth for how asbestos might cause or be contributing to lung cancer. These include: 
• Redox processes in combination with disturbance of iron homeostasis
• Generation of oxidants by inflammation elicited by asbestos fibers and interaction with other
cell types, i.e. macrophages (frustrated phagocytosis)
• Direct action of asbestos fibers on receptors on the alveolar epithelial cell surface
Asbestos fibers have been shown to stimulation the production of reactive oxidative species (ROS) 
and reactive nitrogen species (RNS) through iron-mediated and cell-mediated mechanisms. Cell 
signaling by asbestos is thought to occur when asbestos fibers or products of asbestos fibers, such as 
ROS/RNS interact with the cell membrane or are phagocytosed [174]. After interaction with cells, 
asbestos fibers trigger numerous signaling cascades, including mitogen-activated protein kinases 
(MAPK) and nuclear factor κB (NFκB) (Mossman et al. 1997; Janssen et al. 1995). These events 
promote cellular responses, such as cell transformation, proliferation and apoptosis (programmed cell 
death). It has been shown that asbestos-mediated apoptosis may trigger compensatory cell 
proliferation [168, 169]. 
Relation to lung cancer: 
In lung cancer genetic alterations accumulate during tumor progression, resulting in severe genomic 
complexity in most lung cancers. For the time being, two mutations are tested for targeted therapy: 
EGFR and EML4/ALK translocation. It is not known, if some of the EGFR mutated lung cancers 
responsive to targeted therapy are related to asbestos. 
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Figure A3. Central pathways and interactions involved in asbestos related disease [270] 
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APPENDIX 17. OCCUPATIONAL RISK FACTORS FOR LUNG CANCER 
(4.4) 
Lung cancer has been observed to be associated with many workplace exposures. Among cancers that 
are associated with occupational exposures, cancer of the lung is the most common. Estimates derived 
from case-control studies of the proportion of lung cancer that is contributed to by occupational 
exposures, via independent or shared causal pathways, have ranged widely, but most point estimates 
or ranges have included values from 9 to 15%. Although disagreement persists concerning specific 
estimates, the lung cancer burden is small compared with that of cigarette smoking, but large 
compared with contributions of most other exposure classes [156] and high in occupational groups 
heavily exposed over a long time to workplace agents, such as asbestos.  
Table A14 summarizes the present state of knowledge on occupational carcinogen agents 
evaluated by International Agency for Research on Cancer [1] 
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Compared to cigarette smoking and partly to asbestos, other exposures are far less thoroughly 
evaluated. Often precise data are lacking on dose-response correlations and the extent to which 
cigarette smoking or concomitant occupational exposures potentiate (or attenuate) the effect of other 
occupational lung carcinogens. Effects of smoking were not well controlled in many studies and thus 
might represent a significant bias. In case-control studies very high odds ratios have been reported for 
the risk of lung cancer - for instance a 16 fold increase for lung cancer was reported in industrial 
manufacture of mustard gas – but RR of that order of magnitude are only  rarely observed apart from 
for asbestos and tobacco. 
Because tobacco use is a frequent confounding factor in studies of occupational risk for lung cancer, a 
European multicenter case-control study (650 patients and 1542 controls) was designed to address 
occupational risk factors for lung cancer in non-smokers[178]. An increased risk for lung cancer was 
shown in men and women who had worked in occupations known to be associated with an increased 
risk for lung cancer (shipyard or dockyard and railroad manufacture workers, painters, workers in 
nonferrous metal basic industries). However, the CIs were broad and the only statistically significant 
increase in RR for lung cancer was detected in women who were employed in occupations suspected 
to be associated with an increased risk for lung cancer - e.g., laundry and dry cleaning; work in rubber 
manufacturing; and ceramic, pottery, or glass workers (Table A15). The relative low RRs may reflect 
the fact, that in most European countries, the well-known hazards on IARC’s lists have been 
adequately controlled. 
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Table A15. Risk of occupational lung cancer[178] 
Odds Ratios of Lung Cancer for Ever Working in a List A1)- or List-B Occupation 
Men Women 
Cases Controls Odds Ratio 
95% 
CI2) Cases Controls 
Odds
Ratio
95% 
CI2) 
 Never A, never 
B   101 366 1,00 463 942 1,00 
 Ever A or ever 
B   40 165 1,20 
0,76-
1,92 46 69 1,67 
1,10-
2,52 
 Ever A  17 58 1,52 
0,78-
2,97 5 10 1,50 
0,49-
4,53 
Ever B, never A   23 107 1,05 
0,60-
1,83 41 59 1,69 
1,09-
2,63 
 Total  141 531 509 1011 
1) List A: A subset of the most common used industrial chemical classified in Group 1 by IARC.
List B: A subset of the most common used industrial chemical classified in Group 2A by IARC 
2) Confidence interval
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APPENDIX 18. ENVIRONMENTAL RISK FACTORS FOR LUNG CANCER 
(4.4) 
AIR POLLUTION 
During a typical day, the average adult inhales approximately 10,000 liters of air. Consequently, even 
the carcinogens that are present in low concentrations may be associated to lung cancer risk.  
Air pollution is a complex mixture of particulate matter (PM) and gas contaminants. PM is made up of 
solid and liquid particles suspended in the air: acids (e.g. nitrates and sulphates); organic chemicals 
(e.g. polyaromatic hydrocarbons, PAHs); metals; soil; and dust particles. According to the particles’ 
size, they are categorized into coarse particles (<10 µm and >2.5 µm, PM10), fine particles (2.5 µm 
and >0.1, PM2.5), and ultrafine particles (<0.1 µm) [158]. Combustion of fossil fuels, road traffic, 
industrial sites, and waste dumps are the major sources of air pollution. In industrial areas, high levels 
of PAH air levels correlate with DNA adducts in peripheral lymphocytes, and with an increased 
incidence of lung cancer [271].  PAHs are mutagenic and carcinogenic compounds [187].   
Extrapolation of the risks associated with occupational exposures to the lower concentration of 
carcinogens in polluted ambient air suggests that only a small proportion of lung cancer cases could be 
due to air pollution. A recent World Health Organization report on environment and health concluded 
that 19% of all cancers are globally attributable to environmental factors including occupational 
exposures [189]. Other reviews, not including occupational exposures, resulted in much lower 
estimates [184]. Most estimates are uncertain depending on estimated cancer risk and exposure (i.e. 
dose). 
Air pollution has been assessed as a risk factor for lung cancer in both case-control and cohort studies. 
Early studies, many with inadequate adjustment for smoking and other potential confounders, typically 
showed about 50% higher lung cancer incidence rates in urban areas and in communities polluted by 
industrial sources compared to rural, less polluted areas. Several case-control and cohort studies with 
adequate adjustment for smoking and other potential confounding factors similarly indicated higher 
risks for lung cancer in association with different measures of air pollution [191]. Whitrow et al. [194]  
systematically searched the literature regarding evidence for a causal relationship between air 
pollution and lung cancer. Ten case-control and four cohort studies fulfilled their search criteria. Of 
these eight studies demonstrated significant positive associations between environmental exposure and 
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lung cancer with a RR range of 1.14-5.2. One study found a negative association with RR 0.28. 
Smoking and occupational exposure were addressed in all studies, though often crudely with possible 
misclassification. Dose-response relationships were evident in three studies. The authors concluded 
that evidence for causality is modest, with intermediate consistency of findings, limited dose-response 
evidence and crude adjustment for important potential confounders.  
 
In a European case-control study controlled for potential confounders Vineis et al.[193] estimated lung 
cancer risk among non-smokers attributable to air pollution. They found that 5–7% of lung cancers in 
European never smokers and ex-smokers were attributable to high levels of air pollution, as expressed 
by NO2 or proximity to heavy traffic roads. The latter indicator has limitations, mainly related to the 
fact that it is associated to social class. The authors argue that NO2 is a better indicator for air 
pollution, at least in Europe, compared to fine or ultrafine particles. This has been extensively 
discussed in the recent revision of the WHO World Air Quality Guidelines [195]. The thresholds for 
indicators of air pollution exposure they used correspond to the high levels of exposure that 
characterize mainly Southern European countries (30 µg/m3 or higher) while levels of NO2 in 
Denmark and Sweden are closer to 10–20 µg/m3. 
 
Two prospective Danish cohort studies [190] that partially addressed weaknesses of earlier studies add 
evidence that suggesting that Danish air pollution from traffic is also associated with lung cancer risk. 
The IRRs (incidence rate ratio) for lung cancer were 1.30 with 95% CI, 1.07-1.57 and 1.45 (95% CI, 
1.12-1.88) for NOx concentrations of 30 to 72 and >72 µg/m3, respectively, when compared with <30 
µg/m3. This corresponds to a 37% (95% CI, 6-76%) increase in IRR per 100 µg/m3 NOx. This 
corresponds to results from other similar studies from other parts of the world. Overall it has been 
estimated that 1 to 2% of lung cancer cases are related to air pollution [158]. The Danish studies 
showed tendencies of stronger associations between air pollution and lung cancer among non-smokers. 
Raaschou-Nielsen et al.’s study is remarkable for better exposure data and better control for potential 
confounding factors than most previous studies. The authors state that the proportion of lung cancer 
cases attributable to air pollution in the whole Danish population is probably substantially less than 
14%. A precise estimate was however not given[191]. Doll and Peto [186] estimated that 1 to 2% of 
lung cancer was related to air pollution. Even in light of more recent findings Alberg concludes that 
this still seems to remain a reasonable estimate [156]. Overall it has been estimated that 1 to 2% of 
lung cancer are related to air pollution which is 35-70 cases in Denmark per year. 
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RADON 
The source of radon is uranium. It is estimated, that an average Danish one family house plot contains 
1 kg of uranium. From soil and rocks radon can diffuse through the ground and become concentrated 
in homes. In outdoor air the concentration is diluted by wind and extremely low.  In Denmark radon is 
abundant in soil in the eastern part of Jutland and all the islands in the eastern part of the country, 
especially in the eastern and southern part of Zealand and Bornholm.  
Although radon is chemically inert and electrically uncharged, it is radioactive, which means that 
radon atoms can spontaneously decay. As radon decays, it produces short-lived decay products (radon 
progeny). They are electrically charged and can attach themselves to tiny dust particles in indoor air. 
These dust particles can easily be inhaled into the lung and can adhere to the lining of the lung. As the 
deposited atoms decay, they emit alpha radiation. The unit radiation intensity from radon is Bequerel 
per cubic meter (Bq/m3). One Bq is one decay in one second. Alpha radiation may damage cells in the 
lung by disrupting DNA of lung or bronchial cells. This DNA damage has the potential to be first step 
in a chain of events that can lead to cancer. Alpha radiations travel only extremely short distances in 
the body. Thus, alpha radiations from decay of radon progeny in the lungs cannot reach cells in any 
other organs. This may explain why lung cancer is the only important cancer hazard posed by radon in 
indoor air. 
There is good evidence that a single alpha particle can cause major genomic changes in a cell, 
including mutation and transformation. Even allowing for a substantial degree of repair, the passage of 
a single alpha particle has the potential to cause irreparable damage in cells. In addition, many cancers 
are of monoclonal origin, that is, they originate from damage to a single cell. These observations 
provide a mechanistic basis for a linear relationship between alpha-particle dose and cancer risk at low 
exposure levels. On the basis of these mechanistic considerations and in the absence of credible 
evidence to the contrary, a linear-non-threshold model for the relationship between radon exposure 
and lung cancer risk is generally accepted. Although it is recognized that a threshold relationship 
between exposure and lung cancer risk at very low levels of radon exposure cannot totally be excluded 
. 
About 25% of houses in Denmark are estimated to have a radon concentration >100 Bq/m3. Radon 
concentrations above this level are found in about 5% of Danish houses . 
The epidemiological evidence of the carcinogenicity of radon decay products is derived mainly from 
cohort studies of underground miners that had been exposed to high levels of radon. Occupational 
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exposure in mining can cause lung cancer in humans, while the evidence for an effect on other 
neoplasms is not conclusive [188]. 
 
The excess risk estimated from occupational cohorts, which included over 2500 cases of lung cancer 
occurring among over 60,000 miners, has been estimated in the order of 0.0049 per working level 
month of exposure [183]. Further refinements of this estimate took into account age at exposure and 
time since first exposure as well as smoking status, and showed a stronger effect among never-
smokers than among smokers.  
 
As the higher end of residential exposure range is comparable to exposures that caused lung cancer in 
underground miners with the lowest exposures, and as a linear relationship also applies to the lowest 
levels of exposures, residential exposures might be relevant for lung cancer risk (National Research 
Council, 1999). 
 
Since valid risk estimates could not be derived from a single study, a combined analysis of 7 North 
American case-control studies were carried out by Krewski et al. [181]. A total of 3662 cases and 
4966 controls were included. ORs for lung cancer increased with residential radon concentration. The 
estimated OR after exposure to radon at a concentration of 100 Bq/m3 in the exposure time window 5 
to 30 years before the index date was 1.11 (95% confidence interval = 1.00-1.28). The authors stated, 
that this estimate was compatible with the estimate of 1.12 (1.02-1.25) predicted by downward 
extrapolation of data from uranium miner workers previous published. Analyses restricted to subsets 
with presumed more accurate radon dosimetry resulted in increased risk estimates. The same 
researchers in 2006 published a follow up with an extended data set including 4081 cases and 5281 
controls but with the same exposure time window, 5 to 30 years [172]. The estimated lung cancer OR 
generally increased with radon concentration. The OR trend was consistent with linearity (p = .10) and 
the excess OR was 0.10 per Bq/m3 with 95% confidence limits (−0.01, 0.26). For the subset of the data 
considered previously [181], the excess OR was 0.11 (0.00, 0.28). Further limiting subjects based on 
more strict criteria for exposure (residential stability and completeness of radon monitoring) led to 
increased estimates of the excess OR. For example, for subjects who had resided in only one or two 
houses in the 5–30 exposure time window and who had alfa-track radon measurements for at least 20 
year of the 25-year period, the excess OR was 0.18 (0.02, 0.43) per 100 Bq/m3. Both estimates were 
compatible with the excess OR of 0.12 (0.02, 0.25) per 100 Bq/m3 predicted by downward 
extrapolation of miner data [182].  
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A pooled analysis of European studies of residential radon exposure and lung cancer resulted in a RR 
of 1.08 (95% CI 1.03–1.16) for an increase in radon exposure of 100 Bq/m3 [180]. The population-
weighted average indoor radon exposure in 29 European countries has been estimated to be 59 Bq/m3 
[192] resulting in an attributable fraction of 4.5%. The average radon exposure level was higher than 
the level found in a recent Danish prospective cohort study on long-term association between 
residential radon and lung cancer with 57,053 persons that were recruited during 1993–1997. In that 
study the median estimated radon concentration was 24 and 39.5 Bq/m3 for cases and the control, 
respectively, whilst NOx levels were higher among cases [185]. Cohort members were followed for 
cancer occurrence until 2006 and 589 lung cancer cases were identified. Cohort members’ 173,419 
residential addresses from 1971 to 2006 were traced and radon exposure at each of these addresses 
was calculated using information from central databases regarding geology and house construction. 
Persons living in single detached homes had higher radon levels compared to persons living in 
apartments. IRR and 95% (CI) for lung cancer risk associated with residential radon exposure with and 
without adjustment for sex, smoking variables, education, socio-economic status, occupation, body 
mass index, air pollution and consumption of fruit and alcohol. Potential effect modification by sex, 
traffic-related air pollution and environmental tobacco smoke was assessed. The adjusted IRR for lung 
cancer was 1.04 (95% CI: 0.69–1.56) in association with a 100 Bq/m3 or higher radon concentration. 
Among non-smokers, the IRR was 1.67 (95% CI: 0.69; 4.04) and the IRR was dose-dependently 
higher over four radon exposure quartiles (<17.6, 17.6–39.5, 39.5–66.1, and >66.1 Bq/m3). No 
evidence of effect modification was found, but as cases on average had lower radon concentration than 
controls, other factors than radon and the factors accounted for must play a role – for instance chance 
due lack of statistical strength. The positive association between radon and lung cancer risk in the 
Danish study was consistent with results from previous American and European studies. Also a fairly 
consistence in increased risk or excess OR was found in these studies.  
Several estimates have been proposed of the number of lung cancers attributable to residential radon 
exposure. In one of the most detailed studies, Darby and colleagues estimated that radon is responsible 
for 6.5% of all deaths from lung cancer in the UK, including 5.5% attributable to the joint effect of 
radon and smoking and 1% to residential radon alone. The figure of 1% corresponds to 349 deaths in 
the UK, or 9.4% of lung cancer deaths not due to tobacco smoking [272]. Using this estimate on the 
Danish population corresponds to 36 deaths due to residential radon alone and 200 deaths attributable 
to the joint effect of radon and smoking. 
Summary estimates of the number of lung cancers attributable to environmental factors in Europe 
2002 was given by Boffetta in 2006 [179] (see table A16). The author states that the number of lung 
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cancers attributable to outdoor air pollution is the most uncertain of the figures. No estimate was 
provided for lung cancer due to environmental asbestos exposure because of the lack of statistically 
significant increase in risk found in the meta-analysis. By comparison the number of mesothelioma 
cases was 381. 
Table A16. Estimates of lung cancers attributable to environmental factors (modified from 
Boffetta 2006 [179]) 
Summary estimates of lung cancers attributable to environmental factors, Europe 2002 
Percentage 
Men Women All 
 Number 
of cases 
Outdoor air pollution 8,28 2,42 10,70 27.054 
Second-hand smoke, spouse 0,28 3,35 3,63 2.250 
Second-hand smoke, workplace 0,72 1,24 1,96 1.771 
Residential radon decay products 3,48 1,02 4,50 11.377 
Lung cancers (sum) 15,06 5,81 20,87 42.833 
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Other authors have estimated that about 4–12% or more of lung cancers are related to occupational 
asbestos exposure [273]. In a review of the epidemiology of lung cancer, Alberg and Samet [156] 
claim that about 90% of lung cancers are related to smoking, 9–15% to occupational exposures, 10% 
to radon, and perhaps 1–2% to air pollution. Henderson et al. [273] refer to Scandinavian studies 
where it has been estimated that more than a quarter of all lung cancer cases are related to 
occupational exposures. Therefore it is not possible to give an exact estimate of the significance of the 
different environmental factors. Risks are often expressed in different terms (for instance relative risk, 
odd ratio, or hazard ratio) and are not directly comparable. Furthermore, because two or more causal 
factors are implicated in many cases and the combined effects of those factors may be more than 
additive, the sum of the reported risk factors may exceed 1.0 (100%). A meaningful way of expressing 
risk is as attributable fractions (AF) or attributable fractions of the exposed (AFE). AFE can be 
defined as the proportion of exposed cases attributable to the risk factor, and can be interpreted as the 
proportion of disease cases over a specified time that would be prevented following elimination of the 
exposures, assuming the exposures are causal [273]. However, only very few studies provide risk 
estimates in form of attributable fractions. The estimates given by Alberg et al. [156]  claiming that 
about 90% of lung cancers are related to smoking (primary or second-hand), 9–15% to occupational 
exposures, 10% to radon, and 1–2% to air pollution seems be the best estimate for the times being; at 
least it probably reflects – with some uncertainty – the mutual relationship between the individual risk 
factors. 
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APPENDIX 19. SMOKING AND OTHER LIFE STYLE RISK FACTORS (4.4) 
For the population as a whole the epidemiology of lung cancer is first and foremost the epidemiology 
of smoking. An increase in tobacco consumption is paralleled some 20 years later by an increase in the 
incidence of lung cancer; similarly, a decrease in consumption is followed by a decrease in incidence. 
Occupational and other factors may be important in exposed or predisposed individuals. Asbestos, 
radon and other industrial chemicals, as well as environmental air pollution in general may be 
important risk factors in exposed individuals, and individual susceptibility may also be an important 
factor in disposed individuals. 
 
By far, the most important environmental carcinogen is tobacco smoke. Many men began smoking 
cigarettes during World War I. The incidence of lung cancer among men began a rapid rise 20 years 
later. An identical delayed pattern has been observed in women. The unequivocal role of cigarette 
smoking in causing lung cancer is one of the most thoroughly documented causal relationships in 
biomedical research. 
 
CARCINOGENS IN CIGARETTES  
More than 3,000 chemicals have been identified in cigarette smoke. Some of these chemicals detected 
in cigarette smoke have been extensively studied and more than 60 carcinogens are identified in 
particulate or gaseous phase including: aromatic hydrocarbons, nitrosamines, nitrosonormicotine, 
polonium, and arsenic.  
 
Risk in Smokers: duration of smoking and cigarettes per day  
In general, the risk of developing lung cancer is 10-20 times greater in male smokers than that of non-
smokers. The risk increases with the length of time an individual has smoked, the number of cigarettes 
smoked daily and the depth of inhalation. This observation has been made repeatedly in cohort and 
case-control studies.  
 
Risk models have been derived to estimate quantitatively how lung cancer risk varies with number of 
cigarettes smoked, duration of smoking, and age. In one widely cited analysis, Doll and Peto [198]  
proposed a quantitative model for lung cancer risk on the basis of data from the cohort study of British 
physicians. This model predicted a stronger effect of duration of smoking than of amount smoked per 
day. Thus, a tripling of the number of cigarettes smoked per day was estimated to triple the risk, 
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whereas a tripling of duration of smoking was estimated to increase the risk 100-fold [274]. The 
exponential effect of duration of smoking on lung cancer risk markedly increases the lifetime risk for 
those who become regular smokers in childhood and they also have an increased risk at younger ages.  
In a later study the same researchers [199] reported the findings at 50 years of follow-up of their 
original cohort. Compared with lifelong non-smokers, the risk for lung cancer was increased fourfold 
among former smokers and 14-fold among current smokers. Among current smokers, the RRs 
increased from 7.7 to 13.7 to 24.5 among smokers of 1 to 14, 15 to 24, and >25 cigarettes per day, 
respectively. The risk of developing lung cancer was three to five times greater in female smokers than 
in non-smokers. 
RISK AFTER STOPPING SMOKING 
The likelihood of developing lung cancer decreases among those who quit smoking as compared with 
those who continue to smoke. As the period of abstinence from smoking cigarettes increases, the risk 
for lung cancer decreases, approximately approaching the level of the non-smoker at 10-15 years. 
However, some studies show, that even for periods of abstinence of 40 years, the risk for lung cancer 
among former smokers remains elevated compared with never-smokers [275, 276]. 
The time necessary for decreasing the incidence of lung carcinoma depends on the duration and 
quantity of cigarette smoking. A person who has smoked fewer years will have a risk for lung 
carcinoma equal to the non-smoking population in less than 15 years after smoking cessation. Thus, 
for a given period of abstinence, the decrease in risk increases as the duration of smoking decreases 
[277]. In figure A4 the relative risk of lung cancer is markedly lower five years after quitting, and 
decreases further with time (by comparison with those who continue to smoke).  
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Figure A4. Relative risk of lung cancer after smoking cessation [172] 
 
 
 
FILTERS AND DIFFERENT TYPES OF CIGARETTES AND TOBACCO  
The composition of cigarettes has evolved since the 1950s and consumption has shifted from mainly 
unfiltered cigarettes to predominantly filtered cigarettes. The filters in use in the U.S. and Denmark 
are predominantly cellulose acetate. In the mid-1960s, ventilation holes were added to the filter, which 
dilute the smoke with air drawn through them. There have also been substantial changes in the design 
of the cigarette and in the tobacco used. Reconstituted tobacco has been used increasingly since the 
1960s and there have been changes to the cigarette paper and additives used. Most cigarettes are more 
ammoniated, and a concomitant shift toward lowered levels of “tar” and nicotine was seen.  
 
A very extensive and comprehensive review of the influence and significance of filters and different 
types of cigarettes and tobacco on lung cancer was published in Chest in 2003 by Alberg and Samet 
[156], and the following summary is based on that review:  
 
Tar and nicotine yields are measured with a smoking machine according to a standardized protocol 
established by the US Federal Trade Commission (FTC) that specifies such details as puff volume, the 
frequency of puffing, and the length to which the cigarette is to be smoked. In the course of time 
cigarette producers reduced the yields of tar and nicotine as measured by these machines. The gradual 
reduction in machine-measured tar yield would be expected to have reduced smokers’ exposures to 
carcinogens. But when collecting saliva for analysis for cotinine level and end-tidal breath samples for 
measurement of carbon monoxide level, and taking account of numbers of cigarettes smoked, 
biomarker levels were not associated with the yields of tar and nicotine as measured by smoking 
machines. Other studies using biomarkers of exposure showed little relationship with tar or nicotine 
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yield as measured by the FTC protocol. Comparing actual smokers smoking habits with that of the 
machines showed that smokers had greater puff volumes and frequencies than are specified in the FTC 
protocol and consequently smokers had substantially greater intakes of tar and nicotine than implied 
by the brand listings.  
Epidemiologic studies have been conducted to assess whether the seemingly substantial changes in tar 
and nicotine yield, have resulted in parallel changes in the risk of smoking. Case-control studies that 
compared risks in people who had used filter-tipped cigarettes with people who had smoked non-
filtered cigarettes exclusively suggests that filtered cigarettes and cigarettes with lower tar yields 
slightly reduce the risk for lung cancer associated with cigarette smoking compared with non-filtered 
cigarettes or cigarettes with higher tar yields. Cohort studies where smokers were placed into three 
categories of products smoked: low yield (<17.6 mg per cigarette), high yield (25.8 to 35.7 mg per 
cigarette), and medium yield (intermediate) confirmed that risk for lung cancer death increased with 
tar yield. But on the other hand comparing smokers with disease developing from 1960 to 1972 (when 
tar yield per cigarette was high) with a similar group of smokers with disease developing from 1980 to 
1986 (when tar yield was low) did not show the expected reduction in risk for developing lung cancer. 
In fact, the opposite was observed, with increasing lung cancer mortality in male and female smokers 
in during the last period compared to the first. In an analysis with a similar pattern of findings, Doll et 
al. [200] compared the risks for death from lung cancer and other causes during the first and second 20 
years of the 40-year follow-up of the British physician cohort. Lung cancer mortality increased from 
264 to 314 per 100,000 among smokers in the second 20 years (from 1971 to 1991), even though 
products smoked during this period would have had a substantially lower tar and nicotine yield than 
those smoked during the first 20 years (from 1951 to 1971). 
Successive birth cohorts have had differing patterns of exposure to cigarettes of different 
characteristics and yields. Age-specific trends of lung cancer mortality therefore should be expected to 
decrease when the cohort of individuals who were born between 1930 and 1940 and started to smoke 
non-filtered cigarettes were compared to subsequent birth cohorts who would have had access to the 
increasingly lower yield and filtered products. Data on lung cancer mortality in younger men in the 
United Kingdom have been interpreted as indicating a possible reduction in lung cancer risk 
associated with changes in cigarettes composition when changes in prevalence, duration, and amount 
of smoking, were accounted for. The anticipated pattern of temporal change in age-specific rates of 
lung cancer mortality in younger men however has not taken place in the United States. Uncertainty 
remains with regard to the interpretation of these conflicting data, and alternative explanations have 
been proposed, including less intense smoking at younger ages in more recent birth cohorts. The 
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results highlight the complexity of isolating the precise effect on lung cancer risk of the continually 
changing cigarette. The data available to evaluate these effects have limitations, particularly in 
capturing the experience of successive birth cohorts in either case-control or cohort studies that were 
appropriately designed. The UK mortality data suggest a greater effect of changes in cigarettes than is 
found in the case-control and cohort studies. Several expert panels have reviewed these findings. The 
Institute of Medicine conducted a comprehensive review on various harm reduction strategies for 
reducing the disease burden caused by smoking, including lower yield cigarettes and concluded that 
smoking lower-yield products had not been shown to benefit the health of smokers. This topic was 
also addressed in the 2004 report of the US Surgeon General with the conclusion that “although 
characteristics of cigarettes have changed during the last 50 years and yields of tar and nicotine have 
declined substantially, as assessed by the Federal Trade Commission’s test protocol, the risk of lung 
cancer in smokers has not declined”. Differences in smoking habits for instance higher puff volume, 
the frequency of puffing, and the length to which the cigarette is to be smoked might account for that. 
The same authors [156] also reviewed the literature on menthol cigarettes, which may cause a greater 
increase in lung cancer risk than non-menthol cigarettes, either by increasing systemic exposure to 
toxicants from tobacco smoke or by affecting the metabolism of nicotine and/or tobacco smoke 
carcinogens. Menthol potentially increases nicotine uptake in the respiratory tract and increases the 
smoothness of tobacco smoke, which promotes deeper inhalation; stimulation of cold receptors, which 
results in airway cooling effects that mask the irritation caused by cigarette smoke, promoting deeper 
inhalation and altered inhalation frequency; further masking of irritation through anesthetic effects; 
and increased permeability and diffusibility of smoke constituents has been proposed.  
Black, male, heavy smokers of mentholated cigarettes (37.5 pack-years, or 21 cigarettes per day) had a 
higher risk than white men with similar smoking histories. In the cohort study the RR for lung cancer 
among men but not women was slightly elevated in menthol smokers compared with non-menthol 
smokers, with a graded increase in lung cancer risk with increasing duration of menthol cigarette use. 
The evidence does not indicate that menthol cigarettes are an important contributor to the high rates of 
lung cancer in African-American individuals.  
PASSIVE SMOKING 
Passive smokers inhale a complex mixture of smoke now widely referred to as second-hand smoke or 
as environmental tobacco smoke (ETS). Passive smoking was first considered as a possible risk factor 
for lung cancer in 1981, when two studies that described increased lung cancer risk among never-
smoking women who were married to smokers were published [156]. In 1986 The National Research 
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Council reviewed the epidemiologic evidence and concluded that non-smoking spouses who were 
married to cigarette smokers were approximately 30% more likely to develop lung cancer than non-
smoking spouses married to non-smokers and that this relationship was biologically plausible. Almost 
one fourth of lung cancer cases among never-smokers were estimated to be attributed to exposure to 
ETS [Environmental tobacco smoke: measuring exposures and assessing health effects. Washington, 
DC: National Academy Press, National Research Council, Committee on Passive Smoking, 1986]. 
Since the 1980s more than 50 studies of ETS and lung cancer risk in never-smokers, especially 
spouses of smokers, have been published. These studies were evaluated by IARC in 2004. The excess 
risk is of the order of 20% for women and 30% for men and remains after controlling for some 
potential sources of bias and confounding. The excess risk increases with increasing exposure. Meta-
analyses of lung cancer in never-smokers exposed to second-hand tobacco smoke at the workplace 
have found a statistically significant increase in risk of 12−19%. This evidence is sufficient to 
conclude that ETS is a cause of lung cancer in never-smokers. The IARC expert-group concluded: 
Involuntary smoking (exposure to second-hand or ‘environmental’ tobacco smoke) is carcinogenic to 
humans (Group 1). 
 
PHYSICAL ACTIVITY 
Several studies have reported that more physically active men and women have a lower risk from all-
site cancer than those who are more sedentary, even after adjustment for cigarette smoking. Physical 
activity was also in some studies associated with decreased risk of lung cancer in men and women, 
after adjusting for smoking. However, the proportions of smokers in former studies were low and the 
results may not be generalizable to all smokers. Alfano et al. [278] studied all-site cancer and lung 
cancer incidence and mortality in a sample of current and former smokers (n = 7,045). An association 
with physical activity was found for incidence of all-site cancers but not for lung cancer. Mortality 
was only reduced for physical active women both for all-site cancers and lung cancers. HR associated 
with a 1 SD increase in physical activity were 0.69 (95% CI 0.53-0.90) for lung cancer among women.  
 
The relation between physical activity, inflammation, and lung cancer risk was evaluated by Sprague 
and colleges [279] in a prospective cohort of 4,831 subjects, 43–86 years of age. White blood cell 
count was includes as a marker of chronic inflammation, which was supposed to provide a potential 
mechanistic explanation for the expected reduced incidence of lung cancer. During an average of 12.8 
years of follow-up, 134 incident cases of lung cancer were diagnosed. After multivariable adjustment, 
participants in the highest tertile of total physical activity index had a 45% reduction in lung cancer 
risk compared to those in the lowest tertile (OR=0.55; 95% CI: 0.35–0.86). Participants with white 
blood cell counts in the upper tertile were 2.81 (95% CI: 1.58–5.01) times as likely to develop lung 
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cancer as those with counts in the lowest tertile. These data suggest that physical activity and white 
blood cell count are independent risk factors for lung cancer. 
 
Cardiorespiratory fitness was associated with lung cancer mortality but only among smokers in a 
prospective cohort included 38,000 men followed between 1974 and 200 (Sui, 2010). A total of 232 
lung cancer deaths occurred during follow-up (mean=17 years). After adjustment for age, examination 
year, BMI, smoking, drinking, physical activity, and family history of cancer, hazard ratios (95% 
confidence intervals) for lung cancer deaths across low, moderate and high cardiorespiratory fitness 
categories were: 1.0, 0.48 (0.35–0.67), and 0.43 (0.28–0.65) respectively. There was an inverse 
association between cardiorespiratory fitness and lung cancer mortality in former (P for trend = 0.005) 
and current smokers (P for trend <0.001), but not in never smokers (trend P = 0.14). Joint analysis of 
smoking and fitness status revealed a significant 12-fold higher risk of death in current smokers (HR: 
11.9; 95% CI: 6.0–23.6) with low cardiorespiratory fitness as compared with never smokers who had 
high cardiorespiratory fitness.  
 
DIET 
Research on diet and lung cancer has now been conducted for 3 decades. The possible role of diet in 
modifying the risk for lung cancer has focused on the assumption that specific micronutrients might 
have anti-carcinogenic activity. The most thoroughly investigated dietary factors are also those that 
seem to have the greatest implications for prevention:  fruits, vegetables, and specific antioxidant 
micronutrients that are commonly found in fruits and vegetables. Much of the research on diet and 
lung cancer has been motivated by the hypothesis that diets that are high in antioxidant nutrients may 
reduce oxidative DNA damage and thereby protect against cancer. The results of case-control and 
prospective cohort studies have tended to show that individuals with high dietary intake of fruit or 
vegetables have a lower risk for lung cancer than those with low fruit or vegetable intake [156].  
Evidence from cohort studies published since 2000 has tended to reinforce this notion. The latest 
published update from the European Prospective Investigation into Cancer and Nutrition showed a 
strong protective association was observed in the whole study population for fruit consumption while 
no association was found for vegetable consumption. The cohort data was collected between 1992 and 
2000; detailed information on diet and life-style of 478,590 individuals was primary based on 
questionnaire data. During a median follow-up of 6.4 years, 1,126 lung cancer cases were observed. 
Multivariate Cox proportional hazard models were applied for statistical evaluation. In current 
smokers, lung cancer risk significantly decreased with higher vegetable consumption; this association 
became more pronounced after calibration, the hazard ratio (HR) being 0.78 (95% CI 0.62–0.98) per 
100 g increase in daily vegetable consumption. In comparison, the HR per 100 g fruit was 0.92 (0.85–
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0.99) in the entire cohort and 0.90 (0.81–0.99) in smokers. Exclusion of cases diagnosed during the 
first 2 years of follow-up strengthened these associations. Cancer incidence decreased with higher 
consumption of apples and pears (entire cohort) as well as root vegetables (smokers). In addition to an 
overall inverse association with fruit intake, the results of this evaluation add evidence for a significant 
inverse association of vegetable consumption and lung cancer incidence in smokers [206]. Also a 
stronger protective association was observed for fruit than vegetable consumption in a pooled analysis 
of seven cohort studies. But in this analysis associations were similar between never, past, and current 
smokers [208]. 
The above results suggest that elevated fruit and vegetable consumption is associated with a modest 
reduction in lung cancer risk, which is mostly attributable to fruit. However, the possibility cannot be 
ruled out that the results are due to residual confounding by smoking.  
ALCOHOL 
In a review of eight case-control studies and nine cohort studies published between 1966 and 2000 
Bandera [280] found that the studies reviewed provided some indication that alcohol and particularly 
beer intake may increase lung cancer although the evidence was not conclusive. A meta-analysis 
showed, that alcoholics had a fairly substantial increase in lung cancer risk in relation to general 
population rates, with a pooled RR of 1.99 (95% CI: 1.66-2.39). Studies of brewery workers had a 
questionable excess risk of lung cancer, with a pooled RR of 1.17 (95 % CI: 0.99-1.39). For cohort 
studies, the pooled smoking unadjusted RR in relation to nondrinkers was 1.19 (95 % CI: 1.11-1.29) 
and the pooled smoking-adjusted odds ratio was 1.39 (95 %CI: 1.06-1.83) [205]. Similarly 
Freudenheim et al. [201] found a slight elevated risk of lung cancer associated with the consumption 
of more than 30 g alcohol/day compared with no alcohol consumption. In this study alcohol 
consumption was strongly associated with greater risk in males who did not smoke, which is in 
contrast to later studies that found no excess risk in never smokers [281]. A recent meta-analysis 
exclusively in never smokers showed that alcohol consumption was not associated with lung cancer 
risk in never smokers and that alcohol does not play an independent role in lung cancer etiology [281]. 
The results of studies on association between alcohol consumption and lung cancer are conflicting. 
Since drinking and smoking are strongly associated, residual confounding by smoking may bias the 
estimation of alcohol consumption and lung cancer risk relation. Recent studies on alcohol and lung 
cancer risk in never smokers suggests that alcohol does not play an independent role in lung cancer 
etiology. 
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ANTHROPOMETRIC MEASURES 
Since the 1980s a number of studies have examined the relation between leanness and lung cancer 
risk. Most of these studies showed an increasing risk with decreasing body mass index for current 
smokers, ex-smokers and never smokers. Many of these studies had sufficiently controlled for 
smoking or pre-existing diseases [203].  
Subsequently better controlled studies have shown associations between leanness and lung cancer: 
Gorlova et al. [202] analyzed never smokers, 280 cases compared with 242 hospital-based controls. 
Cases at the time of diagnosis were leaner than controls (BMI 28.5; p < 0.001). Cases also tended to 
have been leaner 5 years prior to enrolment to controls.   
Reeves et al.[207] followed 1.2 million UK women recruited during 1996-2001. Both lung cancer 
incidence and mortality were inversely associated with BMI when adjusted for age, geographical 
region, socioeconomic status, reproductive history, smoking status, alcohol intake, physical activity, 
and, where appropriate, time since menopause and use of hormone replacement therapy. Trend for 
mortality per 10 BMI-units was 0.72 (95% CI 0.66 to 0.79) and for incidence 0.74 (95% CI 0.67 to 
0.82). An inverse relationship between BMI and lung cancer risk was also found in women [204].  
Smith et al. [209] prospectively examined the association between BMI and lung cancer risk among 
271,238 men and 177,494 women. 6,093 men and 3,344 women were diagnosed with lung cancer. Of 
these, 166 men and 249 women were non-smokers. In a multivariate model that adjusted for smoking 
status, BMI was significantly and inversely associated with lung cancer risk in both men and women. 
For men, the HR for men with a BMI of 35 or higher vs. men with a BMI between 22.5 and 24.99 was 
0.81 (95% CI, 0.70-0.94). For women, the decreased risk was even more pronounced, with a HR of 
0.73 (95% CI, 0.61-0.87.).  
Some studies have shown decreased risk of lung cancer with the use of menopausal hormones but 
results are not consistent [197]. The stronger inverse association among women suggests that 
increased estrogen levels may play an etiologic role [209].   
Cigarette smoking is closely associated with less healthy lifestyles. Thus it is difficult to disentangle 
dietary and other lifestyle factors from smoking effects [156].  Smokers tend to have lower circulating 
concentrations of antioxidant micronutrients even after accounting for differences in dietary intake. 
Associations between dietary factors and lung cancer risk are much weaker than smoking associations. 
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Diet estimations are prone to greater error than smoking [156]. Therefore residual confounding from 
smoking cannot be set aside when evaluating lifestyle factors. 
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APPENDIX 20. ACQUIRED LUNG DISEASES AND LUNG CANCER RISK 
(4.4) 
PULMONARY FIBROSIS AND ASBESTOSIS 
For many years it has been observed that lung cancers frequently arise in lung areas with hyperplastic 
epithelium or fibrosis. Idiopathic lung fibrosis (IPF) and systemic sclerosis (SSc) have been 
consistently linked to increased lung cancer risk, also when adjusting for smoking [156].  
Archontogeorgis et al. [210] reviewed 7 IPF studies. Only 3 reported incidences of lung cancer (2.7%, 
22.4%, and 31.3%). The one   study that included a background population showed a RR of 4.96 (95% 
CI 3.00-8.18).  The use of immunosuppressive drugs and radiographs add to lung cancer risk [156].  
Previously the presence of asbestosis was required before concluding that lung cancer was work-
related.   
However, it has been commonly accepted for the past few decades that ARLC can occur in the 
absence of asbestosis. Hessel [211] critically reviewed 7 studies, 5 of which found asbestosis 
unnecessary. As asbestosis reflects considerable asbestos exposure, its presence is useful in risk 
evaluations of possible ARLC. However, some degree of disagreement remains as to whether or not 
asbestosis is required before ARLC can be diagnosed [212].  
TUBERCULOSIS 
In the late 1960s Steinitz evaluated a population in Israel with relatively few heavy smokers, and 
found that patients with previous tuberculosis (TB) had an increased risk of developing lung 
carcinoma, approximately five times greater than the general population males and ten times greater in 
females. Since then several studies of various quality have been published. The latest major systematic 
review was conducted in 2009 by Liang et al. [214]. Using very strict inclusion and exclusion criteria 
they included 37 case-control, 4 cohort studies and one meta-analysis of risk estimates. To avoid the 
potential confounding by tobacco use among subjects with TB they combined data from 31 results of 
24 studies in which proper adjustment was made for smoking. Combined adjusted data showed a 
statistically significant increase in risk of lung cancer, RR = 1.97 (95%CI, 1.60–2.41). There was, 
however, evidence of significant heterogeneity between the studies (Q = 73.56 on 30 df, p < 0.001; I2 
= 59.2%). The total pooled RR based was 1.78 (95%CI: 1.42–2.23) without evidence of significant 
heterogeneity (Q = 19.28 on 13 df, p = 0.115; I2 = 32.6%). The increased lung cancer risk remained 2-
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fold elevated for more than 20 years after TB diagnosis and the association was significant with 
adenocarcinoma (RR = 1.6, 95%CI 5 1.2–2.1), but no significant associations were found for 
squamous and small cell type of lung cancer. The authors concluded, that although no causal 
mechanism has been demonstrated the study supports a direct relation between TB and lung cancer, 
especially adenocarcinomas. 
 
Since 2009 two large studies have been published from Taiwan [216] and [217] where TB, lung 
cancer, and smoking are prevalent in men (50-60%), but not in women (3-4%). The risk estimates 
from these studies were very much higher than in the result from Liang’s review, but smoking was not 
controlled for on an individual level. TB per se seems to be a risk factor for lung cancer. The 
association was not due to confounding by the smoking or ETS.  
 
RISK OF SECOND PRIMARY LUNG CANCER 
Many studies have established that individuals with cancer have an increased risk of developing a 
second cancer. The increased risk for lung cancer as a secondary tumor may be associated with the 
both treatment and smoking. Non-smoking women who received post-mastectomy radiotherapy had 
no higher risk of second primary lung cancer compared to ever-smokers. The joint effects of smoking 
and post-mastectomy radiotherapy showed adjusted OR 10.5 (95% CI, 2.9 to 37.8) for the 
contralateral lung and 37.6 (95% CI, 10.2 to 139.0) for the ipsilateral lung indicating a more than 
additive effect of smoking and post-mastectomy radiotherapy [215].  
 
The risk of second primary lung cancer in lung cancer patients is substantial, and enhanced by 
smoking. In patients with small cell carcinoma who stopped smoking at the time of diagnosis, the RR 
of a second lung cancer was 11 (95 % CI 4.4-23). In those who continued to smoke, the RR was 32 
(95 % CI, 12-69) [218]. Second lung cancer risk was increased 13-fold among those who received 
chest irradiation in comparison to a sevenfold increase among non-irradiated patients. It was higher in 
those who continued smoking, with evidence of an interaction between chest irradiation and continued 
smoking (RR = 21). Patients treated with various forms of combination chemotherapy had comparable 
increases in risk (9.4- to 13-foldl), except for a 19-fold risk increase among those treated with 
alkylating agents who continued smoking [219]. 
 
The risk seems higher for small cell carcinoma. Johnson [224] found, that the risk of developing a 
second lung cancer in patients who survived resection of NSCLC was approximately 1%–2% per 
patient per year. The average risk of developing a second lung cancer in patients who survived SCLC 
was approximately 6% per patient per year.  
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Cancers other than breast and lung have been associated with second primary lung cancer. In a 
retrospective cohort study the RR of second primary cancer was studied in Queensland, Australia 
[222]. Significant elevated SIR of second primary lung cancer was found for all cancers combined, 
head and neck cancers and esophageal cancers.   
Chen et al.[220] found an increased risk of second primary lung cancer.  For esophageal cancer a 
multicenter study was carried out based on 13 population-based cancer registries in Europe, Australia, 
Canada, and Singapore.  SIR for all second primary cancers was 1.15 (95% CI, 1.08-1.22), and second 
primary lung cancers were 1.55 (95 % 1.28-1.87) [221]. 
An elevated risk (8-50%) for second primary lung cancer is associated with head and neck cancers and 
esophageal cancers, radiotherapy affecting the lungs, and various forms of combination chemotherapy. 
Smoking remains the predominant risk factor also for second primary lung cancer especially for 
SCLC.  
CHRONIC OBSTRUCTIVE PULMONARY DISEASES, BRONCHITIS, EMPHYSEMA, AND 
ASTHMA 
The associations between lung cancer and COPD have been demonstrated in many years. In a meta-
analysis comprising 35 studies (22,010 cases and 44,438 controls) Wang et al. [282] found that COPD 
was significantly associated with increased  lung cancer risk (pooled OR = 2.76; 95% CI, 1.85–4.11). 
In the 10 studies where smoking habits were accounted for, the pooled OR for lung cancer among 
persons with COPD was 3.13 (95% CI, 2.02-4.96). A positive association was found for chronic 
bronchitis, OR = 1.88 (95% CI, 1.49–2.36), increased in both smokers (OR 2.38; 95% CI 1.45-3.92) 
and non-smokers (OR=1.54; 95% CI:1.24-1.93). The same pattern was seen for emphysema, OR = 
3.02 (95% CI = 2.41–3.79) but not for asthma, OR = 0.93 (95% CI, 0.32-2.71).  
Smoking is the principal cause of both COPD and lung cancer, being so strongly causally associated 
with both of these illnesses that presuming that statistical adjustment procedures “remove” the effect 
of cigarette smoking may not be well founded. Therefore, clarifying the relevance of COPD to the 
development of lung cancer awaits further proof that this association is not accounted for by cigarette 
smoking [156]. Hypotheses for the association between COPD and increased risk for lung cancer 
include impaired clearance of carcinogenic substances in tobacco smoke and chronic inflammation 
with injury to the bronchial epithelium. Alternatively, COPD and lung cancer may develop 
simultaneously by some process incited by tobacco smoke common to both diseases [166]. Another 
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potential mechanism that is hypothesized to link COPD with lung cancer is α-1-antitrypsin deficiency, 
and evidence to support this notion includes the observation that the prevalence of α-1-antitrypsin 
deficiency carriers was higher in patients with lung cancer than in the general population and higher in 
patients who had lung cancer and had never smoked [156]. The modest association found among non-
smoker might be attributed to environmental or occupational exposures and/or other of the before 
mentioned factors. COPD is, however, a useful clinical indicator of lung cancer risk. 
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APPENDIX 21. NON-OCCUPATIONAL/ENVIRONMENTAL ASBESTOS 
EXPOSURE AND LUNG CANCER (4.4) 
THE CONCEPT OF ENVIRONMENT	  
The term ‘environment’ is often used broadly the medical literature, including all non-genetic factors 
such as diet, lifestyle and infectious agents. In this broad sense, the environment is implicated in the 
causation of the majority of human cancers. In a more specific sense, however, environmental factors 
include only the (natural or manmade) agents encountered by humans in their daily life, upon which 
they have no or limited personal control. The most important ‘environmental’ exposures, defined in 
this strict sense, include outdoor and indoor air pollution as well as soil and drinking water 
contamination [184]. It is in this narrower sense environmental or non-occupational exposures are 
used in this section of the report while host factors are dealt with separately. 
EXPOSURE IN INDOOR AND OUTDOOR AIR	  
The previous widespread use of asbestos-containing building materials and brake linings may have led 
to a general increase in the quantity of asbestos fibers in both surface soil and in the air. The “natural” 
background level may therefore be raised as a result of a general environmental exposure, particularly 
in peri-urban areas and around roads. There is no available information about the Danish background 
asbestos levels in the air. A British study from the 1980s on outdoor concentrations of asbestos fibers 
in the air at two traffic junctions in London showed that the total asbestos fiber levels were from 
0.00055 f/ml to 0.0062 f/ml. The same study found that the content of regulated fibers was > 0.0004 
f/ml. (Regulated fibers include the proportion of asbestos fibers determined analytically with the 
recommended test methods, and includes asbestos fibers with lengths greater than 5 µm, an average 
width of less than 3 µm and a length/width ratio greater than 3: 1). Miljøstyrelsen (The Danish 
environmental protection agency) sets the background level in outdoor air in cities to about 0.0001-
0.0005 fibers/ml based on Dutch and English studies.  
Neither is the asbestos concentrations known in indoor air buildings in Denmark. But Miljøstyrelsen 
quoted foreign studies on asbestos concentrations in indoor air from a level less than the detection 
limit and up to 0.0007 fibers/ml in buildings without building materials containing asbestos, while 
measured concentrations of airborne asbestos particles in the air in buildings with asbestos-containing 
building materials was up to 0.075 fibers/ml. Of 235 samples analyzed 13% showed a concentration 
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greater than 0.01 fibers asbestos/ml. The investigation included determination of airborne asbestos 
fibers and other fibers in 39 buildings with asbestos containing materials in both building 
constructions air-heat supplies. 
 
WHO states, that the actual indoor and outdoor concentrations of asbestos fibers in air range from 
below one hundred to several thousand fibers per m3 [232].  
 
EXPOSURE LIMITS FOR ASBESTOS 
The threshold limiting value for asbestos dust in the working environment laid down by 
Arbejdstilsynet (the Danisk Labour Inspectorate) is 0.1 f/cm3 (f/ml). 
 
Miljøstyrelsen has established a B-value for the content of asbestos fibers in air. A B-value 
(contributory value) is a threshold value for a company's contribution to air pollution in the 
surroundings. B-value for asbestos fibers is 400 fibers/m3 equivalent to 0.0004 f/ml.  
 
WHO’s guideline values based on conclusions from multiple experts is a lifetime exposure of 1,000 
f/m3 (0.001 fiber/ml). This value should be adjusted to 500 f/m3 (0.0005 f/ml), optically measured. In a 
population of whom 30% are smokers, the excess risk due to lung cancer would be in the order of 10–
6–10–5. For the same lifetime exposure, the mesothelioma risk for the general population would be in 
the range 10–5–10–4 [232].  
 
EXTRAPOLATIONS FROM EPIDEMIOLOGICAL STUDIES OF OCCUPATIONAL 
ASBESTOS EXPOSURE	  
Many epidemiological studies are available on asbestos exposed workers. In many epidemiological 
studies, the crucial effect of smoking has not been properly taken into account. Differentiation of the 
observed risks according to smoking habits has been carried out, however, in the cohort of North 
American insulation workers studied by Hammond et al. [229]. 
 
In an extensive review of quantitative risks from asbestos exposure, Hodgson and Darnton [142] 
summarizes information on the risks of lung cancer (and mesothelioma) for various occupational 
exposure levels. Included were mortality studies on asbestos exposed cohorts that gave information on 
exposure levels; 17 such studies were identified.  
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On that basis Hodgson and Darnton generated estimates of risks for various cumulative exposures 
including exposures outside the range for which direct observations were available. Under such 
circumstances there are two primary sources of uncertainty in the estimated risks: 
• Firstly there is the usual statistical uncertainty of inferring underlying risk from observations
in particular groups. This uncertainty can to some extent be quantified and expressed as a
confidence interval
• The second type of uncertainty relates to whether the relationship between exposure and
outcome seen in the observed range is also valid outside that range. This uncertainty cannot be
quantified statistically.
Uncertainty about the slopes of exposure-response lines has an increasing impact with increasing 
distance from the observed range. For these reasons Hodgson and Darnton considered that simply 
presenting a table of risk estimates for different cumulative exposures was not appropriate, as this 
would not capture the changing balance of the different types of uncertainty. They therefore produced 
a table (reproduced below in table A17) giving a numerical and qualitative assessment of lifetime risk 
at a range of cumulative exposures. No estimates were given for lifetime risks lower than 1 in 100.000 
and this level is referred to as 'insignificant'. 
For mesothelioma the results clearly show that exposure to amphibole fibers is more hazardous than 
exposure to chrysotile - broadly in the ratio 1:100:500 for chrysotile. amosite and crocidolite 
respectively. For lung cancer the conclusions are less clear with a risk differential between chrysotile 
and the two amphibole fibers of between 1:10 and 1:50 [142]. 
Table A17. Numerical and qualitative assessment of lifetime risk at a range of cumulative 
exposures. No estimates were given for lifetime risks lower than 1 in 100.000 and this level is 
referred to as 'insignificant'. [142] 
FIBERS MESOTHELIOMA LUNG CANCER 
RISK SUMMARIES FOR CUMULATIVE EXPOSURES BETWEEN 10 AND 100 F/ML.YEARS 
Crocidolite Best estimate about 400 deaths per 100 
000 exposed for each f/ml.yr of 
cumulative exposure. Up to 2-fold 
uncertainty. 
Rising from about 150 (range 100 to 250) 
excess lung cancer deaths per 100 000 
exposed for each f/ml yr of cumulative 
exposure at 10 f/ml.years to 350 (range 250 
to 550) at 100 f/ml.years. 
Amosite Best estimate about 65 deaths per 100 
000 exposed for each f/ml.yr of 
cumulative exposure. 2-fold to 4-fold 
150 
uncertainty 
Chrysotile Best estimate about 2 deaths per 100 000 
exposed for each f/ml.yr of cumulative 
exposure. Up to 3-fold uncertainty. 
Best estimate about 5 excess lung cancer 
deaths per 100 000 exposed for each f/ml yr 
of cumulative exposure. Cautious estimate 
30. In exceptional circumstances (see note c)
it is arguable that an estimate of 100 might 
be justified 
RISK SUMMARIES FOR CUMULATIVE EXPOSURES OF 1 F/ML.YEARS 
Crocidolite Best estimate about 650 deaths per 100 
000 exposed. Highest arguable estimate 
1500, lowest 250 
Best estimate about 85 (range 20 to 250) 
excess lung cancer deaths per 100 000 
exposed. 
Amosite Best estimate about 90 deaths per 100 
000 exposed. Highest arguable estimate 
300, 
lowest 15. 
Best estimate about 2 excess lung cancer 
deaths per 100 000 exposed. Cautious 
estimate 30 per 100 000. In exceptional 
circumstances (see note c) it is arguable 
that an estimate of 100 per 100 000 might be 
justified. The case for a threshold—ie 
zero, or at least very low risk—is arguable. 
Chrysotile Best estimate about 5 deaths per 100 000 
exposed. Highest arguable estimate 20 
lowest 1. 
RISK SUMMARIES FOR CUMULATIVE EXPOSURES OF 0.1 F/ML.YEARS 
Crocidolite Best estimate about 100 deaths per 100 
000 exposed. Highest arguable estimate 
350, lowest 25. 
Best estimate about 4 (range ,1 to 25) excess 
lung cancer deaths per 100 000 exposed. 
Amosite Best estimate about 15 deaths per 100 
000 exposed. Highest arguable estimate 
80, 
lowest 2. 
Best estimate about 4 (range ,1 to 25) excess 
lung cancer deaths per 100 000 exposeed 
Chrysotile Risk probably insignificant, highest 
arguable estimate 4 deaths per 100 000 
exposed 
Excess lung cancer deaths probably 
insignificant. Cautious estimate 3 per 100 
000. In exceptional circumstances (see note 
c) it is arguable that an estimate of 10 per
100 000 might be justified. The case for a 
threshold—ie zero, or at least very low 
risk—is strongly arguable. 
RISK SUMMARIES FOR CUMULATIVE EXPOSURES OF 0.01 F/ML.YEARS 
Crocidolite Best estimate about 20 deaths per 100 
000 exposed. Highest arguable estimate 
100, lowest 2. 
Risk is probably insignificant (range ,1 to 3 
excess lung cancer deaths per 100 000 
exposed). Mesothelioma is now the 
dominant risk, so precise estimation of 
the lung cancer risk is not critical. 
Amosite Best estimate about 3 death per 100 000 
exposed. Highest arguable estimate 20, 
lowest insignificant. 
Chrysotile Risk probably insignificant, highest 
arguable estimate 1 deaths per 100 000 
exposed 
Risk of excess lung cancer very probably 
insignificant except in exceptional 
circumstances (see note c) when it is 
arguable that an estimate of 1 death per 
100 000 might be justified. The case for a 
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threshold—ie zero, or at least very low 
risk—is strongly arguable 
RISK SUMMARIES FOR CUMULATIVE EXPOSURES OF 0.005 F/ML.YEAR AND LOWER 
AT THESE LEVELS ONLY MESOTHELIOMA NEED BE CONSIDERED. THE ABSOLUTE 
RISK IS LOW, BUT QUANTITATIVE UNCERTAINTIES ARE VERY CONSIDERABLE. 
Crocidolite Best estimate about 10 deaths per 100 
000 exposed. Highest arguable estimate 
55, lowest. Best estimate falls to 
insignificant level at 0.0002 f/ml.year, 
and highest arguable risk becomes 
insignificant at 6´1026 f/ml.year 
Insignificant, possibly zero 
Amosite Best estimate about 2 deaths per 100 000 
exposed highest arguable lifetime risk 15, 
falling to ,1 (ie. insignificant) at 7´1025 
f/ml.year 
Chrysotile Insignificant Insignificant, very possibly zero 
EPIDEMIOLOGICAL STUDIES OF NON-OCCUPATIONAL ASBESTOS EXPOSURE 
The assessment of non-occupational exposure to asbestos presents difficulties, since levels are low, 
and the duration and frequency of exposure and the type of fiber are seldom known. Most studies on 
the evaluation of lung cancer and environmental or non-occupational exposure to asbestos have been 
investigations carried out in: 
• Household exposure in cohabitants of asbestos workers and arising from dust brought home
on clothes
• Areas with very high exposures - e.g. residence near a mine or a processing plant
• Areas where asbestos occurs naturally.
From a research point of view this may be reasonable, as large exposure contrast in a study groups 
maximize the study’s ability to detect an elevated risk. However, problems arise when data from these 
studies were extrapolated to the much lower concentrations found in the general environment. If for 
instance the true relationship is not linear, the impact on low dose extrapolations could be significant. 
The same applies from the extrapolation of estimated risks from industrial exposures at relatively high 
levels (> 10 f/ml-years) for long periods of time to the much shorter or lower exposures many asbestos 
exposed workers may be let in for. 
By using residence in mining areas or near processing plants the possibility of confounding by 
employment in the asbestos industry is a source of bias that was not excluded in all studies[184].  
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RISK IN HIGHLY EXPOSED POPULATION 
Bofetta et al [283] reviewed 8 studies on lung cancer risk from outdoor air pollution published before 
2000. 
Five of these studies showed an increased risk, three did not. Relative risk varied from 0.8 to 5.7. The 
available data does not permit a joint estimation for the relative risk but the rough confidence intervals 
varied from 0.4 to 9.3. Results are shown in Table A18. 
Three of the studies considered areas with high concentrations of naturally occurring asbestos in the 
local environment. These included a case control study in New Caledonia [284], where naturally 
occurring asbestos were used in building materials, notably whitewash, and two ecological studies, 
one in China [226] and one in Austria [240]. 
Table A18. Studies of risk of lung cancer and mesothelioma: Modified from: Boffetta et al., 
(2003) [283] (Studies without information on lung cancer are omitted). 
STUDIES OF RISK OF LUNG CANCER AND MESOTHELIOMA 
FROM ENVIRONMENTAL EXPOSURE TO ASBESTOS 
Country SD TF Source of exposure Mesothelioma Lung cancer 
Ca RR 95% CI Ca RR 95% CI 
 South Africa  Ec  A    Res. in mining area a) 61 8,7 6,7–11,4 86 1,7 1,2–2,5 
 South Africa  CC  A    Res. in mining areas a) 16 3,6 1,4–9,3 
 Canada   Ec  C    Res. in mining area b) 7 7,6 3,4–14,9 71 1,1 0,9–1,4 
 USA   CC  A    Res. near to asbestos plant  41 0,9 0,6–1,3 
 Austria   Ec  A    Res. in polluted town a) 36 0,8 0,4–1,6 
 China   CC  C    Res. >20 years <0,2 km from 
asbestos plant a) 
47 1,9 0,5–6,4 
 China  Co  A  Res. in polluted area  NA 182 NA NA 5,7 NA 
 New 
Caledonia 
CC  A    Use of contaminated building 
materials a) 
14 40,9 5,1–325 56 0,9 0,6–1,3 
SD, study design: CC, case–control study; Co, cohort study; Ec, ecological study. 
TF, predominant type of fibers: A, amphiboles; C, chrysotile. 
Ca, Number of cases; RR, Relative Risk; 95% CI, 95% confidence interval.  
a) Results derived from raw data reported in the publication. 
b) Women only.
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Two studies related to environmental exposures resulting from residence in asbestos mining or 
shipping regions. One of these was an ecological study considering the impact of environmental 
exposures on female residents in two chrysotile mining areas in Quebec [285]. The other was a case 
control study considering exposures in mining areas and areas where asbestos was shipped in South 
Africa [228]. The remaining studies, all ecological, investigated the impact of environmental 
exposures from particular industrial plants processing or manufacturing asbestos containing materials 
in Austria [240], Italy [227] and the USA [229]). 
 
For four of the studies considered it was stated that no excess risk of lung cancer was detected in the 
exposed population (Italy, Austria, USA, and Canada). Three of the studies indicated an increased risk 
of lung cancer in the exposed population. The highest RR of 6.7 was a result of exposure from 
naturally occurring asbestos present in a region of China. The New Caledonia study identified an 
increased risk from the use of asbestos containing building materials for women (OR 2.51. 95% CI 
1.01 — 6.22) but not for men (OR 0.89. 95% Cl 0.51 — 1.54). The South African study [228]) 
derived ORs ranging from 1.1 (95% Cl 0.3 — 3.9) to 5.4 (95% Cl 1.3 — 22.5) for individuals in 
asbestos mining or shipping areas, with risks higher in the more heavily polluted mining areas. Only 
one of the studies, Camus et al [285]), included asbestos exposure estimates for the exposed 
populations. For the study an average cumulative lifetime chrysotile exposure of 25 f/ml-years was 
estimated with a range of 5 — 125 f/ml-years. This study of women living in two chrysotile mining 
areas in Quebec [285] generated an age standardised mortality ratio for the exposed population, in 
comparison to the unexposed, of 0.99 with a range of 0.78 to 1.25 and they estimated the excess 
deaths in the population between 0 and 6.5. 
 
Hodgson and Darnton [142] concluded that the best estimate lung cancer risk for cumulative 
chrysotile exposure levels between 10 and 100 f/ml-year was about 5 excess deaths per 100,000 
exposed for each f/ml-year of cumulative exposure. An exposure of 25 f/ml-years would therefore 
imply a risk of 125 deaths per 100,000 exposed.  Using this risk estimate on the Quebec cohorte would 
imply in the region of 15 deaths1 compared to the number 0-6.5 estimated by Camus et al. 1998. So 
the number of cases reported by Camus et al. 1998 was significantly lower than that predicted using 
the standard estimates from Hodgson and Darnton [142]. However, Hodgson and Darnton indicate that 
their best estimate excess lung cancer risks represent an average for a population with a past pattern of 
smoking similar to that of older British men and that for non-smokers the risk would be between a 
third and a sixth of those quoted. Camus et al indicate that smoking levels within the exposed 
                                                      
1 Assuming that the number of exposed persons was about 221.375 person-years/19 years (= 11651 persons) and 
an average exposure of 25 f/ml-years leading to 125 deaths per 100,000 exposed. 
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population were slightly lower than those in the non-exposed populations. This factor however does 
not explain the whole difference and illustrates the broad uncertainty in these estimates. 
Since 2000 a couple of studies were published from Anatolia, Turkey where tremolite and, to a lesser 
extent, chrysotile asbestos is found in high concentration in the environment. In one of these studies 
that dealt with lung cancer risk, the risk was 1.3-fourfold higher in regions with high asbestos 
concentration compared to the general population of Turkey [230]Another approach to evaluate the 
significance of asbestos exposure in a general population was done by Liu 2001 [231]. Pulmonary 
asbestos fibers counts increased in an age-dependent manner (P<0.01) in autopsy cases in Hon Kong 
Chinese. Lung cancer cases (N=65) however had significant more coated fibers (asbestos body) and 
males cases a higher total fibers count in their lungs tissue compared to the non-lung cancer cases 
(N=107). The results suggest that there is an environmental exposure to asbestos in Hong Kong 
Chinese and that asbestos exposure in Hong Kong males may be one of the carcinogenic factors 
leading to lung cancer. 
RISK IN THE GENERAL POPULATION	  
Neither studies from Turkey nor the studies listed in Table 1 or 2 in fact fills the knowledge gap 
between occupational exposures and exposures in the general population for instance in Denmark. 
Few estimates are available of the significance or the proportion of the population experiencing non-
occupational asbestos exposure. 
EXPOSURE-RESPONSE MODELS 
A number of exposure-response models for asbestos have been developed. Peto et al [239] showed 
that the incidence of mesothelioma was dependent on time since first exposure, but not dependent on 
age at first exposure nor smoking habit nor gender. An increased risk of mesothelioma has 
consistently been detected among individuals experiencing residential exposure to asbestos. One 
might therefore expect that recent predictions were based on these models and measurements or other 
reliable estimates of asbestos exposure in the population, and that these estimates could be used as the 
basis for corresponding predictions of frequency of lung cancer caused by environmental asbestos 
exposure. But three of the often cited studies [142, 237, 238]. contain no precise assumptions about 
the actual level of exposure to asbestos, but solely used mathematical extrapolation models based on 
previous disease patterns. Hodgson et al [142] refers to a British Health and Safety Executive 
Regulatory Impact Assessment from 2002 that suggested that population exposure in 2000 was around 
4% of the peak value reached in the 1960s. For their own projections, Hodgson et al assumed a 
continuing decline in asbestos exposure, from 4% of the peak level in 2000 to 2% by 2010 and 0.75% 
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by 2050. However these figures probably comprise both occupational and non-occupational 
exposures. 
Because mesothelioma is and almost exclusive liked to asbestos exposure and not to smoking or other 
known exposures, extrapolations of the incidence of mesothelioma is less complicated than for lung 
cancer and may apply to exposure levels for the general population [235]. Lung cancer on the other 
hand is one of the most common forms of cancer. As several exogenous noxious agents can be 
etiologically responsible for bronchial carcinoma, the extrapolation of risk and comparison between 
different studies is considerably complicated. Exposure-response models for asbestos has also been 
developed for asbestos and lung cancer, but the models proposed by Doll and Peto[143] and other 
researchers, are based primarily on projections of occupational exposures’ significance for lung cancer 
and not based on environmental exposures in the general population. 
A review of the predicted risks for lung cancer from a number of asbestos studies has been carried out 
by WHO with the objective of estimating risks from background environmental asbestos exposure 
levels. The risks were based on evidence from epidemiological studies concerning occupational 
exposure. Data from these studies were conservatively extrapolated to the much lower concentrations 
found in the general environment using a formula that stated, that the relative risk at a given time is 
approximately proportional to the cumulative amount of fine asbestos dust received up to this point, 
for both smokers and non-smokers. The risks for non-asbestos-exposed non-smokers and smokers 
must therefore be multiplied by a factor that increases in proportion to the cumulative exposure. The 
dose–response relationship was described by the following equation:  
IL (age, smoking, fibers dose) = IL0 (age, smoking)[l + KL × Cf × d] 
where: 
KL = a proportionality constant, which is a measure of the carcinogenic potency of asbestos 
Cf = fibers concentration 
d =  duration of exposure in years 
IL = lung cancer incidence, observed or projected, in a population exposed to asbestos concentration Cf 
during time d 
IL0 = lung cancer incidence expected in a group without asbestos exposure but with the same age and 
smoking habits (this factor includes age dependence). 
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The proportionality constant KL is a measure of the carcinogenic potency of asbestos and can be 
derived from different sources.  The WHO report used data from Liddell et al 1985 [234]. In Liddell’s 
study alone this constant varied considerably (by a factor 150). By using KL = 1.0 per 100 
F*years/ml2 and based on the figures for smokers and non-smoker reported by [229] WHO estimated, 
that for a given asbestos exposure, the risk for smokers is about 10 times that for nonsmokers. In 
extrapolating from workers to the general public, a factor of 4 for correction of exposure time was 
applied to KL. Thus the incidence of lung cancer in the general population exposed to 100 F*/m3 was 
calculated as follows: 
IL = IL0 (l + 4 × 0.01 × 10–4 F*/ml × 50 years) 
or 
IL = IL0 (l + 2 × 10–4 F*/ml) 
 
The extra risk is IL - IL0. Values for IL0 are about 0.1 for male workers and 0.01 for male nonsmokers 
Lifetime exposure to 100 f*/m3 (lifetime assumed to be 50 years since, in a lifetime of 70 years, the 
first 20 years without smoking probably do not make a large contribution) is therefore estimated as 
follows.  
 
Table A19. Risk of lung cancer per 100,000 [232] 
Status Risk of lung cancer per 100 000  (using a value of 1 for KL) 
Range (using the highest and 
lowest value of KL) 
Smokers 2 0.08–3.2 
Nonsmokers 0.2 0.008–0.32 
 
 
The estimated risks from the WHO review are for lifetime exposures and do not differentiate between 
asbestos types although WHO acknowledge that chrysotile is less potent than amphiboles; chrysotile 
was as a precaution attributed the same risk in these estimates.  
 
WHO compared this risk estimate, when adjusted to 100 f*/m3, with estimates for male smokers made 
by other authors or groups: 
Breslow (Great Britain): 7.3 × 10–5 
                                                      
2 F* indicates that measurement were based on light (optical) microscope counting, which meant that only fibers 
longer than 5 µm and thicker than 0.5 µm were counted. If concentrations measured by optical microscopy are to 
be compared with environmental fiber concentrations measured by scanning electron microscopy, a conversion 
factor has to be used: 2 F/m3 = 1 F*/m3 
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Schneiderman et al. (Germany): (14–1.4) × 10–5 
US Environmental Protection Agency (USA): 2.3 × 10–5. 
In order to calculate an attributable fraction, one needs an estimate of the proportion of the population 
experiencing circumstances of exposure comparable with those experienced by the populations 
included in the studies on which the calculations in table 3 are based. A meta-analysis estimated the 
relative risk (RR) of mesothelioma from residential exposure to asbestos at 3.5 (95% confidence 
interval [CI] 1.8–7.0); the corresponding RR of lung cancer was 1.1 (95% CI 0.9–1.5). According to 
the model used by WHO, 5% of the European population experience residential exposure to asbestos. 
However, the studies included in the meta-analysis were conducted in populations with high level of 
exposure and a more plausible estimate of prevalence of exposure to such circumstances is in the order 
of 2% [179]. Combining these results leads to estimated annual numbers of 338 cases of mesothelioma 
in men and 43 in women. No estimate is provided for lung cancer because of the lack of statistically 
significant increase in risk found in the meta-analysis [179]. 
CONCLUSION  
Non-occupational asbestos exposure is probably not significantly related to lung cancer except in 
special occasions as for instance in household exposure in cohabitants of asbestos workers, areas with 
very high exposures (e.g. residence in a mining area or near processing plants), and areas where 
asbestos are naturally occurring in the soil.  
The level of environmental asbestos exposure to the general population in Denmark is not known, but 
based on Dutch and English studies the background level in outdoor air in cities is about 0.0001-
0.0005 f/ml, which is orders of magnitude from the levels measured in occupational settings on which 
risk is assessed and extrapolated. WHO estimates that by a lifetime exposure of 1,000 f/m3 (0.001 
f/ml) the excess risk due to lung cancer would be in the order of 10–6–10–5, and for mesothelioma in 
the range 10–5–10–4. In the Danish population this accounts for 10 deaths by lung cancer and 100 by 
mesothelioma. At least for mesothelioma this seems grossly to overestimate the number of deaths as 
the total number of deaths from mesothelioma in Denmark for the time being is just fewer than 100 
per year. However, the figures for mesothelioma probably comprise both occupational and non-
occupational exposures. 
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APPENDIX 22. INTERACTION BETWEEN ASBESTOS AND SMOKING (4.4) 
The risk for lung cancer associated with asbestos exposure varies with the level of exposure and 
possibly fiber type, but the most important concomitant factor being cigarette smoking. In an often-
cited study by Hammond et al. [229] asbestos exposure alone conferred a five-fold relative risk for 
lung cancer; cigarette smoking without asbestos exposure was associated with an 10-fold increase in 
risk, but asbestos exposure with cigarette smoking yielded a relative risk for lung cancer of 59. By 
adding the effect of asbestos exposure and cigarette smokers in the Hammond study a 15-fold risk 
increase might be expected. The observed risk however was nearly 4 times greater suggesting some 
sort of synergistic or perhaps multiplicative effect. A “true” multiplicative effect implies that the effect 
of asbestos exposure is a proportional to the effect of smoking, whereas in an additive model asbestos 
exposure and smoking are independent of each other. 
There is inconsistent information in the literature on the interaction between asbestos exposure and 
smoking and their joint impact on lung cancer risk. Since Hammond’s study a number of other studies 
have dealt with the question of estimating the magnitude of an eventual multiplication factor, and 
different studies have given different result varying from no synergistic/multiplicative factor at all 
[247] to figures comparable to Hammond’s [242]. 
Erren 1999 [241] examined data from 12 epidemiologic studies for quantitative evidence of biologic 
synergy between asbestos and smoking on lung cancer risks. Estimates of the effect associated with 
joint exposure to the two agents exceeded the sum of their separate effects in each study. They also 
used a 'synergy index' S, proposed by Rothman [286] calculated from the relative risks of lung cancer 
due to smoking and asbestos, separately and combined, to examine departures from the additive 
model, for which S = 1. The values of S ranged from 1.22 to 5.30, and the heterogeneity was quite 
slight (P~0.32). The authors found no explanation for it, whether in methodological differences or in 
type of fibers, and despite wide variations of the smoking relative risks and of the relative risks due to 
asbestos alone (1.1-25.0). It was concluded that the excess lung cancer arising from exposure to both 
asbestos and smoking is higher, by a factor of about 1.64, than the sum of the two risks—in other 
words the additive model did not fit but a multiplicative model did. The attributable proportion 
associated with this average S was estimated as 33%, that suggests that one-third of cancer cases 
among smokers who were exposed to asbestos can be attributed to the synergistic behavior of the two 
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carcinogens, as distinct from their separate effects and those attributable to other ("background") 
factors.  
Liddell [243] used a different approach by calculating what he called “Relative Asbestos Effect” 
(RAE) based on the ratio of lung cancer SMRs for non-smokers and smokers. On the multiplicative 
hypothesis, RAE=1, while RAE>1 indicates less synergism. The RAEs for the results from 13 
different papers combined, was 1.8 times that of smokers' and so he argued that this showed, that “the 
multiplicative hypothesis is untenable”. Liddell only reviewed cohort studies, and also found that the 
relative risk of lung cancer from asbestos exposure was about twice as high in non-smokers as in 
smokers, which was in itself interpreted in favor of his rejection of the multiplicative hypothesis.  
Lee reviewed the same cohort studies as Liddell but also included case referent studies [242]). Lee 
analyzed lung cancer risk in subjects unexposed to asbestos or smoking, exposed to asbestos only, to 
smoking only, or to both in order to evaluate if asbestos increased risk in non-smokers. Asbestos 
exposure was associated with a significantly increased risk in non-smokers in six studies and with a 
moderately increased, but not significant, increase in a further six. In 30 of 31 data sets analyzed, risk 
in the combined exposure group was greater than predicted by the additive model. There was no 
overall departure from the multiplicative model except for two of the reviewed studies.   
Reid 2006 et al [244] using of modified form of the Relative Asbestos Effect concluded, that the 
modified RAE of 1.59, which they found, indicated that the interaction between smoking and asbestos 
exposure was not additive but “less than multiplicative”.  
Using a mathematical/statistical approach to the question, Wraith and Mengersen [246]) reviewed the 
literature on the combined association between lung cancer and asbestos exposure and smoking to 
assess evidence of interaction between the exposures. The meta-analysis combined separate indices of 
additive and multiplicative relationships and multivariate relative risk estimates. By making inferences 
on posterior probabilities they explored both the form and strength of interaction and found that this 
analysis was more informative than providing evidence to support one relation over another on the 
basis of statistical significance. Overall, they found evidence for a “more than additive and less than 
multiplicative relation”. 
The most recent major contribution to the effect of smoking and the risk of lung cancer in asbestos 
workers was published in 2011 in Great Britain [245] The aim of the study was to examine the effect 
of smoking and smoking cessation among asbestos workers in Great Britain and investigate the 
interaction between asbestos exposure and smoking. The study population consisted of 98,912 
 160 
asbestos workers with 1,780,233 person-years of follow-up from 1971 to December 2005. There were 
1878 deaths from lung cancer (12% of all deaths). Risk of lung cancer mortality increased with packs 
smoked per day, smoking duration, and total smoke exposure (pack-years). Asbestos workers who 
stopped smoking remained at increased risk of lung cancer mortality up to 40 years after smoking 
cessation compared to asbestos workers who never smoked. The effects of smoking and stopping 
smoking did not differ by duration of asbestos exposure, main occupation, age at first asbestos 
exposure, year of first exposure, or latency period. For those asbestos workers who smoked, an 
estimated 26% (95% CI 14–38%) of lung cancer deaths were attributable to the interaction of asbestos 
and smoking. Among this group, there were more deaths attributable to smoking only than asbestos 
exposure only (68% versus 2%). Consequently, the estimated fraction of lung cancer deaths prevented 
if workers had not smoked (risk attributable to smoking in the presence of asbestos) was 94% 
(=26%+68%); the estimated fraction of lung cancer deaths prevented if workers had not been exposed 
to asbestos (risk attributable to asbestos in the presence of smoking) was 28% (=26%+2%); and the 
fraction of lung cancer deaths prevented if neither exposure had occurred (risk attributable to the 
combined effect of asbestos and smoking) was 96% (=26%+68%+2%) among asbestos workers who 
smoked. The attributable proportion due to the interaction between smoking and asbestos was slightly 
lower than the estimates found in the literature (33%-41%). The differences between the attributable 
proportion could be due to the use of low versus high asbestos exposure rather than unexposed versus 
exposed. This could lead to the estimated attributable proportion of lung cancer due to ‘background’ 
risk being greater than perhaps it should be, and therefore reducing the attributable proportion due to 
asbestos only, smoking only, and the interaction of the two. The authors calculated, that if a 
comparison group was used that was truly unexposed, then the attributable proportion due to asbestos 
among never-smokers would probably have been >37%. 
 
The authors also specifically addressed the question of whether or not the interaction between asbestos 
exposure and smoking was additive or multiplicative. This was examined by using the Synergy (S) 
and Multiplicativity (V) indices, which tested the hypotheses of additive and multiplicative interaction, 
respectively. Index S was statistically significantly >1, providing evidence against the additive 
hypothesis of no interaction between smoking and asbestos exposure (S=1.4; 95% CI 1.2–1.6). Index 
V was <1, but this was not a statistically significant difference and so the multiplicative hypothesis 
could not be rejected (V=0.9; 95% CI 0.3–2.4). The use of different low and high asbestos exposure 
categories did not greatly affect these results. 
 
From a Danish point of view this study is interesting. Regulatory efforts in Great Britain have been 
similar to the Denmark. This study includes not only asbestos miners and workers in asbestos mills as 
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many of the earlier studies, but also asbestos exposed persons in jobs that also are common among 
asbestos exposed workers in Denmark: Carpenters, construction workers, demolition workers, 
electricians, merchant navy workers, metal plate workers, plumbers & gas fitters, production fitters, 
railway industry workers (e.g. carriage building), roofers, sheet metal workers, shipbuilding/dock yard 
workers, steel workers, thermal insulation engineers/laggers (e.g. pipe and boiler insulation), 
transport/haulage workers, vehicle body workers (e.g. brake and clutch linings and spray paint), 
welders. 
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